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Abstract 
 
It has been established that all cells carry an array of glycans attached to proteins and 
lipids that are crucial in the interaction between cells and the surrounding matrix. Proteins are 
mainly glycosylated on asparagines (N-glycosylation) and serine or threonine residues (O-
glycosylation). Compared to N-glycans, O-glycans offer a higher degree of structural ambiguity 
due to the existence of several types and cores. This is believed to contribute to the relative lack 
of knowledge on these molecules. Therefore, improvement to the current methodologies of 
structural studies is a prerequisite to complement the immense functional findings of O-
glycoconjugates in biological systems. This thesis discusses the structural characterisation, 
regulation and biological roles of O-glycans. The overall aim was to optimise O-glycomic mass 
spectrometric analysis to help illuminate the phenotypic findings from our collaborators in three 
separate but related projects. The methodologies utilised involving MALDI-TOF/TOF-MS, GC-
EI-MS, ESI-QTOF-MS and MALDI-QIT-TOF-MS. 
 
The first project investigated the effects of core 2 GlcNAc transferase (C2GnT) 
deficiency in mice. This enzyme exists in three isoforms which are expressed differently in 
different tissues. Analysis of the single knockout of each of these isoenzymes as well as the triple 
knockouts has allowed the investigation of their unique and overlapping functions. The outcomes 
of this study include characterisation of alterations of not just mucin-type O-glycans but also O-
mannose glycan, which could be associated with several organ lesions and system failures. The 
second project focused on the gastric mucosa of mice with deficiency in α1,2-fucosyltranferase 
(FuT2). This enzyme plays an important role in decorating the mucosal mucins with ABH-blood 
group and Lewis antigens that are known to interact with various gut flora including the pathogen 
Helicobacter pylori. It has been shown that the binding of H. pylori via BabA adhesins was 
significantly impaired with the loss of H antigens and Lewis y on O-glycans. The third project 
investigated the regulation of mucin-type O-glycosylation. The protein Src has been recognised to 
play an essential role in the localisation of ppGalNAc transferases, the initiating enzyme of O-
glycosylation, in the endoplasmic reticulum and Golgi apparatus. Therefore, it could be inferred 
that Src influences the regulation of protein O-glycosylation. The NIH3T3 and NBT-II cell lines 
with different levels of Src or different localisation of ppGalNAcT-2 have been analysed in order 
to identify the changes on the structures of O-glycans and the relative abundances of cores 1 and 
2. Valuable information has been gathered which could lead to further investigative work to better 
understand the role of Src in the regulation of protein O-glycosylation. 
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1 Introduction 
1.1 Sweet interactions: biomedically important glycoconjugates 
Glycosylation, the enzymatic synthesis of oligosaccharides attached to biomolecules, is 
an event that reaches beyond the genome and is controlled by factors that differ greatly among 
cell types and species (Spiro, 2002). Glycosylation produces a diverse and abundant set of 
covalently linked oligosaccharides, referred to as glycans. This repertoire of glycans is 
collectively known as the glycome, and is a result of combinatorial expression of, for instance in 
the mammalian genome, more than 200 glycosyltransferases and glycosidases (Marth & Grewal, 
2008). The rising interest in glycoconjugates is largely influenced by the progressive revelations 
of diseases that can be associated with glycosylation and glycans. Indeed, aberrations in 
glycosylation can be correlated to more than 30 types of genetic diseases in humans 
encompassing neurological disorders, congenital muscular dystrophies, connective tissue 
disorders and immune deficiencies (Freeze, 2006; Hennet, 2009).  By acknowledging how 
distressed biological systems can become due to errors in glycosylation pathways, it is becoming 
increasingly clear that glycoconjugates play undeniably important roles in ensuring functional 
integrity. Investigative work on the regulations, structures and functions of glycans spans various 
research fields including immunology, genetics, microbiology etc. with the hub discipline being 
known as glycobiology. 
 
Glycobiology is the field that investigates the biological functions of glycans attached to 
proteins and membranes and determines how these functions are carried out (Taylor & 
Drickamer, 2006). Glycans, together with nucleic acids, lipids and proteins, are important 
macromolecules in a living system. Of these four, glycans are the most abundant and structurally 
diverse biopolymers. Living cells synthesise these molecules, either to be expressed on their 
surface or to be secreted into the blood stream, in the form of glycoconjugates such as 
proteoglycans, glycolipids and glycoproteins.  
 
The high abundance of glycans on cell surfaces illustrates their premier position as the 
interface between cells and interacting cells or molecules (Varki & Sharon, 2009). The structural 
diversity of carbohydrates underlies the potential of this class of biomolecules for storing 
biological information. Turning this potential into an operative sugar code entails the existence of 
efficient decoding devices (Soils et al., 2009). Recognition of glycans by proteins has been shown 
to be central to a myriad of intra- and extra- cellular physiological and pathological processes. 
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Glycans interact with various types of proteins including carbohydrate active enzymes and 
glycan-binding proteins (GBPs). The latter represents the major way in which the information 
contained in glycan structures is recognised, deciphered and transformed into biological actions 
(Cummings & Esko, 2009).  
 
A family of GBPs known as lectins constitute the major mediators or modulators of 
specific glycan biological roles. Lectins were first discovered in plants about 100 years ago but 
their presence is now known to span most living organisms including animals and microbes 
(Varki et al., 2009). The sugar binding activity of typical lectins can be ascribed to a specific 
domain known as the carbohydrate recognition domain (CRD) (Weis & Drickamer, 1996). The 
classification of lectins was initially based on their CRD sequence motifs, which led to the 
designation of C-type lectins (requires calcium ion for recognition) and galectins (galactose 
binding) (Drickamer & Taylor, 1993), both of which are animal lectins. The subsequent discovery 
of a substantive number of other types of lectins, has resulted in various categories of 
classification and at the present time, there is no single universally accepted classification method 
(Varki et al., 2009). 
 
Many lectins are either soluble or membrane integrated proteins with their CRDs located 
in the extracellular space. These lectins are the counterparts of membrane-bound or secreted 
glycoconjugates, with both being the mediators of adhesion and signalling events at the cell 
surface. Upon CRD binding to its substrates, other lectin domains or the substrate itself will 
mediate responses to the recognition events. This outside-in signalling is similar to 
transmembrane signalling from hormones and growth factors to their intracellular targets (Taylor 
& Drickamer, 2006). Outcomes of these signalling processes most commonly involves changes 
in the levels of gene expression, leading to diverse biological functions. These lectin-ligand 
interactions can be classified into several types, as illustrated in Figure 1.1. Interaction A in the 
figure represents antigen capturing by antigen-presenting cells. For instance, dendritic cell-
specific intercellular adhesion molecules-3-grabbing non-integrin (DC-SIGN) binds and induces 
endocytosis of glycosylated pathogens (Svajger et al., 2010). The internalised antigens are then 
digested and the fragments are presented on the cell surface to interact with other immune cells 
(Pöhlmann et al., 2001). The B portion of the figure illustrates selectins and their membrane-
bound glycoprotein ligands. As an example, E-selectin on endothelial cells transiently binds to P-
selectin glycoprotein ligand-1 (PSGL-1) on neutrophils and triggers a signalling cascade through 
Src family kinases to induce integrin expression, leading to reduced neutrophil rolling and 
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eventually migration to sites of inflammation (Yago et al., 2010). C and D denote galectin 
mediated cell-adhesion and glycoprotein receptor clustering, respectively. For instance, galectin 3 
regulates adhesive interaction between breast carcinoma cells, via binding to poly-N-
acetyllactosamine chains on surface glycoproteins, and elastin on connective tissues (Ochieng et 
al., 1999).  Galectin 3 also plays a critical role in cancer metastasis by clustering Muc1 
glycoprotein on cancer cell surface via adhesion to core 1 O-glycans thus exposing the cell 
surface for adherence to endothelial cells and then migrate (Yu et al., 2007). The various types of 
animal lectins and their specificities are discussed in more detail in Section 1.2.3.3. 
 
 
Figure 1.1. Schematic representation of types of interactions mediated by extracellular lectins.  
Interaction at A represents lectin-mediated endocytosis leading to antigen presentation on the cell surface. 
Lectin binding at B, C and D generate signalling cascades that are usually interpreted in the form of gene 
expression. 
 
Many eukaryotic glycoconjugates directly interact with diverse microbial species by 
binding to lectins that are known as adhesins. For example, human and animal pathogens 
including viruses, bacteria, fungi and parasites have been shown to utilise cell surface glycans as 
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‘keys’ to enter and invade host cells leading to various types of diseases (Corfield et al., 2000; 
Nizet & Esko, 2009). Helicobacter pylori for instance, a common opportunistic bacterium in the 
human gut, utilises glycan binding adhesins that bind to fucosylated and sialylated glycans (Ilver 
et al., 1998; Mahdavi et al., 2002). These glycans are very abundant on gastric mucosa 
specifically on mucin glycoproteins that naturally function to protect the inner epithelial cells 
from their harsh environment (Corfield et al., 2001). The interaction between H. pylori and host 
glycans is relevant to one of the projects in this thesis (Chapter 4), and therefore will be discussed 
in more detail in Section 1.2.5.  
 
From the examples given above, it is clear that glycocconjugates are undeniably 
biomedically important. Nevertheless, there are still many missing pieces of information that are 
required to assemble a complete picture of the biochemical mechanisms underlying carbohydrate 
mediated interactions and their functional consequences. This is partly due to the 
underdevelopment of glycomics technologies relative to proteomics and genomics (Pilobello & 
Mahal, 2007). Improvements in glycomics methodologies, in parallel with biochemical and 
phenotypic studies, are essential for better understanding of the structure-function attributes of 
glycoconjugates in health and disease. Of all glycoconjugates, glycoproteins are the most 
abundant and can highly influence how a biological system works due to the fact that they 
include functionally important biomolecules such as hormones, enzymes, antibodies and 
receptors (Brooks, 2002). 
 
1.2 Protein glycosylation 
Glycosylation is the most functionally recognised and complex form of protein 
posttranslational modification. The first glycopeptide linkage was described by Johanssen et al. in 
1961 on ovalbumin (Johansen et al., 1961). There are two main types of protein glycosylation 
depending on the way they are linked to a protein, namely N-glycosylation and O-glycosylation 
(Kornfeld & Kornfeld, 1976). Both of these types of glycosylation share a number of similar 
building blocks but are catalysed through different metabolic pathways, resulting in structure and 
function diversification. At the moment, according to the calculation by the PTM browser 
(www.ptmbrowser.org) based on the biochemical data from Swiss-Prot (www.uniprot.org) 
(Consortium, 2010) and Ensembl databases (www.ensembl.org) (Flicek et al., 2010), it has been 
estimated that about 20% and 15% of all proteins in humans and mice are glycosylated, 
respectively. However, based on the rate of glycosylation site occupancy from Swiss-Prot, it has 
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been estimated that more than half of all proteins in nature are glycosylated (Apweiler et al., 
1999). The relatively very low glycosylation percentage calculated by the PTM browser is mostly 
contributed by the limited information on glycosylated proteins available in the database, for 
instance the lack of data on O-GlcNAc modification meaning that many cytoplasmic and nuclear 
glycoproteins, which are very commonly modified with O-GlcNAc, are not recorded as such.  
 
Throughout this thesis, glycan residues are mostly depicted using cartoon structures 
(Figure 1.2) which were standardised for the Essentials of Glycobiology textbook (Varki et al., 
1999) and later adopted and modified by the Consortium for Functional Glycomics (CFG) 
(www.functionalglycomics.org).  
 
 
 
Figure 1.2. Symbol nomenclature for the most common monosaccharides found on mammalian 
glycoproteins. 
The cartoon structures are according to the guidelines in the Essentials of Glycobiology (Varki et al., 1999) 
and modifications by the CFG (www.functionalglycomics.org). 
 
1.2.1 N-glycosylation 
N-glycosylation is the attachment of oligosaccharides via an N-acetylglucosamine 
(GlcNAc) residue to the amide nitrogen of asparagine (Asn) side chains. This modification can 
determine or influence protein folding, stability, localisation, trafficking and oligomerisation 
(Freeze, 2006). Unlike O-glycans, N-glycans are almost invariably found in a specific target 
sequence, Asn-Xaa-Ser/Thr, where Xaa can be any amino acid except proline (Hart et al., 1979). 
Furthermore, N-glycosylation is exclusively initiated in the lumen of endoplasmic reticulum (ER) 
with en bloc transfer of a Glc3Man9GlcNAc2 oligosaccharide from a lipid dolichol donor by the 
oligosaccharyltransferase complex (Silberstein & Gilmore, 1996).  
 
Figure 1.3 summarises the key steps in the biosynthetic pathway of N-glycans from the 
ER to trans-Golgi. After the transfer of the N-glycan precursor to a protein, the processing and 
maturation of N-glycans begins with the removal of all glucose residues and some of the 
mannose residues in the ER and cis-Golgi, forming Man5GlcNAc2Asn. These actions are carried 
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out by glucosidases I and II, ER mannosidase I and Golgi mannosidases IA, IB and IC. Some 
glycans remain in the high-mannose state, containing between five to nine mannose residues, 
while others are processed to more complicated structures (Taylor & Drickamer, 2006). The first 
branch of an N-glycan is initiated in the cis-Golgi and this is followed by further digestion of 
mannose residues in the medial-Golgi by mannosidase II. Another GlcNAc residue is then added 
forming the biantennary structure Man3GlcNAc4Asn. More GlcNAc residues may be added to 
form triantennary and tetraantennary structures.  N-glycans are then ready for modifications and 
elongations which continue in the trans-Golgi and trans-Golgi network (Stanley et al., 2009). N-
glycans can be classified into 3 types based on their peripheral structures:  high-mannose 
structures which contain only mannose residues, complex structures which contain antennae 
initiated by GlcNAc residues and hybrid structures which contain only mannose residues on the 
Manα1-6 arm of the core and GlcNAc initiated antennae on the Manα1-3 arm. All N-glycans 
share the common core sequence Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1-Asn, 
which is retained from the conserved precursor. 
 
1.2.2 O-glycosylation 
O-glycans are attached via an α or β-O-glycosidic linkage to the hydroxyl group of an 
amino acid residue, usually serine, threonine or hydroxylysine (HLys) on a protein. Peptide O-
glycosylation creates a number of O-glycan classes depending on the first sugar attached to the 
peptide chain, namely O-N-acetylgalactosamine (O-GalNAc), O-mannose, O-GlcNAc, O-
glucose, O-galactose (O-Gal), O-fucose and O-xylose (glycosaminoglycans). Most O-
glycosylation occurs in the ER/Golgi. The exception is β-O-GlcNAcylation which is a common 
modification of nucleocytoplasmic proteins (Hu et al., 2010), and will not be discussed here. O-
GalNAc-linked glycans are known as mucin type O-glycans, due to the fact that mucin 
glycoproteins are highly glycosylated with O-GalNAc. Mucin-type glycosylation is the focus of 
this thesis and will be discussed in detail in Sections 1.2.2.2 (glycans) and 1.2.4 (mucins). First, 
less common classes of O-glycosylation are briefly reviewed (Section 1.2.2.1). 
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Figure 1.3. Summary of the biosynthetic pathways of N-glycans 
Processing of N-glycans from the ER to trans-Golgi results in three types of N-glycan, namely complex, 
hybrid and high-mannose. Asn, asparagine; Dol-P-P, dolicholpyrophosphate. Based on (Dennis et al., 
2009; Stanley et al., 2009). 
 
1.2.2.1 β-O-galactose, α-O-fucose, β-O-glucose and α-O-mannose 
In the mammalian system, O-galactosyl glycans have been found only on protein 
collagen domains (Freeze & Haltiwanger, 2009). Instead of serine and threonine, they are 
attached to hydroxylysine residue usually as a disaccharide Glcα1,2Gal. The quantities and types 
of O-galactose vary considerably among different types of collagen and even the same collagen 
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from different expression sites (Wopereis et al., 2006). O-galactose also has been identified in 
secreted proteins of Schistosoma mansoni eggs and larvae (Jang-Lee et al., 2007).  
 
O-Fucosylation, on the other hand, is a common modification of epidermal growth factor 
(EGF)-like domains that are defined by six conserved cysteine residues which form three 
disulfide bonds. EGF-like domains can be found in several secreted and membrane-bound 
proteins. The consensus site where O-fucose is likely to be glycosylated by protein-O-
fucosyltransferase 1 has been proposed as C2XXGGS/TC3,  where C2 and C3 are the 2nd and 3rd 
conserved cysteines of the EGF repeat, S/T is the modified residue and X can be any amino acid 
(Harris & Spellman, 1993). More recently, O-fucose was detected in another cysteine-rich motif 
known as thrombospondin type 1 repeat  (Luo et al., 2006). On this domain, protein O-
fucosylation is catalysed by protein-O-fucosyltransferase 2 on serine or threonine. O-Fucose can 
exist either as a single monosaccharide or modified for elongation up to tetrasaccharides with 
GlcNAc, galactose (Gal) and sialic acid  (Luther & Haltiwanger, 2009). 
  
Similar to O-fucose, O-glucosyl glycans are generally found at EGF-like domains, but are 
β- instead of α-linked and only to serine. This glycosylation is initiated by protein-O-
glucosyltransferase and the glycan typically exist as a monosaccharide or can be modified with 
xylose residues to form a trisaccharide (Luther & Haltiwanger, 2009).  In addition, the putative 
consensus sequence for O-glucosylation also has been suggested as C1XSXPC2, where 
C1 and C2 are the first and second conserved cysteines of the EGF repeat, respectively, S is the 
glycosylation site and X can be any amino acid (Harris & Spellman, 1993).   
 
O-Linked mannosyl glycans were first identified in 1969 in yeast and were found to be 
very abundant in the cell wall (Sentandreu, 1969), hence it used to be known as yeast-type 
modification (Kukuruzinska, 1987). In mammals, brain proteoglycans were the first found to be 
O-mannosylated (Krusius et al., 1986). To date, O-mannosylation occurrences in humans are 
relatively limited and have only been reported to be present on a small number of glycoproteins 
in the brains, nerves and skeletal muscle (Wopereis et al., 2006). The biosynthesis of O-mannosyl 
glycans is initiated in the ER by protein-O-mannosyltransferase-1 and -2 (POMT-1 and -2) which 
add mannose from dolichol-phosphate-Man to serine or threonine residues (Van den Steen et al., 
1998). Manya and colleagues have proposed a consensus sequence preferred for O-
mannosylation that is IXPT(P/X)TXPXXXXPTX(T/X)XX, where I is isoleucine, P is proline, T 
is threonine and X can be any amino acid (Manya et al., 2007). However, another two more 
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recent studies argued that O-mannosylation is regulated in a much more complicated manner than 
just a simple local sequence (Breloy et al., 2008; Stalnaker et al., 2010). Modification on O-
linked mannose is initiated by protein-O-mannose-β1,2-N-acetylglucosaminyltransferase 1 
(POMGnT1) which adds β1,2-GlcNAc. The resulting disaccharide then can be further elongated 
and branched with sugar compositions including GlcNAc, Gal, sialic acid, glucuronic acid 
(GlcA) and fucose. Unlike POMTs and POMGnT1, it is not known whether the other 
participating enzymes are unique to this pathway (Freeze & Haltiwanger, 2009). Although it is 
not fully understood yet, correct modifications, particularly glycosylation of the glycoprotein α-
dystroglycan (α-DG) by POMT2 and POMGnT1 and two putative glycosyltransferases, fukutin-
related protein (FKRP) and LARGE, were found to be vital in ensuring the integrity of muscle 
tissues (Endo et al., 2010). Accordingly, O-mannosylation of α-DG has been shown to be critical 
in stabilising the link between the extracellular matrix and cytoskeleton in muscle (Moore & 
Hewitt, 2009). α-DG isolated from human and rabbit skeletal muscles has been mapped and 
characterised to have at least 3 and 9 sites modified with O-mannose-initiated glycans, 
respectively (Nilsson et al., 2010; Stalnaker et al., 2010). Campbell and co-workers recently have 
identified a novel phosphorylated O-mannose sequence [GalNAcβ1,3GlcNAcβ1,4(6-PO3)Man] 
on recombinant human α-DG at which LARGE is speculated to participate in an unidentified 
post-phosphoryl glycosylation important for binding to the extracellular matrix protein laminin 
(Yoshida-Moriguchi et al., 2010). 
 
1.2.2.2 Mucin type O-glycans 
Mucin type O-glycans (α-O-GalNAc) are the most commonly found O-glycans on 
secreted and membrane-associated proteins in mammalian tissues, especially on a family of 
glycoproteins known as the mucins (see section 1.2.4).  The biosynthetic pathway is initiated by 
the addition of a GalNAc residue from a UDP-GalNAc on serine or threonine by a family of 
UDP-GalNAc: polypeptide-α-N-acetylgalactosaminyltransferases (ppGalNAcTs). At least 20 and 
13 ppGalNAcTs have been identified in humans (Perrine et al., 2009) and mice 
(www.informatix.jax.org) (Bult et al., 2008), respectively, and they are usually located in the cis-
Golgi. Some isoforms are expressed ubiquitously (ppGalNAcT-1 and -2), but some are expressed 
specifically in a subset of tissues (Ten Hagen et al., 2003).  All ppGalNAcTs are composed of a 
catalytic domain and a lectin domain. It has been suggested that the lectin domain modulates the 
glycosylation of glycopeptide substrates and may contribute to the strict specificities of certain 
ppGalNAcT isoforms. ppGalNAcT specificities are not fully understood yet but it seems that they 
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have similar and unique specificities. For instance, ppGalNAcT-1 & -2 have been shown to prefer 
glycosylating peptides with a common motif (Gerken, 2006), but not ppGalNAcT-10 (Perrine et 
al., 2009). Due to the complex regulation of the addition of the first GalNAc, there is unlikely to 
be a general consensus sequence for mucin type glycosylation. However, a number of statistical 
studies have yielded some calculations to predict O-glycosylation sites, for instance the NetOGlc 
server (Hansen et al., 1998) and the Random Forest algorithm (Hamby & Hirst, 2008) that 
demonstrated over 80% and 90% of accuracy, respectively, for serine and threonine. 
 
The serine/threonine-linked GalNAc residue (known as the Tn antigen) can be further 
modified or elongated to produce up to 8 core-types in mammals (Figure 1.4). The attachment of 
a Gal residue by core 1 β1,3-galactosyltransferase (C1GalT/T-synthase) on position 3 of the 
GalNAc produces core 1 (also known as Thomsen-Friedenreich or T antigen). The core 1 enzyme 
has to compete with α2,6-sialytransferase I which sialylates the Tn antigen at position 6 forming 
sialyl-Tn (sTn) antigen thus preventing substitution at position 3 (Sewell et al., 2006). The T, Tn 
and sTn antigens are largely restricted to mucins secreted by normal and malignant epithelial cells 
and have been correlated with aggressive tumour growth and poor prognosis in a number of 
tumours (Springer, 1989; O'Boyle et al., 1992). Once formed, the core 1 O-glycan can be 
sialylated/disialylated, α-galactosylated, fucosylated, elongated and/or converted to the core 2 O-
glycan. The latter is formed by the attachment of a GlcNAc residue on position 6 of the GalNAc 
of core 1 by core 2 β1,6-N-acetylglucosaminyltransferases (C2GnTs). C2GnTs will be discussed 
in the next section. 
  
On a separate pathway, the Tn antigen can also be extended by the attachment of a 
GlcNAc residue on position 3 of the GalNAc to form core 3, and an additional GlcNAc on 
position 6 to form core 4, by Core 3 β1-3-N-acetylglucosaminyltransferase (C3GnT) and core 2 
β1,6-N-acetylglucosaminyltransferase 2 (C2GnT2), respectively (Vavasseur et al., 1995; 
Schwientek et al., 1999). O-glycan cores 5 to 8 have rarely been observed. Furthermore, enzymes 
involved in their biosynthesis remain to be fully characterised. Core 5 O-glycans were first 
reported from human meconium (Vincent et al., 2008) and are believed to exist in colonic tissues 
and colonic adenocarcinoma (Brockhausen et al., 2009). Core 6 O-glycans were also first 
reported from human meconium (Perrine et al., 2009) and core 7 O-glycans in bovine kappa-
casein (Gerken, 2006), whereas core 8 O-glycans were from human respiratory mucin (Torres & 
Hart, 1984).  
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Figure 1.4. The biosynthetic pathways of mucin type O-glycans. 
Eight cores of mucin type O-glycan have been described in mammals.  All cores can be further elongated 
with LacNAc units and modified with sialylatian, fucosylation, blood groups etc.  
 
All core structures can be further elongated by the repetitive addition of N-
acetyllactosamine (LacNAc) units type 1 (Galβ1-3GlcNAc) or type 2 (Galβ1-4GlcNAc). The 
chain may also be branched on a Gal residue by I β-1,6-N-acetylglucosaminyltrasferase (IGnT) 
and C2GnT and/or modified with fucosylation, sialylation and other capping moieties (Section 
1.2.3). 
 
1.2.2.3 Core 2 β1,6-N-acetylglucosaminyltransferase 
Core 2 β1,6-N-acetylglucosaminyltransferase (C2GnT), which exists in 3 isoforms, 
C2GnT1, C2GnT2 and C2GnT3, is one of the key enzymes in the O-glycan biosynthetic 
pathway. Recently, it has been shown that in the mouse C2GnT2 is highly expressed mainly in 
the stomach and colon, whereas C2GnT3 is highly expressed mainly in the small intestine, liver 
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and spleen (Stone et al., 2009) (Figure 1.5). On the other hand, C2GnT1 is more widely 
expressed in most tissues (Yeh et al., 1999).  
 
 
Figure 1.5. Relative expression levels of C2GnT2 and C2GnT3 in various murine tissues.  
Based on data from (Stone et al., 2009). 
 
The C2GnT gene (C2GnT1) was first cloned from humans in 1992 (Bierhuizen, 1992) 
and since then many efforts have been directed towards fully understanding core 2 O-glycans and 
the enzymes involved. C2GnT1-deficient mice have been shown to suffer severe but selective 
defects in selectin ligand biosynthesis, demonstrated by the reduction in neutrophil rolling but not 
lymphocyte homing (Ellies et al., 1998). These early results already indicated that there is a 
possibility of more than one C2GnT enzyme existing. In 2004, Hiraoka et al. showed that core 2 
O-glycans, via the sialyl Lewisx (SLex) terminal antigen, are crucial for lymphocyte homing in 
mice (Hiraoka et al., 2004). This finding was further clarified by Gauguet et al. in 2004, who 
suggested that C2GnT1 exerts differential control over B- and T-lymphocyte homing (Gauguet et 
al., 2004). Recently, human C2GnT1 has been demonstrated to prefer a core 1 substrate on a 
hydrophilic glycopeptide rather than those having aromatic groups, suggesting a role of the 
peptide moiety in regulating C2GnT1 activity (Brockhausen et al., 2009).  
 
In 1999, Yeh et al. and Schwientek et al. separately cloned a second C2GnT gene from 
humans (C2GnT2), primarily expressed in mucus secretory tissues, and proposed the idea that 
C2GnT2 could also be involved in synthesizing core 4 O-glycans and I-branches on O-glycans 
(Schwientek et al., 1999; Yeh et al., 1999). I-branches were originally thought to be solely 
produced by IGnT isoenzymes (see Section 1.2.3). Murine C2GnT2 also has been characterised 
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to have similar enzymatic properties as the human counterpart (Hashimoto et al., 2007). In line 
with the fact that most cancer cells express simple O-glycan structures (Brockhausen, 1999; 
Burchell et al., 1999), human C2GnT2 has been shown to suppress the adhesion, motility and 
invasion of colorectal cancer cells. It was evident that this enzyme is frequently downregulated in 
cancer patients and cancer cell lines (Huang et al., 2006). C2GnT3, which was first cloned from 
humans in 2000, has been postulated to play an important role in T-cell biology due to its 
relatively high expression in human thymus (Schwientek et al., 2000). It was demonstrated that 
EGF preferentially inhibited C2GnT2 whereas C2GnT1 was moderately affected in the human 
airway adenocarcinoma cell line, contributing to the shifting of the carbohydrate structures of 
MUC1 in the cells from core 2-based towards core1-based (Beum et al., 2003). These findings 
have highlighted potential differences in biological functions and regulation amongst the 
C2GnTs. Accordingly, a human airway epithelial cell line exhibited upregulation of C2GnT2 
upon stimulation by interleukin-4 and -13 and retinoic acid. However C2GnT3 was shown to be 
only moderately upregulated by the interleukins (Beum et al., 2005).  
 
Although oligosaccharide functions are mostly determined by terminal antigens, it has 
been demonstrated that their synthesis is often not regulated through terminal or intermediate 
glycosyltransferases, but by the branching glycosyltransferases, such as C2GnT, that allow the 
generation of the scaffold for terminal epitopes. For example, it has been reported that C2GnT1, 
but not C2GnT2 or C2GnT3, regulates the synthesis of SLex structures that are preferentially 
downregulated during human B cell differentiation (Kikuchi et al., 2005). Even though many 
biological functions of C2GnTs have been suggested, particularly of human C2GnT1, previous 
studies have provided little evidence to associate their findings specifically with glycan structures 
that are initiated by the different isoenzymes.  
 
In addition to the ambiguities regarding the roles of C2GnT2 and C2GnT3, it is also still 
unclear how much these three isoenzymes compensate each other’s activities in vivo. Therefore, it 
is important to investigate the correlation between C2GnT properties and the aetiology of 
diseases and the necessities of having multiple enzymes to produce core 2 O-glycans. To this end, 
mice with separate deficiencies of C2GnT2 and C2GnT3 as well as all three C2GnTs have been 
generated by our collaborators Jamey Marth and colleagues from the University of California San 
Diego, USA. Results of comprehensive O-glycomic analysis of these mice correlated with the 
phenotypic findings of our collaborators are presented in Chapter 3 of this thesis.  
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1.2.3 Glycan extension, branching and terminal epitopes 
Both N- and O-glycans can be extended with poly-N-acetyllactosamine (poly-LacNAc) 
chains and decorated with various types of sialylation and fucosylation. There are two types of 
poly-LacNAc chain based on the N-acetyllactosamine (LacNAc) constituent units. The type 1 
LacNAc unit sequence is Galβ1-3GlcNAc, whereas the type 2 unit is Galβ1-4GlcNAc. The slight 
distinction of monosaccharide linkages between these two units when polymerised in a chain can 
highly influence the conformation of the overall glycan structure, thus providing different binding 
surfaces. Furthermore, different poly-LacNAc chains could lead to the synthesis of different 
terminal epitopes. Poly-LacNAc chains are produced by concerted actions of β1,3-N-
acetylglucosaminyltransferase (i-extension enzyme or iGnT) and β1,3/4-galactosyltransferases 
(β3/4Gal-T) (Seko et al., 1996; Ujita et al., 2000). It has also been proposed that poly-LacNAc 
chains on core 2 O-glycans and core 4 O-glycans are most efficiently synthesised by β4Gal-T IV 
and β4Gal-T I (Ujita et al., 2000). However, to date only type 2 LacNAc units have been shown 
to be capable of polymerisation to form poly-LacNAc chains on N- and O-glycans (Ujita et al., 
1998; Ujita et al., 1999). Elongated type 1 LacNAc units have only been demonstrated on the 
oligosaccharides of lactosylceramides (Fan et al., 2008).   
 
Linear LacNAc chains can be branched on position 6 of a Gal residue by IGnT and 
C2GnT (Yeh et al., 1999). There are two types of I-branching activities. Distally-acting IGnT 
(dIGnT) initiates branching at sites closer to non-reducing termini whereas centrally acting IGnT 
(cIGnT) acts at internal sites of poly-LacNAc chains (Figure 1.6). It has been demonstrated in 
vitro that on a branched oligosaccharide, extension is more common on the backbone chain than 
on the I-branch when incubated with iGnT and  β4Gal-T I (Ujita et al., 1999). Originally, the 
importance of I-branches was demonstrated by the analysis of band 3 glycoprotein of human 
erythrocytes. The conversion of i-antigen (linear LacNAc chain) to I-antigen (branched LacNAc 
chains) is critical in the development of erythrocytes (Fukuda et al., 1979). The I-branch allows 
multivalent terminal epitopes to be synthesised, therefore replicating binding possibilities. For 
example, H antigens present on both termini of branched LacNAc chains provide better avidity to 
anti-ABO antibodies than a single epitope on linear LacNAc chains (Romans et al., 1980). 
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Figure 1.6. The bionsynthesis and elongation of I-antigen/I-branch. 
I-antigen is biosynthesised from i-antigen by C2GnT2 or IGnTs and the elongation is initiated by β1,4-
galactosyltransfrase. dIGnT and cIGnT activities are independent of each other.  
 
Terminal epitopes are often the functionally important component of a glycan molecule. 
Certain terminal epitopes are classified based on the type of LacNAc chain they are residing on, 
for instance histo-blood group antigens type 1 and type 2. Histo-blood group antigens include A, 
B, H/O, Lewis (Le) antigens and their derivatives (Lewis antigens will be discussed in more 
detail in the next section). In addition to these antigens, Sda, Galα1,3Gal, LacdiNAc, and 
sialylated LacNAc are also common  terminal epitopes on N- and O-glycans. The structures of 
these terminal epitopes are shown in Figure 1.7. Protein-glycan interactions, as has been 
discussed earlier, are mostly mediated by these sequences. For example, P and E-selectins have 
been shown to bind to SLex structures on O-glycans of PSGL-1 and this is important for 
leukocyte homing on endothelial cells (Kawar et al., 2008). 
 
Chapter 1    31 
 
 
Figure 1.7. The most common terminal epitopes found on mammalian glycans. 
Type 1 Lewis antigens and the Galα1,3Gal epitope are known to be absent in mice and humans, 
respectively. Some of the epitopes including Lea/x and Leb/y could be duplicated on the penultimate LacNAc 
unit. Sialic acids depicted could be either N-acetylneuraminic acid (NeuAc) or N-acetylglycolylneuraminic 
acid (NeuGc). Red and blue numbers/letters represent LacNAc type 1 and type 2, respectively, whereas 
those in black are for general annotations. S, sulphate group. 
 
Glycan epitopes on host cell surfaces are also specifically recognised by microbial agents 
to initiate colonisation. These microbes sometimes exploit molecular mimicry by expressing host 
glycan epitopes to avoid being recognised as foreign by the host immune systems. As an 
example, the human gut is a home for millions of bacteria that mutually and continuously interact 
with the mucosal layer (mostly in the intestine) which have important effects, including host 
immune function and nutrient processing (Hooper & Gordon, 2001). There are also pathogenic 
interactions for instance, as mentioned earlier, those utilised by H. pylori aided by its host-glycan 
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mimicry to infect human stomach. Another example would be Pseudomonas aeruginosa, which 
infects human lungs and kidneys. This bacterium expresses the lectin LecB, that binds to SLea, 
and, interestingly, with much lower affinity to SLex (Imberty et al., 2004). A number of species of 
human parasitic helminths also express Lex epitopes on glycoproteins and glycolipids found on 
their surface or within their secretory products in all life stages (van Die & Cummings, 2010). 
 
1.2.3.1 Lewis antigens 
Lewis (Le) antigens are biochemically related to the ABH blood group antigens, that are 
formed as terminal epitopes on carbohydrate chains type 1 or type 2 of both glycolipids and 
glycoproteins (Moran, 2008), as shown in Figure 1.7. The biosynthesis of Lewis antigens starts 
from the competitive actions of glycosyltransferases including α1,2-fucosyltransferases, α1,3/4-
fucosyltransferases and  α2,3-sialyltransferases. The first enzyme leads to the synthesis of H 
antigens type1/2, which then serve as substrates for the synthesis of A, B, Leb/y, and A/B-Leb/y 
antigens. The actions of α1,3-fucosyltransferase and α1,4-fucosyltransferase on the penultimate 
GlcNAc  produces Lex and Lea antigens, respectively. If the terminal Gal is readily sialylated 
prior to the fucosylation, the antigens Sialyl-Lex (SLex) and Sialyl-Lea (SLea) are formed instead. 
These determinants could also carry sulfate esters, mainly at the 3-hydroxyl of Gal and/or the 6-
hydroxyl of GlcNAc (Brockhausen, 1999). 
 
The most common Lewis antigens in human secretions are Lea, Leb, Lex, Ley, SLex and 
SLea. However in mouse, the orthologous gene for human FuT3, the only enzyme known to 
produce 4-linked fucose, is found to be a pseudogene (Gersten et al., 1995). Therefore, it has 
been assumed that mice do not synthesise Lea, Leb, SLea and their sulphated derivatives although 
this assumption is now being questioned due to preliminary findings by our collaborators, Celso 
Reis et al. from University of Porto, Portugal. Anti Lea and anti Leb monoclonal antibodies were 
found to be able to bind to murine gastric mucosa, suggesting the existence of a functional α1,4-
fucosyltransferase in mice.  
 
Structural evidence that assertively distinguishes Lea and Leb from Lex and Ley in murine 
tissues has not been applied to previous H. pylori adhesion studies, therefore leaving ambiguities 
in their binding/staining-based characterisation. Parry et al., as an example, have proven that 
mass spectrometric analysis is able to identify SLex in mice (Parry et al., 2007). It is anticipated 
that with further improvement and modification, this technique in addition to chemical and 
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enzymatic digestion, can shed light on the Lewis antigen repertoire in the highly complex 
glycosylation of the murine GI tract. 
 
Classical models assume that Leb and Ley structures are synthesised from H antigen type 
1 and 2, respectively. However, it has been shown in some human cancer tissues and cells that 
there is an unusual α1,2-FuT activity that could add fucose to monofucosylated antennae, i.e. 
allowing the synthesis of Leb from Lea or Ley from Lex (Wang et al., 1999). It has been revealed 
that in mucinous tissues, FuT2 (secretor enzyme) is the main enzyme that catalyses the addition 
of α1,2-fucose residues (Hurd et al., 2005), however there is no evidence so far on which 
pathway is the most dominant in the murine GI tract. In order to better understand the 
biosynthesis of the fucosylated Lewis antigens in the mouse, it is best to first explore the 
fucosyltransferase population in this organism.  
 
1.2.3.2 Functional significance of fucosyltransferases 
Fucosylation appears to be one of the most frequent modifications in eukaryotic cells 
involving oligosaccharides including N- and O-glycans, but rather limited in prokaryotic 
organisms (Ma et al., 2006). Changes in the levels of fucosylation in mammalian cells point to its 
significance in a number of pathological conditions, including inflammation and cancer, and the 
biological functions of adhesion molecules such as selectin ligands (Miyoshi et al., 2008). The 
regulation of fucosylation seems to be complicated with the existence of fucosyltransferases 
(FuTs) with distinct but overlapping specificities and different tissue expressions, in addition to 
other enzymes involved in the synthesis and transport of GDP-fucose, the sugar nucleotide donor 
for fucosylation (Becker & Lowe, 2003). Generally, FuTs are a group of enzymes that catalyse 
the addition of fucose from GDP-fucose, either to amino acid residues or to other sugars. On 
oligosaccharides, fucose can be linked at position 2 of Gal or 3, 4 or 6 of GlcNAc, contributing to 
the vast variety of glycan epitopes and functional properties. Even though mice have become a 
very important model in human biological research (see Section 1.3.1), little is known regarding 
their FuTs and they are often confused with the relatively better studied human FuTs. To date, 
there are 8 FuTs in mouse that have been cloned or described in publications (Table 1.1); 
nonetheless, there are still many ambiguities with respect to their specificities. Humans, on the 
other hand, have at least 11 FuTs with known biological activities (Becker & Lowe, 2003).  
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Table 1.1. Fucosyltransferases in mice and humans with their respective activities. 
The list of fucosyltransferases were extracted from the database of Murine Genome Informatics 
(www.informatics.jax.org) (Bult et al., 2008)  without including protein-O-fucosyltransferases. 
Name Enzymatic activity Major biological activity(s) 
FuT1 (Humans & 
mice) 
α1,2 fucosylation Synthesises blood group H antigens in 
erythrocytes (Larsen et al., 1990; Domino et al., 
2001) 
FuT2/ Secretor 
(Humans & mice) 
α1,2 fucosylation Synthesises blood group H antigens in secretions 
(Kelly et al., 1995; Domino et al., 2001) 
FuT3 (Humans) α1,3/4 fucosylation Synthesises Lewis antigens type 1 and 2 
(Kukowska-Latallo et al., 1990) 
FuT4 (Humans & 
mice) 
α1,3 fucosylation Controls LeX synthesis (Kumar et al., 1991; 
Homeister et al., 2001) 
FuT5 (Humans) α1,3 fucosylation Synthesises Lewis antigens (Weston et al., 1992) 
FuT6 (Humans) α1,3 fucosylation Direct the synthesis of Lex and SLex (Weston et 
al., 1992) 
FuT7 (Humans & 
mice) 
α1,3 fucosylation Controls leukocyte trafficking via E, L and P-
selectin ligand formation- SLex (Sasaki et al., 
1994; Malý et al., 1996) 
FuT8 (Humans & 
mice) 
α1,6 fucosylation N-glycan core fucosylation (Yanagidani et al., 
1997; Becker & Lowe, 2003) 
FuT9 (Humans & 
mice) 
α1,3 fucosylation Controls LeX and Ley but not SLex synthesis in 
brain and stomach (Kaneko et al., 1999; Kudo et 
al., 2007)  
FuT10 (Humans 
& mice) 
α1,3 fucosylation Core fucosylation of biantennary N-glycans 
(Baboval & Smith, 2002; Mollicone et al., 2009) 
FuT11 (Humans 
& mice) 
α1,3 fucosylation Core fucosylation of biantennary N-glycans 
(Baboval & Smith, 2002; Mollicone et al., 2009) 
 
In humans and mice, FuT2 is responsible for the synthesis of α1,2-fucose on a terminal 
Gal and also the associated structures derived from this sequence in epithelial cells and body 
fluids. FuT2 was shown in vitro to have higher affinity for type 2 LacNAc chains but lower 
affinity for type 1 LacNAc chains, as compared to FuT1 (Sarnesto et al., 1992). Individuals with 
inactivating mutations in the FuT2 gene are known as non-secretors and they appear to have 
limitations in synthesising ABO blood group antigens in their epithelial secretions. Unlike non-
secretors, who can only produce Lex and Lea histo-blood group antigens and their sialylated 
counterparts, secretors (normal individuals) have the capability to also produce H antigens and 
difucosylated Lewis antigens which can be found along the GI tract (Lindén et al., 2008). 
Chapter 1    35 
 
However, it has been reported that MUC5B mucin from the non-secretors demonstrated higher 
expression levels of sialylated epitopes (Thomsson et al., 2005). 
  
  An interesting variation in susceptibility towards H. pylori’s infection relating to the 
secretor status in humans has been observed (Ikehara et al., 2001). It was shown that secretor 
individual are more prone to be infected by blood group antigen-binding adhesin (BabA) positive 
strains than the non-secretors, the latter consisting of about 20% of the western population 
(Azevedo et al., 2008). Infected secretor animals have been shown to have higher gastric mucosal 
density of H. pylori, gastritis and sialylation compared to the non-secretors (Lindén et al., 2008). 
Furthermore, individuals with blood group O phenotype have a higher incidence of gastric ulcers 
than other blood group individuals, which might indicate the importance of exposed fucosylated 
terminal epitopes in H. pylori infection (Borén et al., 1994). However, incapability of producing 
α1,2-fucose is not always a health advantage. A statistical analysis has shown significant data  
that non-secretor individuals have higher susceptibility towards Crohn’s disease (McGovern et 
al., 2010).  
 
To help resolve ambiguities concerning the H and Lewis antigens and the adhesion of H. 
pylori, a mouse model with deficiency in FuT2 has been generated and characterised. 
Furthermore, this model closely resembles the non-secretors, which could provide tools to better 
understand the differences between this phenotype and the secretors (wild type) as well as the 
diverse pathogenicity of H. pylori (see Section 1.2.5). Results of this study are presented in 
Chapter 4.      
 
1.2.3.3   Carbohydrate recognition by lectins 
As discussed earlier, glycans are capped with a variety of functionally important terminal 
structures. Turning biological information stored in these epitopes into an operative sugar code 
entails the existence of efficient decoding devices such as lectins (Soils et al., 2009). Lectins 
comprise various intracellular and extracellular receptors that bind to carbohydrate molecules. 
Lectins are most commonly classified according to their CRD properties (Taylor & Drickamer, 
2006). Because this thesis focuses on murine glycosylation, it is pertinent to consider which 
lectins are found in this animal. Known murine lectins are listed in Table 1.2 with their respective 
properties. In the context of the mouse as a model animal (see Section 1.3.1), it is important to 
bear in mind that not all human lectin genes have an orthologous partner in the murine genome. 
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For instance, the human genome codes for at least 13 functional siglecs (Crocker et al., 2007), in 
contrast to only 9 in mice. Furthermore, at least 10 functional galectins have been identified in 
humans (www.uniprot.gov) (Consortium, 2010) whereas in mice there are only 7 known so far. 
 
Table 1.2. Families of the most common murine lectins and their properties. 
The list of lectins were extracted from the database of Murine Genome Informatics 
(www.informatics.jax.org) (Bult et al., 2008) and the CFG, Consortium for Functional Glycomics glycan 
array data (www.functionalglycomics.org).  
Family Typical members Expression sites Main ligands 
C-type Selectins: 
L-selectin (CD62L) 
 
 
P-selectin (CD62P) 
 
 
E-selectin (CD62E) 
 
 
Lymphocytes (Lasky 
et al., 1989). 
 
Activated endothelial 
cells (EC), platelets 
(Sanders et al., 1992). 
Activated EC (Becker-
Andre et al., 1992). 
 
 
SLex on core 2 and sulphated 
tyrosines on PSGL-1 and 
endoglycan (Leppänen et al., 2010). 
SLex on core 2 and sulphated 
tyrosines on PSGL-1 (Leppänen et 
al., 2010). 
SLex on N-glycans of CD44 and 
ESL-1 and core 1 and core 2 O-
glycans of PSGL-1 (Ellies et al., 
1998; Yago et al., 2010). 
Collectins: 
Mannose-binding 
protein/receptor. 
Surfactant proteins 
A and D. 
 
Serum/ liver (Sastry et 
al., 1991). 
Alveolar  (Motwani et 
al., 1995) 
 
Terminal mannose, fucose, glucose, 
GlcNAc (Weis et al., 1992). 
Glucosyl residues of cells, virus and 
microbes (Kishore et al., 2006).  
SIGNR1 and 
SIGNR5 
Macrophages 
(Galustian et al., 
2004) 
High-mannose N-glycans, Lex, Lea 
on microbial surface polysaccharides 
(Galustian et al., 2004; Powlesland 
et al., 2006).  
SIGNR3 (DC-SIGN) Dendritic cells, 
macrophages, 
monocytes (Nagaoka 
et al., 2010). 
High-mannose N-glycans, 
fucosylated glycans (Galustian et al., 
2004; Powlesland et al., 2006).  
SIGNR7 Testis, liver 
(Powlesland et al., 
2006). 
SLex and Sulfo-SLex (Powlesland et 
al., 2006). 
Macrophage 
galactose lectin 
(MGL) 1 and 2. 
Macrophages and 
dendritic cells (Sato et 
al., 1992; Denda-
Gal, GalNAc, Lex (Oda et al., 1989; 
Sato et al., 1992; Tsuiji et al., 2002). 
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Nagai et al., 2002). 
Galectins Galectin 1 
 
Galectin 3 
 
Galectin 4 and 6 
 
 
Galectin 7 
 
Galectin 9 
 
 
 
Galectin 12 
Thymus (Earl et al., 
2010). 
Various immune cells 
(Liu, 2005). 
Small intestine, colon, 
kidney, liver (Markova 
et al., 2006). 
Epithelial cells (Sato 
et al., 2002). 
Lymphocytes, liver, 
small intestine, 
thymus (Wada & 
Kanwar, 1997). 
Adipocytes (Hotta et 
al., 2001). 
β-galactosides including H antigen 
(CFG). 
β-galactosides including H antigen 
(CFG). 
α-GalNAc and α-Gal (Markova et al., 
2006). 
 
β-galactosides including H antigen 
(CFG). 
β-galactosides including H antigen 
(CFG). 
 
 
β-galactosides including H antigen 
(CFG). 
I-type Siglec-1/ 
sialoadhesin 
Siglec-2/ CD22 
 
Siglec-3/ CD33 
 
 
 
Siglec-4/ Myelin-
associated 
glycoprotein  
 
Siglec-5/ Siglec F 
 
 
Siglec-15 
 
 
 
Siglec-E 
 
 
Siglec-G 
 
Macrophages 
(Crocker et al., 1994) 
B cells (Crocker et al., 
2007). 
Myeloid precursors in 
bone marrow 
(Brinkman-Van der 
Linden et al., 2003). 
Oligodendrocytes, 
Schwann cells 
(O'Reilly & Paulson, 
2009). 
Eosinophils (Zhang et 
al., 2004). 
 
Macrophages/ 
dendritic cells 
(humans) (Angata et 
al., 2007). 
Various cells of innate 
immune system 
(Zhang et al., 2004). 
B cells (Hoffmann et 
al., 2007). 
NeuAcα2,3Galβ1,3GalNAc (Crocker 
et al., 1994). 
α2,6-linked sialic acid (Hoffmann et 
al., 2007). 
Short O-glycans and sialyl-Tn 
(Brinkman-Van der Linden et al., 
2003). 
 
NeuAcα2,3Galβ1,3GalNAc (O'Reilly 
& Paulson, 2009). 
 
 
α2,8-linked disialic acid (Zhang et al., 
2004), 6-sulfo-SLex (Tateno et al., 
2005). 
NeuAcα2,6GalNAc (humans) 
(Angata et al., 2007). 
 
 
α2,3/6-linked sialic acid (Hoffmann et 
al., 2007). 
 
α2,6-linked sialic acid (Nitschke, 
2009). 
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Siglec-H Dendritic cell 
precursors and 
macrophages in 
spleen, lymph nodes 
and interferon-
producing cells 
(Blasius et al., 2006; 
Zhang et al., 2006). 
Sialylated glycans (Blasius et al., 
2006). 
 Calnexin and 
Calreticulin 
Ubiquitous Glc1Man9GlcNAc2 (Ware et al., 1995; 
Spiro et al., 1996) 
 
The selectins are arguably the best characterised family of C-type lectins (which bind 
sugars in a Ca2+-dependent manner). They are expressed on endothelial cells, leukocytes and 
platelets, and have extensively documented roles as mediators for leukocyte and platelet rolling. 
In humans, selectins bind to sulphated/non-sulphated sialyl (NeuAc) Lex and (in some instances) 
sulphated amino acids on selective carriers (Carlow et al., 2009). Recently, it has been proven 
that selectins can bind to both N-acetylneuraminyl and N-glycolylneuraminyl forms of SLex and 
6-sulfo SLex, the latter form is the most prominent in murine tissues (Mitoma et al., 2009). The 
same study also highlighted that a number of anti-Lex antibodies raised against human cells do 
not recognise murine SLex ligands, illustrating disparities in the binding mechanism between 
anti-carbohydrate antibodies and lectins. Weak α1,3-fucosylation activity by FuT7 was shown to 
have higher impact on E-selectin than on P-selectin or L-selectin binding efficiency on PSGL-1, 
which is explained by the latter two selectins’ requirement of tyrosine sulphation in addition to 
core 2 O-glycans for proper binding (Prorok-Hamon et al., 2005). The molecular basis for 
differential ligand recognition by selectins has started to be elucidated. For instance it was 
revealed that the substitution of a single residue in the CRD of L-selectin increases its affinity 
towards the sulphated peptide binding site but not to the sulphated glycan binding site (Klopocki 
et al., 2008).  
 
As lectin receptors play central roles in mediating and modulating immune responses, 
elucidation of their ligand-binding properties is definitely of importance. For instance, C-type 
lectins have been identified to play crucial roles in regulating immune responses towards 
Candida albicans and thus are now an important target for vaccine development (Ferwerda et al., 
2010). Similarly, galectin-1, but not galectin-3, increased human immunodeficiency virus-1 
(HIV-1) infectivity on macrophages, most likely due to the distinction in virus adsorption kinetics 
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with galectin (Mercier et al., 2008). This finding is in parallel with previous analysis on the 
binding thermodynamics of galectin-1 and -3, with one of the disparities being the former’s lower 
affinity towards 2,6-sialylated diLacNAc (Ahmad et al., 2002). In addition, HIV-1 also has been 
shown to utilise the binding to DC-SIGN to induce kinase Raf-1 signalling cascades leading to 
the generation of full-length viral transcript for its replication (Gringhuis et al., 2010). 
 
DC-SIGN plays critical functions in immune regulation by recognising a wide variety of 
pathogens not just viruses but also bacteria, yeast and parasites via the binding of mannose and 
Lex structures. Additionally it serves as an adhesion receptor via binding to intracellular adhesion 
molecule 2 (ICAM 2) and ICAM 3 present in the membrane of leukocytes and endothelial cells 
(van Kooyk & Geijtenbeek, 2003). For instance, mice deficient in DC-SIGN, but not those that 
are deficient in SIGNR-1 or -5, exhibited reduced resistance towards Mycobacterium tuberculosis 
infection, illustrating its unique contribution to host protection (Tanne et al., 2009). Detailed 
specificity of human DC-SIGN has been demonstrated with the highest binding being attributed 
to Lex (preferably multivalent type) followed by high-mannose and fucosylated biantennary N-
glycans, but no binding to core fucosylated N-glycans was observed (van Liempt et al., 2006). 
 
Siglecs have been regarded as positive and negative regulators of the immune system 
expressed mainly on various subsets of leukocytes (Crocker & Redelinghuys, 2008). For instance 
human MUC2 was shown to bind to siglec-3 on the surface of monocyte-derived dendritic cells 
and induces apoptosis (Ishida et al., 2008). As mucins are commonly expressed by cancer tissues, 
this mechanism confers protection from immune cells. Several other siglecs including siglec-1 
and -5, on the other hand, have been postulated to mediate the interactions between macrophages/ 
neutrophils and sialylated bacteria lipopolysaccharide thereby playing a potentially protective role 
during infections (Jones et al., 2003). The restricted expression of several siglecs to specific cell 
types makes them attractive targets for cell-directed therapies (O'Reilly & Paulson, 2009). 
 
Some lectins play important intracellular roles and are mostly involved in protein sorting 
and dislocation in the ER, illustrating the importance of proper glycosylation on the fate of newly 
synthesised glycoproteins. Calreticulin, a soluble protein in the lumen of the ER, together with its 
membrane-bound homologue, Calnexin, independently associates with a disulfide isomerise 
ERp57 and functions in capturing misfolded or incompletely folded proteins tagged with 
Glc1Man9 N-glycans. This is to ensure proper protein folding by Erp57 before further 
glycosylations and modifications on the glycan structures (Maattanen et al., 2010). This event has 
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been indirectly demonstrated by the analysis of C2GnT1 with a mutation in one of its two N-
glycosylation sites by Prorok-Hamon et al. The N-glycan on Asn-95 was found to be essential for 
Golgi targeting and the ability of the enzyme to initiate the formation of a functional PSGL-1 
(Prorok-Hamon et al., 2005). Recent findings have suggested that Calreticulin might be secreted 
into the extracellular milieu where it could perhaps regulate a wide range of cellular responses 
including immune responses (Gold et al., 2010).      
 
1.2.4   Mucins 
Mucins are large and filamentous glycoproteins that can be either membrane-bound or 
secreted. Typically, the backbone of a membrane-bound mucin (apomucin) contains a long 
extracellular domain, a hydrophobic transmembrane domain and a short cytoplasmic tail (Taylor 
& Drickamer, 2006). Membrane bound mucins also contain several other conserved domains 
including epidermal growth factor (EGF)-like, sea urchin sperm protein Enterokinase and Agrin 
(SEA) and tandemly repeated proline/threonine/serine (PTS) domains (Dekker et al., 2002; Van 
Seuningen & Jonckheere, 2008) (Figure 1.8). Secreted mucins, on the other hand, can be found in 
secretory cells such as gastric mucous cells and intestinal goblet cells and can be either gel-
forming (for instance Muc2, Muc5AC, Muc5B, Muc6 and Muc19) or non gel-forming (for 
instance Muc9). The polypeptide backbone can be grouped into several domains including the 
amino terminal disulphide-rich von Willebrand factor (VWF)-D-like and VWF-C-like domains, 
the cystine-rich CK (cystine-knot) and CYS domains and PTS-rich tandem repeat domains 
(Perez-Vilar & Hill, 1999; Dekker et al., 2002) (Figure 1.8). The PTS domain is an important 
substrate for O-glycosylation especially O-GalNAc. 
 
 
Figure 1.8. Schematic representation of typical mucin domains 
Top, membrane-bound mucins (MUC1); bottom, secreted mucins (MUC2). Empty spaces represent 
unique sequences.   
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The main characteristic of mucins is the variable number of tandem repeat (VNTR) 
regions that are rich in serine and threonine (PTS domain) and are highly glycosylated with O-
GalNAc glycans. These regions lack any secondary structure, thus facilitating O-glycosylation of 
the folded protein. The O-glycans are hydrophilic and usually negatively charged and therefore 
promote the binding of water and salts which are the main contributors to the viscosity and 
adhesiveness of mucus (Brockhausen et al., 2009). Oligosaccharides which often comprise 50 – 
80% of mucin mass also play important roles in providing binding sites for microorganisms, 
mimicking those expressed by epithelial cells, thereby promoting their removal by mucus flow 
(Hurd et al., 2005).  Glycosylation patterns contribute different properties to the mucins and thus 
alter the potential for their biological interactions (Patsos & Corfield, 2009). The biophysical 
properties of mucins are speculated to be related to their extensive O-glycosylation rather than 
directly to their polypeptide backbones (Dekker et al., 2002). For these reasons, comprehensive 
characterisation of glycans attached on the mucins as well as mucinouse tissues is necessary to 
better understand their biological roles. However, many of these functionally and structurally 
important glycans have only relatively recently become the focus of rigorous characterisation. 
Despite this, considerable progress has been made. For example, the application of sensitive mass 
spectrometry techniques has enabled detailed structural profiling on isolated human 
MUC16/CA125- and MUC2-derived glycans (Kui Wong et al., 2003; Holmen Larsson et al., 
2009). In addition, Issa and colleagues recently described rigorous sequencing of 
oligosaccharides derived from semi-purified salivary agglutinin, a mucin-like glycoprotein, using 
LC-ESI-MSn in the negative ion mode (Issa et al., 2010). Nevertheless, analyses on mucinous 
tissues/organs so far have provided data mostly restricted to glycan mass and compositions 
without rigorous structural profiling, for example analyses on human intestinal tract (Robbe, 
2004; Robbe-Masselot et al., 2009) and murine colon (Hurd et al., 2005). 
 
The nomenclature of mucins is based on their protein backbones, which are encoded by 
MUC genes. Nevertheless, a standard criteria to define a glycoprotein as a mucin is not readily 
available, which has resulted in some discrepancies in the number of designated MUC genes 
(Dekker et al., 2002; Rose, 2006). According to the Human Genome Organization Gene 
Nomenclature Committee (www.genenames.org) (Bruford et al., 2008), currently there are 20 
MUC genes in humans. However, their homologs in the murine genome are poorly characterised 
and are associated with a number of ambiguities (Escande et al., 2004) (Table 1.3). For example, 
earlier characterisation of murine Muc5B and Muc6 showed expression of these mucins in 
stomach and submaxillary glands, respectively (Escande et al., 2002; Desseyn & Laine, 2003), 
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but they were not detected in more recent work (Escande et al., 2004). Furthermore, a previous 
study revealed that murine Muc3 has higher sequence identity to human MUC17 than human 
MUC3 (Moniaux et al., 2006), thus raising the possibility of discrepancy in other human-mouse 
orthologue assignments that can complicate the understanding of their respective biological 
functions.  
 
Table 1.3. List of known murine mucin genes with respective human orthologues and expression 
sites.  
This information was extracted from the database of Murine Genome Informatics (www.informatics.jax.org) 
(Bult et al., 2008).  
Mucin name Human orthologue Expression sites 
Membrane-bound 
Muc1  MUC1 /polymorphic 
epithelial mucin (PEM) 
(70% homology) 
Colon, breast (Spicer et al., 1991; Van 
Seuningen & Jonckheere, 2008) 
Muc4  MUC4 (60% homology) Human trachea-bronchial  mucosa (Desseyn 
et al., 2002; Van Seuningen & Jonckheere, 
2008) 
Muc12 MUC12 Colon (Williams et al., 1999; Van Seuningen 
& Jonckheere, 2008) 
Muc13 MUC13 Intestines, trachea, stomach, kidney (Van 
Seuningen & Jonckheere, 2008) 
Muc16  MUC16 /CA125 (48% 
homology) 
Female reproductive organ, cornea, trachea 
(Cheon et al., 2009) 
Muc3/ Muc17  MUC17 (60% homology) Intestine (Moniaux et al., 2006) 
Muc20  MUC20 (61% homology) Kidney, placenta, lung, liver (Van Seuningen 
& Jonckheere, 2008) 
Epiglycanin MUC21 Lung, large intestine, thymus, testis (Itoh et 
al., 2008) 
Secreted mucins 
Muc2 MUC2 Small & large intestines  (Van Klinken et al., 
1999; Escande et al., 2004) 
Muc5AC MUC5AC Stomach (Escande et al., 2004) 
Muc5B MUC5B Laryngo-tracheal tissue (Escande et al., 
2004) 
Muc6 MUC6 Stomach (Escande et al., 2004) 
Muc9/ Oviductal 
glycoprotein 1 
MUC9 Ovary tract (Lyng & Shur, 2009) 
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Muc19/ 
submandibular gland 
protein c 
MUC19 Sublingual gland (Das et al., 2009) 
 
The properties of a mucin are highly influenced by internal and external factors. For 
example, the composition of mucinous layers is regulated by various genes and epigenetic factors 
such as DNA methylation and histone modifications (Vincent et al., 2008). The thickness of the 
layers has been shown to vary throughout the gastrointestinal tract (Atuma et al., 2001), probably 
to adapt to the specific environment of each section. It is also believed that mucin expressions are 
influenced by other exogenous factors, for instance the colonisation by commensal and temporary 
microorganisms (Marcos et al., 2008).  
 
Mucins are the main component of the mucosal barrier in the respiratory, reproductive 
and gastrointestinal (GI) tract. The highly O-glycosylated domains of mucin (the tandem repeats) 
form a semi-rigid and relatively inflexible structure (Perez-Vilar & Hill, 1999), making these 
molecules excellent as a component of protective barriers. The mucosal barrier is made up of 
several layers (Patsos & Corfield, 2009). The uppermost layer is the mucus gel which constitutes 
many secreted mucinous proteins and peptides. Beneath the mucus gel is the glycocalyx which 
mainly consists of membrane-bound mucin glycoproteins and glycolipids. The final component 
of the mucosal barrier is comprised of the mucosal cells that supply mucins and serve as a 
physical barrier against invasion by bacteria. In addition, mucosal layers also integrate both 
innate and adaptive immune elements (Corfield et al., 2001). Their strategic position places the 
mucins at centre stage in many disease processes in which interactions between epithelial cells 
and their surroundings have been interrupted (Dekker et al., 2002), usually involving lectins, as 
discussed earlier. However, most of these interactions and many other properties of the mucus 
barrier remain to be fully elucidated. 
 
Mucins have been implicated in many important biological events including 
inflammation, host-pathogen interactions and cancer metastasis (Hanisch & Muller, 2000). For 
example, mucins are expressed or secreted by epithelial cells towards the lumen of a healthy 
vesicular organ, but in malignant cells, mucins are expressed on all aspects of the cells and could 
enter the extracellular space or body fluids (Varki et al., 2009). Cancer cells also express aberrant 
amounts or forms of mucin, the knowledge of which is being utilised towards the prevention, 
detection, control of and cure for carcinoma (Hollingsworth & Swanson, 2004). For instance, 
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CA125 has provided a useful serum tumour marker for monitoring responses to treatments for 
ovarian cancer (Bast et al., 2005). The density of glycosylation on mucins expressed by different 
tumours and normal cells is also highly variable, and is believed to contribute significantly to 
normal and aberrant functions during pathogenesis of cancer and other diseases (Hanisch & 
Muller, 2000). However, due to the mucinous biophysical characteristic and the relatively large 
mass, it has been very challenging to fully define mucin oligosaccharide components, which has 
resulted in a very limited understanding of their functions and regulations. 
 
1.2.5 Helicobacter pylori: a specialist in human stomach colonisation 
H. pylori, a gram negative bacterium, infects more than 50% of the human population and 
is the only bacterial agent known to cause cancer (Fritz & Van Der Merwe, 2009). There might be 
no single most prominent method of human infection, but it has been shown that H. pylori infects 
humans from childhood (Dore et al., 2002) and, when present, it is the most dominant microbe in 
the human stomach (Cover & Blaser, 2009). The outcome of this infection ranges from 
asymptomatic to gastric lesion to gastric adenocarcinoma. Nevertheless, only a small subset of 
the infected population develops any disease. The mechanism of H. pylori infection transmission 
remains unclear but appears to be infrequent compared to other microflora, thus making its 
adherence to host cell surfaces a critical early step in colonisation (Testerman et al., 2001).  
 
The complete genome sequence of H. pylori strain 26695 published in 1997 has identified 
many putative adhesins, lipoproteins and other outer membrane proteins, highlighting the 
potential complexity of host–pathogen interactions (Tomb et al., 1997). Variation in both host and 
H. pylori in the expression of glycan epitopes and also the types of bacterial adhesins may explain 
the wide range of clinical outcomes following the colonisation of H. pylori (Victor & Esko, 
2009). Although the mechanism of how H. pylori infects humans and causes diseases has been 
intensively studied, it remains to be fully understood. The existence of various strains of H. pylori 
with up to 25% variations in gene content (Fritz & Van Der Merwe, 2009) adds to the complexity 
of these studies. The lipopolysaccharide (LPS) of H. pylori is replete with fucosylated Lewis 
antigens including Lea, Leb, Lex and Ley (Wang et al., 2000), and this could facilitate the evasion 
of the host immune response (Appelmelk et al., 1996). This phenomenon is known as bacterial 
mimicry, as it is trying to imitate the surface of stomach mucosa that is highly O-glycosylated and 
often decorated with ABO blood group and Lewis antigens. This illustrates how evolution has 
well adapted H. pylori to colonise the human stomach. 
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Mucin type O-glycans play important roles in the pathogenesis process of H. pylori 
infection. The establishment of a successful infection is highly dependent on the bacterium’s 
capability to tightly adhere to the highly O-glycosylated gastric mucosal layers and epithelial 
cells (Blaser, 1993). This binding is mediated by H. pylori adhesins that recognise glycan 
structures on host glycoconjugates. The inability to adhere to the mucosal layer will result in the 
bacteria’s rapid removal by host-defense mechanisms including peristalsis and ciliary activity 
(Borén et al., 1994) (illustrated in Figure 1.9). The two most studied adhesins of H. pylori are 
blood group antigen-binding adhesin (BabA) and sialic acid-binding adhesin (SabA). A few 
lipoproteins of H. pylori have been speculated to also contribute to the adherence capacity of this 
organism, for example H. pylori adhesin A (HpaA) and HpaA orthologue (Tomb et al., 1997).  
Successful adhesion is critical for efficient delivery of bacterial virulence factor, for instance the 
cytotoxin-associated gene A (CagA), via type IV secretion system that will damage host tissues 
and induce pathological conditions (Hatakeyama, 2004). The binding of the most studied H. 
pylori adhesins and the translocation of its virulence factor is illustrated in Figure 1.10. 
 
BabA-mediated binding of H. pylori is important for initial adhesion to mucosal and 
epithelial layers. BabA is encoded by the babA2 gene and has been shown to bind to fucosylated 
histo-blood group antigens Leb and H type 1 but not to H type 2 (Borén et al., 1994; Ilver et al., 
1998). However, this binding was only demonstrated in vitro using synthetic oligosaccharides and 
antibody staining. Furthermore, the influence of these antigens in successful adhesion of the 
whole bacterium using BabA has not been demonstrated. Bovenkamp et al. later clearly showed 
that H. pylori strains which bind to Leb also bind to MUC5AC in gastric tissue, indicating that 
MUC5AC is an important carrier of Leb in the stomach (Bovenkamp et al., 2003). H. pylori 
binding to H type 1 and type 2 antigens however remains ambiguous. Recently, loss of expression 
of BabA during a course of experimental infection was demonstrated in H. pylori strain J166, 
indicating dynamic expression of BabA as a mechanism to adapt to changes in host glycan 
expression (Styer et al., 2010). Persistent colonisation by H. pylori results in inflammation with 
concomitant expression of sialylated glycans including SLea and SLex, which are aimed to guide 
leukocyte migration via selectins. Sialylated glycans are recognised by SabA. Therefore this 
adhesin functions mainly in maintaining H. pylori binding as the host responds to epithelial 
damages (Mahdavi et al., 2002), taking over the responsibility from BabA.  
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Figure 1.9. H. pylori adherence to gastric mucosa prior to colonisation on epithelial cells.  
Schematic diagram of a stomach cross-section showing H. pylori crucial initial binding to the mucins of 
mucosal layer and later to the surface of epithelial cells to avoid being swept away by gastric flow and 
mucus flow. 
 
 
Figure 1.10. Interaction of the most studied H. pylori adhesins with host cell receptors leading to 
the translocation of CagA. 
TLR, toll-like receptors; LPS, lipopolysaccharides. Based on (Testerman et al., 2001; Algood & Cover, 
2006). 
 
1.2.6 Regulation of protein O-glycosylation 
As discussed earlier (Section 1.2), protein N-glycosylation is initiated on newly 
synthesised unfolded/partially folded proteins in the endoplasmic reticulum (ER) with en bloc 
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transfer of dolichol-linked precursors to Asn. One of the types of O-glycosylation, the O-
mannosylation of serine/threonine, also occurs in the ER. The synthesis of O-GalNAc-linked 
glycans, on the other hand, begins in the cis-Golgi on matured and already folded proteins, and 
only those with serine/threonine containing domains appropriately accessible to the ppGalNAcTs 
will be glycosylated with mucin-type glycans. Most extension and capping glycosyltransferases 
are localised on the membranes of medial- and trans-Golgi, though some enzymes are distributed 
throughout the cisternae. A schematic diagram of N-glycan, O-GalNAc and O-mannose 
biosynthesis on polypeptides from the ER to trans-Golgi, illustrating some of the main 
glycosylating enzymes involved, is shown in Figure 1.11. The distribution of glycosyltransferases 
in specific cisternae of the Golgi favours the synthesis of certain glycans by dictating the order of 
action of the enzymes and limiting enzymatic competition (Tu & Banfield, 2010). It is envisaged 
that the localisation of these glycosyltransferases greatly influences the final glycosylation 
products, which normally varies according to the state of the cell and external inputs.  
 
Cells adapt multiple aspects of their physiology including protein synthesis and 
glycosylation following cues from extracellular molecules, for example growth hormones. 
Regulation of these processes involves signal transduction molecules forming complexes with 
specific subcellular components. A family of signalling molecules known as the Src family 
kinases (SFKs) has been shown to form complexes on Golgi membranes (David-Pfeuty & 
Nouvian-Dooghe, 1990). SFKs are non-receptor tyrosine kinases that interact and modify 
numerous cellular cytosolic, nuclear and membrane proteins by phosphorylating tyrosine 
residues. SFKs comprise nine members including Src, Yes and Fyn that are expressed in a broad 
range of tissues (Boyer et al., 2002). 
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Figure 1.11. Biosynthesis of N-glycans, O-GalNAc and O-mannose on proteins from endoplasmic 
reticulum (ER) to trans-Golgi. 
Structures shown are symbolic of the most common products for each compartment with 
glycosyltransferases involved. OST, oligosaccharyltransferase; GnTs, GlcNAc  transferases; ST3Gal, 
α2,3-sialyltransferase; ST6GalNAc, α2,6-sialyltransferase. 
 
Src is known for its involvement in the regulation of Golgi structure and KDEL-receptor 
(KDEL-R)-dependent retrograde transport from the Golgi to the ER via coat protein complex-I 
(COP-I) mediated transport (Yamamoto et al., 2001; Bard et al., 2003). KDEL-R recognises the 
sequence Lys-Asp-Glu-Leu, an ER-retention sequence which exists in most membrane-bound 
proteins (Yamamoto et al., 2001). Specifically, it has been demonstrated by Bard et al. that in the 
absence of Src, the transport of a KDEL-R-bound protein from Golgi to ER was accelerated, 
which means it was not properly regulated (Bard et al., 2003). However, the exact physiological 
roles of Src at the Golgi remains poorly characterised. COP-I-coated vesicles are vesicular 
carriers that function in the secretory pathway. The mechanism of cargo (Golgi resident enzymes) 
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uptake and delivery by COP-I vesicles involves several cytosolic and transmembrane molecules 
(Béthune et al., 2006). The retrograde transport of luminal and membrane proteins in the ER-
Golgi network is the best characterised function of COP-I-dependent transport (Beck et al., 2009) 
(Figure 1.12). According to Beck and colleagues (Beck et al., 2009), first, GTPase Arf1 is 
activated by a GTP exchange factor GEF1 before dissociating from a dimeric p24 (a family of 
transmembrane proteins) and then Arf1 itself dimerises. Activated Arf1-GTP then recruits 
coatomer to form a complex together with monomeric p24 on the cytoplasmic surface of Golgi 
membrane. Coatomer functions to capture Golgi resident transmembrane proteins including 
KDEL-R. The coat then polymerises and pinches off from the Golgi membrane to form a COP-I 
vesicle carrying KDEL-R possibly bound to its ligands as well as soluble lumen proteins trapped 
in the vesicles. Arf1 can be deactivated by the action of GTPase activating protein 1 (GAP1) 
through GTP hydrolysis, causing the coat to dissociate from the vesicle (Beck et al., 2009). It was 
also suggested that KDEL-R could induce the interaction between GAP1 and Arf1 (Yamamoto et 
al., 2001). The ‘nude’ vesicle can then fuse to the target membrane (ER) and deliver the cargo. 
Retrograde traffic contributes to an ER quality control mechanism that ensures correct assembly 
of certain membrane proteins (including glycosyltransferases) by recycling material back to the 
ER in opposition to anterograde traffic by COP-II (Béthune et al., 2006). 
 
 
Figure 1.12. COP-I-mediated retrograde and COP-II-mediated anterograde transportation between 
cis-Golgi and ER. 
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Elevation of Src kinase activity has been implicated in the manifestation of cancer 
(Ottenhoff-Kalff et al., 1992) and also in metastases relative to normal tissues (Talamonti et al., 
1993). A recent study documented the positive correlation of Src activity with the loss of 
epithelial differentiation associated with the increase of the metastatic potential of carcinoma cells 
(Boyer et al., 2002). Accordingly, it has been shown many times that O-glycosylation and O-
glycan structures vary dramatically during inflammation and in cancer. For example, as has been 
discussed earlier, inflammation caused by H. pylori infection induces sialylation of the gastric 
mucosa (Mahdavi et al., 2002). During the progression of carcinomas, O-glycan structures (O-
GalNAc) were shown to be simplified with Tn, sialyl Tn, core 1 and sialylated core 1 in colon 
and breast cancer cells (Itzkowitz et al., 1990; Brockhausen, 1999; Burchell et al., 1999). In 
addition, the level of ppGalNAcT-3 has been demonstrated to correlate with tumour 
differentiation, disease aggressiveness and prognosis in patients with colorectal carcinoma 
(Shibao et al., 2002). The reported changes in glycan structures and enzyme levels are among the 
cellular responses that are likely to carry a physiological importance by altering cell adhesive 
properties in order to facilitate the invasion and metastasis through interactions of O-GalNAc 
glycans with lectins and cell surface receptors (Brockhausen, 2006).  
 
Whether Src activation regulates the aforementioned cellular transformations is yet to be 
ascertained. However, recent findings from Bard et al. have intriguingly indicated a possible 
connection between Src activation and the regulation of protein O-glycosylation (Gill et al., 
2010). They have demonstrated that growth hormone stimulation redistributes ppGalNAcTs from 
the Golgi to the ER and this was dependent on Src activation. Simultaneously, the stimulation 
also induced the redistribution of COPI-I vesicles from Golgi to ER with ppGalNAcTs being 
found to colocalise with the coat components and remained active in the ER. Furthermore, 
constitutively active mutant Arf1 was shown to block or delay the redistribution of ppGalNAcTs, 
indicating its involvement in the regulation of COP-I transport. Redistribution of ppGalNAcTs to 
the ER allows the enzyme access to unfolded or partially folded protein substrates. Accordingly, 
ppGalNAcTs were speculated to be able to initiate more O-glycosylation than normally occurs on 
folded proteins in the cis Golgi. This was supported by an increase of total helix pomatia lectin 
(HPL) staining (which recognises GalNAc residues) between Src-deficient cells and activated Src 
cells. In addition, modified Muc1 coexpressed with active Src was shown to contain a 
significantly higher density of incorporated GalNAc analogue, GalNAz (N-
azidoacetylgalactosamine acetylated), as judged by anti-GalNAz staining on Western blotting 
relative to coexpression with inactive Src.  
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Furthermore, initial O-glycomic screening by a colleague at Imperial College of some of 
the Bard group’s cells (unpublished data of Aristotelis Antonopoulos, reproduced with permission 
in Figure 1.13), interestingly showed a significant reduction of core 2 O-glycans relative to core 1 
O-glycans in cells with active Src (SYFsrc) compared to those with inactive Src (SYF). This 
observation could be explained by assuming that the postulated higher number of glycosylated 
serine/threonine residues resulted in O-glycans that are attached nearer to each other on the same 
peptide and consequently become less accessible for C2GnTs modification in the cis-Golgi. 
Putting all this information together, it is tempting to postulate that Src responds to signals from 
extracellular molecules and regulates protein O-glycosylation (O-GalNAc) to alter the properties 
of the cell surface by influencing the localisation of ppGalNAcTs from cis-Golgi to ER via COP-I 
-mediated retrograde transport. This model is illustrated in Figure 1.14. 
 
 
Figure 1.13. MALDI-TOF mass spectra of O-glycans derived from (TOP) cells with inactive Src 
(SYF) and (BOTTOM) cells with active Src (SYFsrc).  
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Peaks for core 1 and core 2 O-glycans are coloured green and red, respectively. Inset depicts the T 
antigen at m/z 534. Reproduced from the work of Aristotelis Antonopoulos, Imperial College London. 
 
 
 
Figure 1.14. Illustrative model for Src-induced COP-I-mediated retrograde trafficking of 
ppGalNacTs. 
Stimulation of EGF via its cell surface receptor activates Src at the Golgi. High levels of activated Src 
kinase induce relocalisation of ppGalNAcTs from the Golgi to the ER via COP-I mediated retrograde 
transport. Modified from (Gill et al., 2010). 
 
To provide more evidence for this proposed mechanism of the regulation of protein O-
glycosylation and to confirm that their findings are a general phenomenon, not an artefact of the 
cell line chosen for study, our collaborators, Frederic Bard et al. from the National University of 
Singapore have generated several cell lines with different levels of activated Src or ER/Golgi-
bound ppGalNAcT-2. O-Glycomic analyses of these cell lines is presented in Chapter 5 and 
discussed in correlation with the data from our collaborators.  
 
1.2.7   Glycomics and glycoproteomics 
Glycobiological research has been well supported and enriched by glycomic and 
glycoproteomic analysis. Glycomics is the profiling of the total glycan population in a sample 
under study which usually requires prior glycan isolation from glycoconjugates. N-glycans can be 
released specifically from glycoproteins by using the enzyme N-glycanase whereas O-glycans are 
preferably removed by using a chemical method, reductive β-elimination, as there is no enzyme 
known so far that can release all types of O-glycans efficiently. These techniques will be 
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discussed in detail in Section 1.4.8.1. O-Glycomics, which is the focus of this thesis, is a 
glycomic analysis optimised to achieve the best characterisation of O-glycans. 
 
Glycoproteomics refers to studies defining glycan repertoires on specific peptides or even 
individual glycosylation sites in glycoproteins. This type of analysis requires prior purification 
and isolation of the glycoproteins of interest. In other instances where the glycomic analysis of 
specific tissue or cells has revealed interesting glycan structures, the glycoproteomic approach is 
utilised to identify the glycoprotein that carries that particular glycan. 
 
 Together with the advancement of mass spectrometry, structural studies of the glycome 
and glycoproteome are continuing to steer glycobiology to become an essential complement for 
other life science research. For instance, glycobiology is now integral to some aspects of other 
longer-established fields such as immunology, parasitology and oncology (Ni & Tizard, 1996; 
Kui Wong et al., 2003; Lee et al., 2005). A complete structural characterisation of 
oligosaccharides demands definition of branching, linkages, configurations and the identification 
of same-mass sugar isomers (Dell & Morris, 2001). All these approaches require continuing 
optimisation and enhancement to address the increasing complexity and specificity of biological 
samples under study.  
 
1.3   Animal models in functional glycomic research 
Functional glycomics requires the continuous development of reliable and sensitive 
methods for the characterisation of glycan structures and their integration into studies of 
structure-function relationships. As described earlier, distortions in glycosylation related genes 
cause a series of human diseases. To explore the biochemical aetiology and systemic view of 
these diseases, suitable animal models are required to delineate oligosaccharide functionality. 
Among available animal models, the mouse model is the most widely used because of its close 
genetic and physiological similarities to humans. Moreover, its genome is easier to manipulate 
and analyse. Nevertheless, the use of other animal models especially from non-mammalian 
organisms are necessary for instance to understand glycan function from an evolutionary point of 
view (Honke & Taniguchi, 2009).  
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1.3.1   Mouse models 
Mus Musculus, the house mouse, appeared as a distinct species at about 8000 years ago. 
Since the late 19th century, scientists have shown great interest in research on murine genetics. 
The draft sequence of the mouse genome was published in 2002 and it was discovered that about 
40% of the human genome can be directly aligned with the mouse genome, and about 80% of 
mouse genes have one corresponding gene in the human genome (Waterston, 2002). On top of 
that, mouse development, body plan, physiology, behaviour and diseases have much in common 
with those of humans. However, there are still some limitations that need to be taken into 
consideration when interpreting glycomic data from mouse models, for instance as discussed 
earlier, there are different numbers and patterns of expression of mucin and glycosyltransferase 
genes in humans and mice. 
 
 With the introduction of more sophisticated technologies, new mouse strains were 
created, for instance via gene knock-in, knock-down or knockout (KO), which have specific 
characteristics that resemble a human disease or disorder. The knockout mouse technique was 
first created between 1987 and 1989 separately by Mario Capecchi, Martin Evans and Oliver 
Smithies, winners of the 2007 Nobel prize in Medicine (Honke & Taniguchi, 2009). Since then, 
this technique has been extensively used to reveal important aspects of glycan functions in 
mammalian systems (Austin et al., 2004). Knockout experiments on glycosyltransferase genes 
were first reported by two groups separately in 1994 (Ioffe, 1994; Metzler, 1994). Both groups 
had knocked out the gene Mgat-1 in the murine genome to produce mice with deficiency in β-
1,2-N-acetylglucosaminyltransferase I, the enzyme that catalyses the initiation of the first 
complex-type antenna of N-glycans (see Figure 1.11), which resulted in murine embryonic 
lethality. After more than 20 years, the knockout mouse technique in glycobiological research is 
still relevant and improving and now even allows investigations on specific isoforms of a 
glycosyltransferase. For instance, Akama et al. have demonstrated the mutual compensatory roles 
of α-mannosidase-II and α-mannosidase-IIx in N-glycan processing in mice (Akama et al., 2006).  
 
Although mice models have been widely used for almost 100 years, there are still many 
aspects of murine biological systems, glycosylation for instance, yet to be fully understood. Even 
for wild type mice, very little work has been done until now to rigorously characterise their O-
glycosylation despite the importance of mouse models in human biomedical research. For 
example, as has been discussed earlier, basic information such as the type of Lewis antigens that 
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can be synthesised in mice is still debatable. The functional properties of C2GnTs, the enzymes 
producing the most abundant O-glycan core type in mouse, have not yet been fully elucidated. 
There has been only a limited amount of detailed O-glycomic profiling of normal murine tissues, 
for instance the partially characterised O-glycan structures at the CFG database 
(www.functionalglycomics.org) and also the work of Dell’s group (North et al., 2010), let alone 
the delineation of glycan alterations in glycosylation-related diseases induced in mouse models. 
 
It is essential then to rigorously characterise the mouse biological system to take full 
advantage of this model and to have better insights into human biology and diseases. Therefore, 
while addressing important biological questions, the present work also intended to provide a more 
comprehensive structural characterisation of the O-glycomes of various wild type murine tissues. 
 
1.4   Mass spectrometry: principles and applications 
Mass spectrometry is currently the technology of choice to fulfil the needs of glycomic 
and glycoproteomic research. This technique has been at the forefront of this research for more 
than two decades (Haslam et al., 2006) and is still remarkably evolving with advancing 
modifications.   Mass spectrometry can be exploited with various types of instrumentation, 
including matrix assisted laser desorption ionization- time-of-flight (MALDI-TOF/TOF), 
electrospray-quadrupole-time-of-flight (ESI-QTOF), MALDI- quadrupole ion trap-TOF 
(MALDI-QIT-TOF) and gas chromatography-electron ionisation (GC-EI), which will be 
discussed in the following sections. The combination of various mass spectrometric techniques is 
very powerful and has advanced our understanding of glycan structures and functions. 
 
1.4.1   History 
Mass spectrometry is said to begin with the work by J.J. Thomson in the year 1897 when 
he discovered the electron and determined its mass-to-charge ratio (m/z) (De Hoffmann & 
Stroobant, 2007). He won a Nobel Prize in 1906 and six years later he constructed the world’s 
first mass spectrometer (Thomson, 1913). Electron ionisation (EI), formerly known as electron 
impact, is the original mass spectrometry ionisation technique introduced by A.J. Dempster in 
1918. Since this pioneering work, vast improvements of mass spectrometers, as well as the 
invention and optimisation of ways to introduce and separate samples in a mass spectrometer, 
have been made. For instance, GC was first coupled to a mass spectrometer in 1956 by F.W. 
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McLafferty (McLafferty, 1957) and R.S. Gohlke (Gohlke, 1959). About 30 years later, another 
important addition to the mass spectrometry repertoire was the discovery of MALDI-MS by two 
groups separately, Tanaka et al. and Hillenkamp et al. (Karas et al., 1987; Tanaka, 1988). The 
invention of the time-of-flight mass analyser (TOF) preceded MALDI by 40 years (back in 1946 
by W. E Stephens (Wolff & Stephens, 1953), whereas the reflectron mode, which is a major 
improvement of TOF, was introduced in 1972 (Mamyrin et al., 1973) but not effectively 
exploited until the 1990’s. Now, MALDI and TOF is a common and powerful combination.  ESI, 
on the other hand, is the brainchild of M. Dole (Dole et al., 1968) but did not become a useful 
tool until the pioneering efforts of J. Fenn in the 1980s. In a landmark piece of research, Fenn 
produced the first spectra of proteins above 20 kDa in 1988 (Fenn et al., 1989). Both Tanaka and 
Fenn shared a chemistry Nobel Prize in 2002 for their excellent work in analysing biomolecules 
using mass spectrometry. In 2004, Tanaka supplemented his contribution to the mass 
spectrometry world by inventing the MALDI-QIT-TOF-MS (Ojima et al., 2005).  
 
In the past 100 years, mass spectrometry has progressed from the analysis of elements 
and small volatile molecules to large biological macromolecules, practically with no mass 
limitations (El-Aneed et al., 2009). This has been made possible by refinements of every 
component of mass spectrometers, which have led to spectacular improvements in resolution, 
sensitivity, mass range and accuracy. In the last 20 years especially, the rapid development of 
mass spectrometers has seen the invention of entirely new instruments as well as hybrid 
instruments which were realised by combinations of the same or different analysers (De 
Hoffmann & Stroobant, 2007). Discussion all of these however, is beyond the scope of this thesis. 
Therefore, only instruments that are relevant to this thesis plus a few other prominent instruments 
will be discussed below. 
 
1.4.2   Components 
Mass spectrometry instruments generally consist of three main components, namely an 
ionisation source, one or more mass analysers and one or more detectors. The instruments may 
include collision cells for ion activation in tandem mass spectrometric analysis. All these 
components are important in order to form a robust instrument and their different combinations 
can produce unique analytical capabilities.  
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An ionisation source is where samples are converted to gaseous ions. How this is 
achieved is crucial for the successful application of mass spectrometry to diverse samples 
including those which are neutral and/or large. Some ionisation techniques are very energetic and 
can cause fragmentation during the ionisation process, for example EI. On the other hand, there 
are softer ionisation techniques that produce mainly ions of the molecular species, for instance 
ESI and MALDI. All the aforementioned ionisation sources are applied in the work included this 
thesis and therefore each will be discussed in more detail in later sections. 
 
The mass analyser is the component of a mass spectrometer that separates gas-phase ions 
according to their m/z. The separation can be based on many principles; hence, there are several 
types of mass analysers with different advantages and limitations. Among the important 
characteristics of a mass analyser include resolution, mass range, scan rate and detection limit 
(Van Bramer, 1997). The current trend in mass analyser development is to combine different 
analysers in order to increase the versatility and allow multiple experiments to be performed (De 
Hoffmann & Stroobant, 2007). The mass analysers that are relevant to this thesis are TOF, 
quadrupole and QIT and will be discussed in more detail in the subsequent sections. 
 
A detector transforms mass analysed ions into usable signals, usually electric currents, 
which are proportional to the ion abundances. A detector is selected based on its speed, dynamic 
range, gain and high voltage. There are two types of detectors utilised in the mass spectrometry 
instruments relevant to this thesis, microchannel plate (MCP) and photomultiplier. In both 
detectors, mass analysed ions that strike a conversion dynode (electrode) are first converted to 
secondary electrons before being transferred to an electron multiplier. The MCP detector consists 
of a plate in which parallel cylindrical channels have been drilled with the inner sides covered by 
a semiconductor substances, each serves as a continuous electron multiplier dynode (De 
Hoffmann & Stroobant, 2007). The secondary electrons are then amplified by a cascade effect 
every time they hit the inner side of a dynode and are finally collected by a metal anode to 
produce a current signal and submitted to the data system (Smith, 2004). The photomultiplier 
detector, on the other hand, contains a phosphorescent screen that converts secondary electrons to 
photons prior to entering a high vacuum photomultiplier tube in which photons are converted 
back to electrons by a photocathode. The secondary electrons are then multiplied based on the 
same principles as the MCP except that the electrons are transferred between several discrete 
dynodes according to a potential gradient. 
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Ion activation is a group of numerous techniques where mass separated/selected ions 
(precursor ions) are given excess energy either by collision or by irradiation to dissociate. 
Dissociations may either occur spontaneously (metastable ions) or can result from intentionally 
supplied additional activation in a collision cell (Gross, 2004). Spontaneous fragmentation 
occurring within the ion source is known as in-source decay, whereas outside the ion source is 
known as post-source decay (Harvey, 2010).  Methods for ion activation include surface-induced 
dissociation, infrared multiphoton dissociation, electron capture dissociation and collision-
induced dissociation (CID). The most prominent ion collision technique is the CID, which 
generally involves passing an ion beam through a collision cell that contains collision gas, for 
instance helium, argon and nitrogen, at high pressure. CID is very useful for structural 
elucidations of ions of low internal energy because it allows for the fragmentation of gaseous ions 
that were stable before the activating process (Gross, 2004). In tandem mass spectrometric 
analysis, the precursor ions are normally dissociated between the two mass spectrometric stages. 
Tandem mass spectrometers can be categorised in two ways: performing tandem MS in space by 
the coupling of two physically distinct analysers (for example TOF/TOF and QTOF), or in time 
by performing a sequence of fragmentations in an ion storage device (for example QIT) (De 
Hoffmann & Stroobant, 2007). In an MS/MS (MS2) experiment, selected precursor ions are 
cleaved into smaller fragments which then will be separated and detected. In multiple stage MS 
analyses (MSn), the fragments of the precursor ions can be selected and further fragmented and 
this process is repeated during the course of each of the activation stages. 
 
1.4.3 MALDI-TOF/TOF mass spectrometry 
In oligosaccharide analysis, MALDI-TOF/TOF-MS is currently the most powerful mass 
spectrometric method for mass fingerprinting because of its sensitivity of detection and ability to 
analyse glycans from complex mixtures derived from a variety of organisms and cell lines 
(Haslam et al., 2006; Parry et al., 2007). This instrument consists of a MALDI source, a short 
linear TOF, a collision chamber for CID, a second TOF with a reflectron and two MCP detectors, 
one each for the linear and reflectron modes (Figure 1.15). 
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Figure 1.15. Schematic view of a MALDI-TOF/TOF mass spectrometer. 
The schematic shows ion paths of reflectron mode during tandem mass spectrometric experiment. Circles 
of different sizes represent ions of different m/z while circles of similar size but with different colours 
represent ions of similar m/z but with different level of kinetic energies. After passing the reflectron, ions of 
the same m/z but differing initial kinetic energy are eventually recorded at the detector as the same signal. 
 
 As the name implies, ionisation in a MALDI source requires biomolecules to be mixed 
with a low molecular weight ultraviolet-absorbing compound, known as the matrix. As the 
solvent dries on the target plate, the matrix compound crystallises together with the dissolved 
biomolecules. Sample spots are then irradiated with a laser beam, that causes evaporation and 
ionisation, and then the ions are directed towards the TOF analyser (Figure 1.15). The ionisation 
process is still not fully understood but it is widely believed that the matrix allows the energy 
from the laser to be dissipated and assists the formation of ions by proton transfer and chemical 
processes (Dell et al., 2008). It has been suggested that incorporation of analyte into the matrix 
crystal and the amount of contact between analyte and the matrix surface can influence the 
strength of MALDI signals (Harvey, 2010). Important features of a matrix, additional to having 
an absorption frequency compatible with the MALDI laser, include sample solubility, reactivity, 
volatility and suitable desorption properties (Hossain & Limbach, 2010). Most matrices 
employed for analysing substances in the positive ion mode are acidic, for example α-cyano-4-
hydroxy cinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB), which helps the 
ionisation of biomolecules (Kinter & Sherman, 2000). The MALDI ion source produces mainly 
singly charged molecular ions with minimal fragmentation, making it ideal for accurate overall 
glycan profiling (Dell et al., 2008). In-source metastable fragmentation was found to be 
prominent in early MALDI studies of glycans. Although this allows PSD of oligosaccharides in 
MALDI-TOF instruments it also complicates MS profiling. This drawback was dealt with by 
increasing the pressure in the MALDI source and by stabilising glycan molecules via 
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derivatisation (Zaia, 2004). Furthermore, ionisation in MALDI produces a pulsed sample ion 
current, which is ideally suited to the TOF mass analyser.  
 
In a MALDI-TOF-MS analysis, excited ions from the ion source are attracted towards the 
TOF analyser where ions of different m/z are dispersed in time during their flight along a field-
free drift linear path of known-length; the lighter ions arrive earlier at the detector than the 
heavier ones (Gross, 2004). Ions generated by hundreds of laser shots are accumulated from 
different points of laser irradiation, which make the MALDI-TOF technique excellent in mass 
spectrum reproducibility (Wada et al., 2007). TOF analysers were originally designed for GC 
(Gohlke, 1959), but at present TOF is very commonly coupled to MALDI with the capability to 
produce mass spectra of proteins of at least 100 000 Da. Over the years, various modifications 
have been made to instruments with TOF analysers, for example incorporation of delayed pulsed 
extraction and reflectrons, both targeted to improve the mass resolution by correcting the energy 
dispersion of ions with the same m/z but with different kinetic energy so that they arrive at the 
detector at the same time. In the delayed pulsed extraction, ions are initially allowed to separate 
according to their kinetic energy in a field-free region before an extraction pulse, thus permitting 
the initially less energetic ions to receive more kinetic energy and join the initially more energetic 
ions at the detector. The reflectron, meanwhile, creates a retarding field at the end of the TOF tube 
and acts by deflecting the ions back through the flight tube. Ions with higher kinetic energy and 
hence with more velocity will penetrate the reflectron much deeper than ions with less kinetic 
energy, thus the high energy ions will spend more time in the reflectron (De Hoffmann & 
Stroobant, 2007). TOF has almost unlimited mass range but the reflectron mode is restricted to 
analyses below masses of about 10,000 Da (Dell et al., 2008).  
 
Each component of the MALDI-TOF mass fingerprint can be rigorously characterised by 
subjecting each molecular ion to collisional activation in MS/MS experiments. The combination 
of a short linear TOF and a reflectron TOF analyser (TOF/TOF) separated by an ion selector and 
a collision cell (Figure 1.15) enhances tandem mass spectrometric analyses in MALDI-MS and is 
currently the leading type of mass analyser for MALDI instruments. In MALDI-TOF/TOF-
MS/MS, excited ions from the MALDI source are separated in the first TOF analyser and 
selected with a timed ion selector (TIS) or mass "gate" based on their arrival time at the TIS gate. 
The TIS is used to isolate specific molecules for fragmentation based on their m/z before entering 
a collision cell which contains the collision gas. The selected precursor ions are then fragmented 
in the collision cell before being accelerated by a second source into the second TOF analyser 
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with the reflectron capability. Ions and fragmented ions are resolved according to their m/z before 
arriving at the detector. This technique has greatly enhanced the sensitivity and resolution of 
tandem mass spectrometric data which leads to exceptional determination of glycan compositions 
and sequences.  
 
1.4.4   ESI-QTOF mass spectrometry 
The ESI-QTOF hybrid mass spectrometer combines the benefits of ESI and the 
Quadrupole-TOF (QTOF) mass analyser, thus becoming a great complement to MALDI-
TOF/TOF tandem mass spectrometry. In this thesis, the ESI-QTOF technique has been most 
beneficial in sequencing of very low abundance glycans.  Figure 1.16 shows a schematic diagram 
of an ESI-QTOF-MS/MS, which consists of a nano ESI source, three quadrupoles, a reflectron 
TOF analyser and an MCP detector. 
 
 
Figure 1.16.  A schematic diagram of an ESI-QTOF-MS. 
The schematic shows ion paths during tandem mass spectrometric experiment. Samples can be 
introduced into the ion source directly after separation in LC or from a needle filled by manual injection 
using a syringe. Inset diagram (reproduced from www.waters.com) shows the mechanism of ion 
desolvation in the ESI source. Sample ions are represented by circles of different colours and sizes as 
described in Figure 1.15. 
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In the ESI source, samples dissolved in solvent emerging from a liquid chromatography 
(LC) column or syringe are introduced via a capillary at high voltage and at atmospheric pressure. 
The sample solution eventually emerges as tiny droplets at the needle tip possessing a strong 
positive or negative charge due to the strong electric field. When the charged liquid first exits the 
tip, it briefly forms a cone shape known as a Taylor cone before the droplets burst away into a 
fine spray (Cole, 2010). The droplets in the spray then pass through a curtain of heated inert gas, 
most often nitrogen, to remove the remaining solvent molecules. When the electric field on their 
surface is large enough, ion desorption from the droplet surface will occur before entering the 
QTOF mass analyser (De Hoffmann & Stroobant, 2007). One of the advantages of this ionisation 
method is that the molecules remain intact (soft ionisation) (Gross, 2004). The most notable 
benefit of ESI is the ability to produce multiply charged ions that is very helpful especially in 
characterising biomolecules with high masses. Most commonly, ESI is connected to an LC 
system which enables direct analysis of LC separated biomolecules in mass spectrometers. For 
example, the nano-liquid chromatography interface (nano-LC) on ESI is outstanding for 
glycosylation site specific analysis in addition to the detection of other protein modifications such 
as phosphorylation and alkylation (Thomsson et al., 2000; Dell & Morris, 2001). However, 
manual injection into the ESI needle via a syringe is also excellent for ESI especially when 
involving very low amounts of samples or when LC separation is not required. Ionisation of 
glycans and glycoconjugates in conventional ESI used to be relatively poor compared to peptides 
and proteins, until the introduction of nano ESI that produces smaller droplets with better ion 
signals (Wilm & Mann, 1996). Smaller droplets reduce the hydrophilicity of oligosaccharides 
leading to increases in surface activity rather than in volatility (Karas et al., 2000), resembling the 
effects of glycan derivatisation. 
 
The QTOF mass analyser which was first proposed by H.R. Morris (Morris et al., 1996) 
is currently the commercially most successful hybrid system (Gross, 2004). The quadrupole 
analyser consists of four cylindrically shaped rod electrodes with the pairs of opposite rods being 
each held at the same potential and commonly assembled in three sets to form an instrument with 
ion activation capability. A direct current voltage and an oscillating radio-frequency are applied to 
each pair of opposite rods creating an electric field that acts as a mass filter. The quadrupole 
allows high-speed scanning at relatively high pressure that is perfect for the continuous beam of 
ions from the ESI source (Dell et al., 2008). The additional reflectron TOF mass analysis 
immediately after the quadrupole analysis improved the ion detection, transmission, resolution 
and mass accuracy of a quadrupole instrument (Morris et al., 1997). However, it was not feasible 
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to directly combine a TOF analyser, a pulsed instrument, with continuous ionisation from 
electrospray source. This was solved by the orthogonal arrangement of the quadrupole and TOF 
analysers (Morris et al., 1996), a design that was successful because of the incorporation of an ion 
modulator/pusher, originally devised by Dawson and Guilhaus (Dawson & Guilhaus, 1989), at 
the interface.  
 
The first quadrupole analyser, shown in Figure 1.16, is a radio frequency (RF)-only 
quadrupole (Q0) where ions are collimated and transferred into the adjacent high vacuum region 
of the second quadrupole, which is known as the mass filter quadrupole (Q1). In the MS mode, 
Q1 transmits ions over a wide mass range, whilst in the MS/MS mode, ions are resolved 
according to their m/z. This is followed by the third quadrupole (Q2), which is an RF-only 
quadrupole filter housed inside a collision cell. In the MS mode, Q2 acts just by focusing the ion 
beam, similar to Q0. In the MS/MS mode however, Q2 transmits ions through the collision cell 
that contains the collision gas (nitrogen) for fragmentation to occur. Precursor and/or fragment 
ions then enter the ion modulator in the TOF analyser.  A pushout pulse applied orthogonal to the 
ion beam direction then extracts the ions to travel through the TOF tube. Ions are separated 
according to their m/z value before being detected and recorded (Cole, 2010). The TOF analyser 
contains a reflectron similar to what has been discussed for MALDI-TOF/TOF-MS in the 
previous section. 
 
1.4.5   GC-EI mass spectrometry 
Another essential requirement for a complete characterisation of glycans is linkage 
analysis. Gas chromatography-electron ionisation-MS (GC-EI-MS) has been shown to be a 
robust tool for that purpose (Haslam et al., 1997; Haslam et al., 2006; Parry et al., 2006). 
Fragmentation data from this instrument, when used in concert with enzymatic or chemical 
digestion, provides information on individual monosaccharide linkages within a sample. Glycan 
linkage analysis will be discussed in Section 1.4.8.5. Here the principles of GC-MS are described. 
 
GC is known for its capability to perform chromatographic separation of volatile 
molecules from complex samples prior to mass spectrometric analysis. Because EI results in 
complex fragment-ion patterns, a high resolution separation technique such as the GC is vital 
because it ensures that only a limited number of components enter the ion source at any given 
time even when complex mixtures are examined (Dwek et al., 1993).  From the GC, the sample 
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of interest is vaporised into the EI source and collided with a beam of electrons produced by a 
filament (commonly rhenium and tungsten wire). When the electron beam is close enough, 
energy can be transferred to the sample molecules. When there is sufficient energy, an electron 
can be expelled from the sample molecule, thus generating molecular ions (De Hoffmann & 
Stroobant, 2007) (Figure 1.17). Excess energy usually can be converted into activation energy 
that causes single or multiple stages of fragmentation. Several types of mass analysers can be 
coupled to this instrument, however the single quadrupole is best suited due to its high scan 
speeds (Gross, 2004). This instrument usually utilises a photomultiplier detector. 
 
 
Figure 1.17. Schematic view of the ion source based on electron ionisation and the single 
quadrupole mass analyser typically found in a GC-MS instrument. 
Black circles represent neutral sample molecules. Circles of other colours represent charged sample 
molecular ions and fragments. Reproduced from (Wittmann, 2007).  
 
1.4.6   MALDI-QIT-TOF mass spectrometry 
MALDI-QIT-TOF-MS is a relatively new type of instrumentation that utilises the benefits 
of MALDI-MS in mass fingerprinting and sequencing of biomolecules and brings them to a new 
level. The instrument’s most prominent advantage is the capability it provides for performing 
multiple stage mass spectrometric analysis (MSn). Figure 1.18 shows a schematic diagram of a 
Chapter 1    65 
 
MALDI-QIT-TOF-MS, which consists of a MALDI source, quadrupole-ion trap (QIT) and TOF 
mass analysers and an MCP detector.  
 
 
Figure 1.18. Schematic diagram of a MALDI-QIT-TOF-MS. 
The schematic shows ion paths during multiple stage mass spectrometric (MSn) experiment. Sample 
ions are represented by circles of different colours and sizes as described in Figure 1.15. 
 
The primary concern of coupling a low pressure MALDI source to a QIT was to be able 
to efficiently trap the axially injected gas-phase ion inside the analyser. The QIT (also known as 
Paul trap) mass analyser consists of two end cap hyperbolic electrodes and a ring electrode. The 
trap is formed when voltages are applied to these electrodes forming a 3D quadrupole. The use of 
dampening gas (usually helium) improves the trapping ability by cooling the kinetic energy of 
sample ions to the centre of the trap (Cole, 2010). The mass analysing principle of the QIT is 
based on creating stable trajectories for ions of a certain m/z or m/z range while removing 
unwanted ions from the trap due to their unstable trajectories (Gross, 2004). The ability to trap 
ions means that a sufficient number of ions can be stored for subsequent MSn analyses with high 
detection sensitivity (Dell et al., 2008). Other than MALDI, the QIT analyser can also be coupled 
to ESI and GC. The reflectron TOF analysis after the QIT analysis, similar to what has been 
described for MALDI-TOF/TOF-MS and ESI-QTOF-MS, enhances ion resolution by efficiently 
separating the precursor and/or product ions in MS or tandem MS experiments. Koy et al. have 
utilised MALD-QIT-TOF to determine the amino acid sequences of previously unassigned 
peptides of human haptoglobin and highlighted the advantages of this instrument including easy 
parent ion creation and minimal sample consumption (Koy et al., 2003).  
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1.4.7   Other prominent mass spectrometry instrumentation 
Prior to the wide usage of modern instruments such as MALDI and ESI, fast atom 
bombardment (FAB)-MS was at the forefront of oligosaccharide structural analysis (see sections 
1.4.8.3 and 1.4.8.4). Advancement in technology has led to the invention of even more sensitive 
and robust instrumentations, and two of the techniques that are starting to receive much attention 
within this field are the electron capture dissociation (ECD) and the electron transfer dissociation 
(ETD), two powerful multiple stage ion activation methods. FAB, ECD and ETD instruments are 
discussed briefly here.  
 
The introduction of FAB ionisation in the early 1980’s (Barber, 1981) revolutionised the 
structural analysis of a wide range of carbohydrate-containing biopolymers (Dell & Ballou, 1983; 
Dell, 1987). In FAB-MS, a high primary current beam of neutral atoms or ions accelerated from a 
gun is focused on a droplet of viscous matrix, for example thioglycerol or m-nitrobenzylic 
alcohol, placed on a small metal target. The sample of interest is dissolved in the matrix droplet 
prior to bombardment with the atom or ion beam (Barber, 1981). When the beam collides with 
the droplet, the surface mono-layer is destroyed by the impact. Excess energy is transmitted to the 
underlying molecules (matrix plus sample) some of which become ionised and are ejected out of 
the solution into the high vacuum of the ion source. They are then accelerated towards the 
analyser by a potential difference. In the positive mode, ionisation occurs by protonation or the 
addition of a cation such as sodium, whilst in the negative mode ions are primarily formed by loss 
of a proton. Fragmentation of labile bonds is common during the ionisation process, thus 
allowing both compositional and sequence data acquisition in a single experiment (Dell & 
Morris, 2001). The most prominent type of mass analyser coupled to a FAB-MS instrument is the 
double-focusing magnetic sector. Other common analysers include a single-focusing magnetic 
sector  in tandem with a quadrupole (Hogg, 1983). The introduction of high magnetic field 
technique to FAB-MS by H.R. Morris and colleagues was pivotal to oligosaccharide analysis 
because of the resulting extended mass range (Morris et al., 1981; Dell & Morris, 1982). 
  
ECD is an ion activation technique that was discovered by Zubarev et al. in 1998 
(Zubarev et al., 1998). ECD involves irradiation of multiply charged molecular ions with low 
energy electrons. Negatively charged electrons can be captured by the cationic molecular ions to 
create a radical species with one charge less than the original ion. This charged reduced radical 
then rapidly undergoes dissociation into product ions (Cole, 2010). To date, ECD can only be 
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implemented in Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometers. FT-
ICR-MS is a promising mass spectrometry instrument that possesses unprecedented levels of 
resolution and mass accuracy (Gross, 2004; Zhao et al., 2008). The development of FT-ICR was 
inspired by ICR spectroscopy and FT- nuclear magnetic resonance and can be traced back to 
1973 (Comisarow & Marshall, 1996). MALDI and ESI are both compatible as ionisation sources 
for FT-ICR-MS. In a cyclotron (also known as a Penning trap), ions are ‘trapped’ on a circular 
trajectory in a high magnetic field. Ions of different m/z are separated by the cyclotron frequency. 
The trapped ions are then excited to a large and coherent cyclotron orbit by an oscillating electric 
field perpendicular to the magnetic field. An image current generated by the ions as they drop 
back to their natural orbit can be measured and a Fourier transform is applied to give a mass 
spectrum (Solouki et al., 1998).  
 
Although ECD is very useful, one of its drawbacks is the difficulty of implementing this 
technique on instruments other that FT-ICR-MS, which is expensive and requires highly skilled 
users. D.F. Hunt and colleagues have come up with a solution to this issue by inventing the 
technique known as ETD (Syka et al., 2004). ETD uses an anion electron carrier rather than a 
free electron to trigger electron capture by multiply charged cationic molecular ions (Cole, 2010). 
One of the most commonly used anion electron carriers is anthracene, a singly charged anion of a 
polycyclic aromatic hydrocarbon (De Hoffmann & Stroobant, 2007). After the electron transfer, 
similar to ECD, charge state reduction occurs to produce a radical positive sample ion that can 
then dissociate. ETD can be implemented in instruments including the quadrupole linear ion trap 
and QTOF (Syka et al., 2004; Xia et al., 2006).  
 
The latest additions to the mass spectrometry family are mostly hybrid instruments. They 
are constructed by the combination of different types of mass analysers with different 
advantageous properties in a single machine (Gross, 2004). Examples of hybrid instruments, 
other than ESI-QTOF-MS and MALDI-QIT-TOF-MS, are quadrupole-FT-ICR-MS (Patrie et al., 
2004), linear quadrupole ion trap-FT-ICR-MS (Syka et al., 2004) and magnetic sector-TOF 
(Strobel et al., 1991). 
 
1.4.8   Strategies for glycan structural analysis 
Modern analytical techniques such as mass spectrometry, nuclear magnetic resonance, X-
ray crystallography and lectin/ glycan array have revolutionised structural studies and are among 
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the popular methods for structural and functional glycan analysis (Dell & Morris, 2001; 
Drickamer & Taylor, 2002; Wormald et al., 2002). Mass spectrometry is increasingly becoming 
the method of choice for rigorous structural characterisation of biomolecules  since the 
introduction of desorption based ionisation methods back in the late 1970’s (De Hoffmann & 
Stroobant, 2007). 
 
Mass spectrometric analysis of glycans can be traced back to about 4 decades ago with 
the analyses of monosaccharides and hydrolysed small oligosaccharides using GC-MS, for 
instance the work of the Carlson and Albersheim groups (Sweet et al., 1974; Weber & Carlson, 
1982). The analysis of oligosaccharides without hydrolysis, on the other hand, started later with 
the analysis using FAB instruments pioneered by the Morris and Dell group (Dell, 1987; Dell, 
1990; Dell et al., 1993). Since then, tremendous developments and achievements have been made 
on both analytical methods and instrumentation. Currently, other than MALDI-TOF/TOF and 
ESI-QTOF that are the main glycan profiling and sequencing instruments applied in this thesis, 
LC-ESI-MS is another extensively used technique (Karlsson et al., 2004; Wada et al., 2007). The 
complete structural characterisation of oligosaccharides is more challenging than that of proteins 
or oligonucleotides due to the existence of additional specific characteristics such as isomeric 
states, linkage positions and branching capabilities. The determination of all this structural 
information for a comprehensive characterisation can be obtained by mass spectrometry, although 
sometimes it may require more than a single mass spectrometric technique. Various sample 
treatments prior to analysis might also be crucial for a successful experiment. A few important 
strategies for glycan mass spectrometric analysis are discussed below. 
 
1.4.8.1 Release of oligosaccharides from glycoproteins 
In order to perform an efficient glycomic analysis, glycans are released from their 
glycoconjugates. As mentioned earlier, glycoproteins contain two types of glycans, namely N-
glycans and O-glycans. All N-glycan structures can be digested from proteins by peptide:N-
glycanase F (PNGase F) except for α1,3 core fucosylated N-glycans commonly found in plants 
and invertebrates which can be removed by peptide:N-glycanase A (PNGase A) (Tretter et al., 
1991). However, recently it has been suggested that the two newly cloned FuT10 and FuT11 can 
catalyse α1,3-fucosylation to N-glycan core in humans (Mollicone et al., 2009). In contrast to N-
glycans, chemical release of O-glycans, known as reductive elimination, is the most practical and 
preferred method. A number of enzymes that possess the capability to digest O-glycans have been 
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reported previously, however so far have they been shown only to release simple sialylated and 
fucosylated O-glycan structures (Umemoto et al., 1978; Abdullah et al., 1992). Reductive 
elimination, also known as alkaline β-elimination, was first introduced in 1966 in an analysis of 
oligosaccharides from porcine submaxillary mucins (Carlson, 1966). Currently, this is the most 
common method used to release O-glycans from proteins. In this technique, unwanted 
degradation or ‘peeling’ of the oligosaccharides is avoided by reducing the monosaccharide of the 
reducing terminal to an alditol using reducing agents such as potassium borohydride (KBH4) in 
an alkaline solutions such as potassium hydroxide (KOH)  (Carlson, 1966). During the chemical 
degradation hydroxide from the alkali attacks the hydrogen on the backbone of the glycan-linked 
amino acid leading to the elimination of the O-linked sugar (Figure 1.19). The reducing terminal 
glycan (O-GalNAc) is then reduced, thus breaking the ring structure. Reductive elimination is 
permissible with or without prior digestion of N-glycans, but the latter usually results in some 
contamination with reduced and non-reduced N-glycans especially when high mannose N-
glycans are present.  
 
 
Figure 1.19. Reaction steps for reductive elimination of O-linked GalNAc. 
The reactions lead to the release and reduction of the GalNAc residue and usually the partial destruction of 
the peptide chain. Reproduced from (Morelle & Michalski, 2007). KOH, potassium hydroxide; KBH4, 
potassium borohydride. 
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1.4.8.2 Chemical and enzymatic digestions 
Chemical and enzymatic digestions are an essential adjunct to glycan screening and 
sequencing because they can provide information on structural features such as stereochemistry 
and linkage (Dell et al., 2007). Mass spectrometry is an ideal method to monitor the products of 
these reactions because of its sensitivity. Enzymatic digestions are normally stereochemistry 
and/or linkage specific but must be carried out on native glycans. For example, β1,4-
galactosidase digestion is used to determine the type of terminal Gal population in the sample of 
interest. On the other hand, chemical digestions are used to degrade sugar residues with broader 
specificities and can be carried out on either native or permethylated glycans. For example, 
trifluoroacetic acid (TFA) degradation at room temperature is used to remove terminal fucose 
residues. By taking advantage of the fact that certain fucose linkages are more labile, time course 
degradation is possible. Thus, 3- and 4-fucose residues are more likely to be released first than 2- 
and 6-fucose, allowing easy confirmation of fucose and rough determination of their linkages. 
 
1.4.8.3 Permethylation 
As oligosaccharides do not ionise as efficiently as peptides, derivatisation is commonly 
performed to improve the analysis by most of mass spectrometric techniques including MALDI 
and ESI (Dell et al., 2008). Derivatisation reduces the hydrophilicity of oligosaccharides so that 
they are easier to ionise. The types of derivatisation technique utilised in the analysis of 
oligosaccharides include fluorescence labelling of the reducing terminal via reductive amination 
(Anumula, 2006) and stable isotope labelling for instance with deuterium (Price, 2006), 
peracetylation and permethylation (Dell, 1990). Permethylation has become the preferred 
oligosaccharide derivatisation method because it results in a smaller mass increase and a greater 
volatility.  
 
In the methylation of carbohydrates, successive base-catalysed ionisation of the hydroxyl 
groups followed by reaction with the methylating agent occurs, a method that was introduced by 
Sen-itiroh Hakomori (Hakomori, 1964). The Hakomori permethylation technique uses 
methylsulfinyl carbanion in dimethyl sulfoxide (DMSO) with methyl iodide being the methyl 
donor.  However, permethylation nowadays is commonly catalysed by less strong bases such as 
solid sodium hydroxide with rapid derivatisation without the formation of non-sugar products, as 
initially demonstrated by I. Ciucanu and F. Kerek (Ciucanu & Kerek, 1984). Increased 
hydrophobicity allows glycans to be extracted from the methylation slurry using chloroform. The 
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permethylation technique was matured during the era of FAB-MS (Section 1.4.7) and has 
positioned itself as an essential technique in most oligosaccharide analytical strategies, and what 
was learnt is now being applied using current instrumentation (Dell, 1987; Dell et al., 1994; Wada 
et al., 2010).  
 
Sulphated glycans, however, are not compatible with the standard NaOH-permethylation 
technique because of the low efficiency of chloroform extraction of negatively charged glycans 
(Zaia, 2004). Instead, a method based on the short Hakomori permethylation technique can be 
used for this analysis (Dell et al., 1994). Alternatively, the NaOH permethylation procedure can 
be rendered compatible with sulphated glycans as has been recently demonstrated by Khoo’s 
group (Yu et al., 2009) (details in Chapter 2). To improve the recovery and stability of sulphated 
glycans in the latter, the permethylation reaction is carried out in small scale at 4oC but for a 
longer period. Conventional partitioning against chloroform is replaced by direct reverse phase 
extraction and followed by a microscale fractionation using an amine column to separate 
negatively charged from neutral glycans, which gives an advantage to the isolation of sulphated 
glycans as they are the only remaining charged oligosaccharides. 
 
Permethylated oligosaccharides are most often analysed in the positive ion mode as 
[M+Na]+ molecular ions producing reducing and non-reducing terminal product ions with 
preferential fragmentation to the reducing side of (N-acetylhexosamine) HexNAc residues (Dell, 
1987) (see next section). Compared to non-derivatised glycans, permethyl derivatives are better 
ionised and are capable of forming abundant fragment ions thus increasing the sensitivity of mass 
spectrometric analysis (Dell & Morris, 2001). In fact, permethylated glycans fragment very 
selectively and provide structurally diagnostic fragments, hence aiding data interpretation (Dell, 
1987; Wada et al., 2007). Ions arising from single and multiple cleavages also can be easily 
discriminated (Dell et al., 2008). Furthermore, permethylation is a prerequisite for glycan linkage 
analysis (1.4.8.5). Other than that, permethylation also stabilises sialic acids, thus avoiding errors 
in glycan profiling. Sialic acid is large family of molecules with various types of naturally 
occurring derivatives, bearing of N-acetyl and N-glycolyl, and less frequently O-acetyl, O-lactyl, 
O-methyl and O-sulphate substituents. These added groups are chemically labile and very 
challenging to detect (Varki, 1992; Schauer, 2000).  
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1.4.8.4 Glycan fragmentation 
In tandem mass spectrometry, sample molecular ions are activated and fragmented in 
order to provide detailed structural information. The MS2 experiment is the most common type of 
analysis and can be done in most modern mass spectrometric instruments. However, multiple 
stage mass spectrometric analysis (MSn), especially MS3, is gaining recognition as a useful 
strategy for glycomic and glycoproteomic analyses due to the increasing demand for detail 
structural information. Furthermore, MSn data could indicate from which fragmentation pathway 
the MS2 fragment originated, which is particularly useful for analysis on complex glycan 
structures (Harvey, 2010). The fragmentation pathways of glycans in tandem mass spectrometric 
analysis are overviewed below. It is important to highlight that most of the current knowledge on 
glycan fragmentations is derived from the analysis of oligosaccharides using FAB-MS 
instruments during the 1980’s, for instance the work of Dell & Ballou (Dell & Ballou, 1983).  
 
In contrast to native samples, permethylated glycans fragment in a very predictable 
manner in both positive and negative ion modes. Generally, the positive ion mode is the method 
of choice due to the better fragmentations most commonly observed with singly charged sodiated 
([M+Na]+) and protonated ([M+H]+) molecular ions in MALDI, or as multiply charged ions in 
ESI. In the negative ion mode, on the other hand, the molecular ion is deprotonated and therefore 
this mode of ionisation is best suited to molecules that have an intrinsic negative charge, for 
example sulphated or sialylated glycans, provided the latter are not permethylated. The negative 
mode is also well suited to the analysis of underivatised glycans provided the resulting molecular 
ions are stable during analysis. This is often not the case in MALDI where sulphates and sialic 
acids are readily lost. On the other hand ESI is well suited to handling fragile molecular ions. For 
instance, Karlsson et al. have very successfully performed rigorous characterisation of neutral 
and underivatised O-glycans reductively eliminated from human MUC5B using LC-ESI-MSn 
(Karlsson et al., 2004). 
 
In MALDI and ESI instruments, various types of cleavages can be observed in CID 
analyses of permethylated glycans (exemplified in the fragmentation of a sialylated core 2 O-
glycan in Figure 1.20). The most common type of cleavage is the glycosidic cleavage with 
hydrogen transfer, or also known as β-cleavage, with charge residing on either end (Figure 1.20). 
This type of cleavage can occur in both positive and negative modes. An important cleavage 
normally accompanying glycosidic fragmentation with hydrogen transfer is β-elimination of the 
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substituent from position 3 of a HexNAc residue (Dell, 1987; Dell et al., 2008) (Figure 1.20). 
These glycosidic and β-eliminated fragment ions can provide information on sites of sialylation, 
fucosylation and branching as well as the number of LacNAc repeats. The other type of 
fragmentation commonly observed in oligosaccharide analysis is ring cleavage (cross-ring 
fragmentation) (Figure 1.20). Cross-ring fragmentation is prominent in multiple stage MS (MS3 
and higher) but it can also occur in MS2 experiments provided it is carried out in a high-energy 
collisional activation. Sodiated molecular ions produce better ring-cleavages relative to their 
protonated counterparts (Dell & Ballou, 1983; Dell, 1987; Zaia, 2004). In a cross-ring 
fragmentation, the charge can remain on either the reducing or the non-reducing end, depending 
on the nature of the sample and the ionisation mode. This type of fragmentation is most helpful 
for assigning linkages.  
 
In other mass spectrometric techniques, especially FAB instruments, permethylated 
derivatives most commonly undergo A-type cleavages on the non-reducing side of a glycosidic 
bond to give oxonium-type fragment ions, which may carry sodium if the parent ion is sodiated. 
This A-type cleavage is often favoured at HexNAc residues and can only occur in the positive ion 
mode. Secondary cleavage β-elimination of the substituent from the position 3 of a HexNAc 
residue is often observed as well (Dell, 1987; Dell et al., 2007). It is important to note that the 
cleavage of sialic acid residues often leads to the formation of oxonium ions even in MALDI and 
ESI instruments (Figure 1.20). 
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Figure 1.20. Common fragmentation pathways of permethylated glycans. 
By using the O-glycan structure NeuAcα2,3Galβ1,3(Galβ1,4GlcNAcβ1,6)GalNAcitol as a model, various 
cleavages can be observed following the fragmentation in MALDI or ESI CID. For example, glycosidic 
cleavages (red lines) with charge retained on the reducing end (fragments Y1 & Y2) or non-reducing end 
(fragments B1 & B2). β-elimination of a substituent from the position 3 of a HexNAc residue (green lines) is 
demonstrated by fragments C2 and Z1,. Cleavage of sialic acids (purple lines) often results in the formation 
of oxonium ions (fragment B1). Examples of ring cleavages (blue lines) often seen in O-glycan 
fragmentations are 1,5X, 0,4X and 0,3A. Based on the nomenclature proposed by (Domon & Costello, 1988). 
 
1.4.8.5 Glycan linkage analysis 
Tandem mass spectrometry using MALDI-MS or ESI-MS can provide specific but 
limited linkage information based on the fragments acquired. To acquire overall glycan linkage 
data from a particular sample, linkage analysis using GC-MS is a better method. In this analysis, 
monosaccharides from the glycans of a particular sample are separated according to their mass 
and the number and position of their former linkages. This technique was first introduced by 
Albersheim et al. while analysing polysaccharides from plant cell-wall (Albersheim et al., 1967). 
GC-EI-MS linkage analysis accompanied by chemical or enzymatic digestions has been shown to 
be a reliable method to aid the overall structural assignment by MS and MS/MS analyses by 
identifying monosaccharide constituents and glycosidic bond positions (Haslam et al., 1996; Kui 
Wong et al., 2003). Figure 1.21 illustrates the preparation of permethylated glycans for linkage 
analysis. 
Chapter 1    75 
 
 
 
Figure 1.21. The conversion of permethylated oligosaccharides to PMAAs. 
Similar sugar residues derived from different positions (reducing or non-reducing terminal) and linkages (4-
linked) in oligosaccharide chains are differentiated by their respective PMAA mass due to the variations in 
derivatisation and C-1 labelling. Reproduced from (Manzi & van Halbeek, 1999). 
 
Prior to the analysis, glycans are permethylated in order to permanently tag the hydroxyl 
groups that are not involved in any linkage with other sugar residues or in ring formation. The 
permethylated glycans are first subjected to acid hydrolysis releasing the partially methylated 
monosaccharides. The monosaccharides are then reduced (by breaking the ring structures) 
producing alditols with borodeuteride and the C-1 that is formerly involved in a linkage is 
labelled with deuterium (Manzi & van Halbeek, 1999). Free hydroxyl groups are then O-
acetylated to label the positions of the former linkages, thus the residues are now partially 
methylated alditol acetates (PMAA). PMAAs can be identified by comparison of their retention 
times on the GC column and the EI-MS spectra with those of known standards (Albersheim et 
al., 1967; Manzi & van Halbeek, 1999).  
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1.5   Thesis aims 
The general aims of this thesis were to optimise current O-glycomic methodologies and to 
perform more in-depth structural analysis on O-glycoconjugates, in order to help deliver a new 
level of understanding of the regulation and biological roles of O-glycans, as well as 
glycosyltransferases involved in their biosynthesis. This thesis encompasses glycomic mass 
spectrometric analyses of O-glycans derived from glycoproteins of mice and cell cultures from 
three separate but related projects. The projects are: 
 
1. High sensitivity O-glycomic analysis of wild type and C2GnT knockout murine tissues. 
This project aimed at characterising the changes in O-glycan structures resulting from 
partial and complete absence of C2GnT, and to associate the observed structural 
aberrations with murine pathology.  
 
2. O-glycosylation profiling of gastric mucosa from FuT2-null mice in relation to 
Helicobacter pylori adhesion. In this study, we performed detailed glycoepitope 
sequencing of murine gastric tissues in order to better understand the functional 
importance of fucosylated glycoconjugates in the pathogenicity of H. pylori.  
 
3. Investigation of cellular regulation of protein O-glycosylation by Src. High sensitivity O-
glycomic methodology that was optimised in the above projects was applied in this 
analysis to investigate the significance of Src activation and/or ppGalNAcT relocalisation 
in modulating the biosynthesis of O-glycans in a number of cell lines.  
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2 Materials and methods 
2.1 Materials 
2.1.1 Biological samples 
2.1.1.1 High sensitivity O-glycomic analysis of wild type and C2GnT knockout murine 
tissues 
Murine tissues including stomach, colon, small intestine, thyroid/trachea, thymus and 
kidneys from 129/SvJ wild type, C2GnT2 knockout (KO), C2GnT3 KO and C2GnT triple KO 
mice were supplied by our collaborators, Jamey D. Marth and colleagues from the University of 
California San Diego, USA. Details on the preparation of the murine tissues have been published 
(Stone et al., 2009). Mice singly deficient for C2GnT1, C2GnT2 and C2GnT3 were cross-bred to 
produce C2GnT triple KO mice. As illustrated in Figure 2.1, C2GnT1 KO mice were crossed to 
C2GnT3 KO mice and the progenies were bred to each other to generate mice doubly deficient 
for both C2GnT1 and C2GnT3 (T1/T3). T1/T3 mice were then bred to C2GnT2 KO mice and the 
progenies were bred together to produce mice deficient for all three genes (T1/T2/T3). 
 
2.1.1.2 O-glycosylation profiling of gastric mucosa from FuT2-null mice in relation to 
Helicobacter pylori adhesion 
Murine stomach and gastric mucosa scrapings from C57BL/6 wild type and FuT2-null 
mice were supplied by Celso A. Reis and colleagues from the University of Porto, Portugal. 
Details on the preparation of these samples have been published (Magalhaes et al., 2009). In 
addition, Lea and Muc5AC immunoprecipitated glycoproteins from murine stomach lysates of 
wild type and FuT2-null mice were also supplied. Immunoprecipitated samples were prepared by 
isolating Lea carrier glycoproteins and Muc5AC from stomach lysates separately using Sepharose 
beads conjugated with antibodies SPM279 and 45M1, respectively. Then the purified samples 
were confirmed by running on electrophoresis gel followed by Western blotting using similar 
antibodies. Selected bands for mass spectrometric analysis are shown in Figure 2.2.  
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Figure 2.1. Generation of mice deficient in all three C2GnT genes. 
Schematic diagram shows steps in cross-breeding between mice with different C2GnT genotypes. T1, 
C2GnT1 allele; T2, C2GnT2 allele; T3, C2GnT3 allele. Alleles written in black are normal, alleles written in 
blue are null. 
 
2.1.1.3 Investigation of cellular regulation of protein O-glycosylation by Src 
NIH3T3 Src mouse fibroblastic and NBT-II rat epithelial cell lines were supplied by our 
collaborators Frederic Bard and colleagues from the National University of Singapore. The first 
cell line was induced to have different levels of Src by transforming cells with low Src level (3T3 
WT) with viral Src (3T3 vSrc). The latter cell line was prepared with different localisation of 
exogenous human ppGalNAcT-2 in the ER (H2ER and WT ER) or the Golgi (WT Golgi). Wild 
type NBT-II cells were also supplied. Each sample consisted of around 35-50 million cells. 
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2.1.2 General chemicals and reagents 
The following materials were obtained from the sources indicated: Methanol, chloroform, 
propan-1-ol, ammonia solution, acetic acid, dimethylsulfoxide (DMSO) trifluoroacetic acid 
(TFA), and acetonitrile were purchased from Romil (Cambridge, UK). α-cyano-4-
hydroxycinnamic acid (CHCA), ethylenediaminetetraacetic acid (EDTA), potassium borohydride 
(KBH4), iodoacetic acid (IAA), hexane, 48% (v/v) hydrofluoric acid in water (HF), 
Tris(hydroxymethly)aminomethane (Tris), ammonium hydrogen carbonate (Ambic), formic acid, 
potassium hydroxide, Dowex 1-X8, 2,5-dihyroxybenzoic acid (DHB), sodium hydroxide 
(NaOH), sodium tetradeuteroborate (NaBD4), potassium hydroxide (KOH) and phosphate 
buffered saline tablets were from Sigma-Aldrich Company Ltd (Dorset, UK). Methyl iodide and 
acetic anhydride were from Alfa Aeser (Lancashire, UK). 8M guanidine-HCl (Gu-HCl) was from 
Pierce (Northumberland, UK). Dithiotreitol (DTT) and 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) were from Roche (West 
Sussex, UK). Sodium chloride (NaCl) was from Rose Chemicals (London, UK). 3,4-
diaminobenzophenone (DABP) and Macherey-Nagel Nucleosil NH2 polar phase was acquired 
from Fisher Scientific (Loughborough, UK). Tubes, bottles and beakers were washed thoroughly 
Figure 2.2. Western blotting of Lea and Muc5AC immunoprecipitated gastric mucosa from 
wild type and FuT2-null mice after gel electrophoresis.  
The blots were probed using antibody against (A) Muc5AC (45M1) and (B) Lea (SPM279). The 
yellow boxes indicate the bands of interest. The bands in the red boxes correspond to the antibodies 
(IgG) that were conjugated with the beads for the IP procedure. Data from Ana Magalhaes, 
University of Porto, Portugal. WB, Western blotting; IP, immunoprecipitation; wt, wild type. 
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with ultra high quality water which was generated from Purite Neptune water purification system 
from Purite Ltd. (Oxfordshire, UK) to avoid contamination. 
 
2.1.3 Enzymes, antibodies and proteins/peptides  
TPCK treated bovine pancreas trypsin (EC 3.4.21.4), albumin from bovine serum (BSA), 
IgA kappa from murine myeloma and goat anti mouse IgM peroxidase conjugate was purchased 
from Sigma-Aldrich Company Ltd. (Dorset, UK). Peptide: N-glycosidase F (PNGase F) 
containing 50% glycerol (Flavobacterium meningosepticum –recombinant from Escherichia coli, 
EC 3.5.1.52; 25000 U/mg) was purchased from Roche (West Sussex, UK). Sialidase A (from 
Escherichia coli, EC 3.2.1.18; > 5 U/ml), α1,3/4/6-galactosidase (from green coffee bean, EC 
3.2.1.22; 10 U), α1,2-fucosidase (Xanthomonas sp, 3.2.1.51; activity > 100 mU/ml) and β-N-
acetylhexosaminidase (HEXase I) (from E. coli, EC 3.2.1.52; 1.6 U) were purchased from 
Prozyme (Ely, UK). β1,4-galactosidase (Steptococcus pneumoniae, EC 3.2.1.23; specific activity 
> 600 pmol/min/µg) was from R&D Systems (Abingdon, UK). The 4700 mass standards kit 
which contains a peptide mixture of des-Arg 1-bradykinin (FW 904.0), angiotensin I (FW 
1296.5), [glu1]-Fibrinopeptide B (FW 1570.68) and adrenocorticotropic hormone 1-17 (FW 
2093.4) was obtained from Applied Biosystems (Warrington, UK). 
 
2.1.4 Labware and Equipment 
Homogenisation and sonication of tissues were performed by using a CAT X120 
homogenizer from CAT Ingenieurburo (Denmark) and Vibra-Cell VCX130 ultrasonic processor 
from Sonic & Materials Inc (Switzerland). Samples were concentrated by using a Savant SPD 
SpeedVac concentrator and lyophilized by using a Savant ModulyoD freeze dryer, both were 
from Thermo Fisher Scientific Inc (Basingstoke, UK). Sep Pak C18 cartridges and Oasis HLB 
extraction cartridges were from Waters Corporation (Hertfordshire, UK). SnakeSkin dialysis 
tubing (7kDa molecular weight cut off) was from Pierce (Northumberland, UK). Nitrogen and 
argon gases were supplied by BOC (Guilford, UK). RTX-5MS GC column was purchased from 
Thames Restek UK Ltd (Saunderton, UK). All aqueous solutions were made up using ultra high 
quality water which was generated from Purite Neptune water purification.  
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2.2 Methods 
2.2.1 Isolation of glycopeptides/peptides 
2.2.1.1 Tissue homogenisation (without glycolipid removal) 
This procedure has been described previously (Sutton-Smith & Dell, 2006). Tissues were 
first weighed and then were disrupted on ice by using a homogenizer in the presence of 5 ml 
homogenisation buffer (25 mM Tris, 150 mM NaCl, 5 mM EDTA and 1% CHAPS at pH 7.4) 
(for tissues between 0.1 g to 3 g). Lysates were then transferred into dialysis tubing (pre-soaked in 
water) dialysed against 50 mM ambic buffer pH 8.5 at 4oC for 48 hours with several buffer 
changes. After dialysis, lysates were transferred into 15 ml tubes and lyophilised. Then, samples 
were ready for reduction and carboxymethylation.  
 
2.2.1.2 Tissue homogenisation (with glycolipid removal) 
This method has been described previously (Parry et al., 2007). Tissues were first 
weighed. With assumption that 80% of the tissue weight is water, at least 4 volumes of ice cold 
water were added to the sample which was then homogenised. After the samples were completely 
homogenised, based on the total water volume in sample, 2.67 volumes of methanol were added 
and then the samples were mixed vigorously. Next, 1.33 volumes of chloroform were added, 
followed by vigorous mixing. The samples were then centrifuged (3000 rpm, 10 min). The 
supernatants which contain glycolipids were carefully removed. Protein pellets were blown for a 
few minutes under a nitrogen stream to remove excess methanol and chloroform without 
completely drying the samples. 50 µl of 0.6 M Tris buffer was added to each sample and then 
removed under a nitrogen stream without completely drying the samples. Protein pellets were 
then either reduced and carboxymethylated immediately or kept at -20oC.  
 
2.2.1.3 Cell sonication 
A sufficient amount (1- 2 ml) of ice-cold cell lysis buffer (25 mM Tris, 150 mM NaCl, 5 
mM EDTA and 1% (w/v) CHAPS, pH 7.4) was added to cell preparations to ensure complete 
suspension before transferring into 15 ml tubes. The suspensions were sonicated on ice in 
continuous mode at 40 Amps for 10 seconds. The sonication was repeated for 4 or 5 times with a 
pause for about 15 seconds between each repeat. Then lysates were transferred to dialysis tubing 
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and dialysed against 50 mM ambic buffer pH 8.5 at 4oC for 48 hours with several buffer changes. 
Samples were finally transferred into 15 or 50 ml tubes and lyophilised.      
 
2.2.1.4 Protein reduction and carboxymethylation 
Proteins were reduced and carboxymethylated as previously described (Parry et al., 
2007).  Lyophilised tissue lysate or protein pellet were reduced by incubation in 0.6 M Tris/4 M 
Guanidine-HCl buffer pH ~8.5 containing 2 mg/ml dithiothreitol at 50oC for 2 hours. This was 
followed by carboxymethylation in 0.6 M Tris buffer containing 12 mg/ml of iodoacetic acid 
incubated in the dark at room temperature for 2 hours. Carboxymethylation was then terminated 
by dialysis against 50 mM Ambic buffer pH 8.5, at 4oC for 48 hours with several buffer changes, 
followed by lyophilisation in 15 or 50 ml tubes. 
 
2.2.1.5 Cleavage into peptides and glycopeptides 
Protein digestion using TPCK treated bovine pancreas trypsin and purification was 
performed as previously described (Sutton-Smith & Dell, 2006). For each mg of tissue sample, 
1.5 µg of trypsin from a 1 mg/ml trypsin solution in 50 mM Ambic buffer (pH 8.5) was added to 
the lysates. For cell samples, about 1 mg of trypsin was used for every 2- 3 million cells. 
Incubation was performed at 37oC for 14 hours, followed by purification with Oasis HLB 
extraction cartridges.  
 
The cartridges were first attached to 10 ml polypropylene/polyethylene syringes and each 
successively conditioned with 5 ml methanol, 5 ml of 5% (v/v) acetic acid, 5 ml propan-1-ol and 
15 ml of 5% (v/v) acetic acid. The digested samples were then loaded onto the cartridges, washed 
with 20 ml of acetic acid (5% v/v) to remove hydrophilic contaminants, and then eluted 
sequentially with 5 ml of each 20% and 40% propan-1-ol solution in 5% (v/v) acetic acid. The 
propan-1-ol elutions, which contain glycopeptides and peptides, were concentrated with the 
Savant SpeedVac, combined and subsequently lyophilised overnight.  
 
2.2.2 Digestion of N-glycans from glycopeptides 
The lyophilised glycopeptide and peptide fractions were dissolved in 200-300 µl of 50 
mM ambic buffer (pH 8.4) before adding a total of 3 unit of PNGase F and incubating at 37oC for 
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24 hours. Another 2- 3 unit of PNGase F were added after a few hours of incubation. The samples 
were then lyophilised and re-dissolved in 200 µl of 5% (v/v) acetic acid for solid phase extraction 
with Sep-Pak C18 cartridges as described previously (Sutton-Smith & Dell, 2006). 
 
The cartridges were first attached to 10 ml glass syringes and each was successively 
conditioned with methanol (5 ml), 5% (v/v) acetic acid (5 ml), propan-1-ol (5 ml) and 5% (v/v) 
acetic acid (15 ml). The samples were then eluted sequentially with 5 ml of 5% (v/v) acetic acid, 
4 ml of each 20% and 40% propan-1-ol solution in 5% (v/v) acetic acid. All elutions were 
concentrated with Savant SpeedVac. The acetic acid fractions, which contain the released N-
glycans, were lyophilised and later permethylated. The propan-1-ol eluents, which contain O-
glycopeptides, were combined prior to lyophilisation and subsequent release of O-glycans. 
 
2.2.3 Release of O-glycans from glycopeptides 
Reductive elimination of O-glycans was performed as described previously (Sutton-
Smith & Dell, 2006). 400 µl 0.1 M KOH containing KBH4 (54 mg/ml) was added to the dried 
glycopeptide sample and incubated at 45oC for 14-16 hours. The reaction was terminated by 
adding a few drops of 5% (v/v) acetic acid followed by purification with a Dowex 1-X8 desalting 
column. 
 
To prepare the desalting column, a 150 mm Pasteur pipette was fitted with a small piece 
of glass wool inside it and a piece of silicone tubing at its tapered end and then packed with 
Dowex beads for each of the samples. The columns were first washed with 15 ml of 5% (v/v) 
acetic acid. Next, the samples were loaded carefully on top of the column and then eluted with 7 
ml of 5% (v/v) acetic acid. The volume of the eluents was reduced with a Savant Speedvac 
followed by lyophilisation overnight. Excess borates in the samples were removed by co-
evaporating with 10% (v/v) acetic acid in methanol (4 x 0.5 ml) under a stream of nitrogen at 
room temperature. The purified native O-glycans were subsequently permethylated. 
 
2.2.4 Permethylation and purification for non-sulphated glycan analysis 
Sodium hydroxide (NaOH) permethylation was performed according to an established 
procedure as described previously (Dell, 1990). Samples ware ensured to be completely dried 
before permethylation.  About 7- 8 NaOH pellets were ground to a fine powder in a dried mortar 
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and mixed with 5 ml of anhydrous DMSO. Then, about 1 ml of the resulting slurry was 
immediately added to each sample, followed by the addition of about 0.7 ml of methyl iodide. 
The samples were then mixed rigorously on an automatic shaker for 15 min at room temperature. 
The reaction was quenched by drop wise addition of water, while constantly shaking the sample 
tube to lessen the exothermic effect.  Permethylated glycans were extracted by adding about 1 ml 
of chloroform to the sample. This was followed by another rigorous shaking before removing the 
water layer that contains hydrophilic contaminants. The chloroform layer was later washed 
several times with water by rigorous shaking. Finally, the chloroform layer was dried down under 
a gentle stream of nitrogen.  
 
Purification of permethylated samples were done by using Sep-Pak C18 cartridges. The 
cartridges were first attached to 10 ml glass syringes and each successively conditioned with 
methanol (5 ml), water (5 ml), acetonitrile (5 ml) and water (15 ml). Each sample was dissolved 
in 200 µl of methanol:water (1:1) solution before loading onto the cartridges. The cartridges were 
washed with 5 ml of water and then eluted sequentially with 3 ml of each 15%, 35% and 50% 
acetonitrile/water. All eluents were then concentrated with a Savant SpeedVac and subsequently 
lyophilised. Samples were then ready for mass spectrometric analysis or derivatisation for linkage 
analysis. 
 
2.2.5 Permethylation and purification for sulphated O-glycan analysis 
The methodology was based on the work of  K.H. Khoo’s group (Yu et al., 2009). A dried 
glycan sample in a glass tube was redissolved in a slurry of finely ground NaOH pellets in about 
0.2 ml DMSO, similar to that described for the non-sulphated glycans. About 0.1 ml of methyl 
iodide was added and the sample was gently vortexed for 3 hours at 4oC. The reaction was 
quenched by the drop wise addition of with 0.2 ml of cold water while placing the glass tube on 
ice, followed by careful pH neutralisation using 30% aqueous acetic acid by checking on a pH 
indicator paper. The sample was then purified by using a C18 Sep-Pak cartridge. The cartridge 
was conditioned as described above (Section 2.2.4). However, after sample application, the 
cartridge was washed to remove hydrophilic salts and contaminants by using 5 ml each of 
ultrapure water and 2.5% and 10% acetonitrile/water. This was followed by glycan elution with 5 
ml each of 25% and 50% acetonitrile/water and the fractions were concentrated with the 
SpeedVac. The 25% fraction was then subjected to amine column fractionation. 
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2.2.6 Fractionation of sulphated O-glycans by an amine column 
Amine beads (Nucleosil NH2, 5 µm particle size) were packed into a 5 ml pipette tip with 
the tapered end plugged by a small piece of filter paper. The volume of the packed beads was 
around 5 µl.  The column was first conditioned and washed sequentially with 5% 
acetonitrile/0.1% formic acid, 50% acetonitrile/0.1% formic acid and 95% acetonitrile/0.1% 
formic acid. The permethylated glycan sample was dissolved in 100% acetonitrile and then 
loaded to the column, and hydrophobic contaminants were washed off with 95% acetonitrile. 
Sulphated glycans were eluted with 2.5 mM and 10 mM ammonium acetate in 50% acetonitrile. 
Eluents were then concentrated by using a SpeedVac prior to mass spectrometric analysis. 
  
2.2.7 Derivatisation of glycans for linkage analysis 
Partially methlyated alditol acetates for GC-EI-MS analysis were prepared from 
permethylated glycans according to procedures described previously (Sutton-Smith & Dell, 
2006). Samples were first hydrolysed to partially methylated monosaccharides by incubation in 
200 µL of 2 M TFA at 121oC for 2 hours. This was followed by a reducing process with 200 µL 
of 10 mg/ml NaBD4 in 2 M ammonia solution at room temperature for 2 hours. Samples were 
then acetylated by incubation in 200 µl of acetic anhydride at 100oC for 1 hour and then dried 
under a very slow nitrogen stream. The resulting partially methylated alditol acetate 
monosaccharides were extracted with chloroform the same way as permethylated glycans. The 
samples were finally dried under a very slow nitrogen stream. 
 
2.2.8 Enzymatic/chemical glycan degradation 
2.2.8.1 α-galactosidase, sialidase A and α1,2-fucosidase digestions 
Released O-glycan samples after the borate removal step were dissolved in a small 
amount of ultrapure water and then lyophilised. Each of the samples was dissolved in 100 μl of 
50 mM ammonium acetate pH 5.4 (pH adjusted with acetic acid) and 55 μl of ultra pure water. 5 
μl (25 mU) of α-galactosidase, 35 μl (175 mU) of sialidase A and 5 μl (0.5 mU) of α1,2-
fucosidase were added to each sample. Incubation was done at 37oC overnight and followed by 
lyophilisation. Digested samples were then purified by using solid phase extraction with Sep-Pak 
C18 cartridges as described in Section 2.2.2. Only the acetic acid fraction was collected, 
lyophilised and permethylated. 
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2.2.8.2 β-N-acetylhexosaminidase/HEXase I digestion 
Released O-glycan samples after the borate removal step were dissolved in a small 
amount of ultrapure water and then lyophilised. 10 µl of the supplied reaction buffer, 40 µl of 
ultrapure water and 10 µl (80 mU) of the enzyme were added to the each of the samples. 
Incubation was done at 37oC for 24 hours followed by lyophilisation. The samples were then 
purified by using solid phase extraction with Sep-Pak C18 cartridges as described in Section 
2.2.2. Only the acetic acid fraction was collected, lyophilised and permethylated. 
 
2.2.8.3 β1,4-galactosidase digestion 
Released O-glycan samples after the borate removal step were dissolved in a small 
amount of ultrapure water and then lyophilised. 70 µl of 50 mM ammonium acetate pH6.0 and 40 
µl (0.012 µmol) of the enzyme were added to each of the samples. Incubation was done at 37oC 
for 24 hours followed by lyophilisation. The samples were then purified by using solid phase 
extraction with Sep-Pak C18 cartridges as described in Section 2.2.2. Only the acetic acid fraction 
was collected, lyophilised and permethylated. 
 
2.2.8.4 TFA  defucosylation 
1 ml of TFA was added to native or permethylated glycans and incubated at 20oC in water 
bath for 20 hours. The samples were then lyophilised, permethylated and purified as explained 
earlier. 
 
2.2.9 Mass spectrometric analysis 
2.2.9.1 Preparation of matrices 
2,5-dihyroxybenzoic acid (DHB) solution was prepared by dissolving the powder in 
either 70:30 methanol: water at a concentration of 20 mg/ml (for all O-glycan analysis in the 
positive ion mode of MALDI-TOF/TOF) or 80:20 methanol/water at a concentration of 10 mg/ml 
(for all O-glycan analysis using MALDI-QIT-TOF). α-cyano-4-hydroxycinnamic acid (CHCA) 
solution was prepared by dissolving the powder in 50:40:10 methanol: water: TFA at a 
concentration of 10 mg/ml (for peptide calibration standards). 3,4-diaminobenzophenone 
(DABP) was prepared by dissolving the powder in 75% acetonitrile/0.1% TFA at a concentration 
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of 10 mg/ml (for sulphated O-glycan analysis in the negative ion mode). The matrices were 
prepared fresh every week. 
 
2.2.9.2 MALDI-TOF/TOF mass spectrometry and tandem mass spectrometry 
Permethylated glycan samples were resuspended in 10 µL of methanol. 2 µl of sample 
was then mixed with 2 µl of DHB matrix solution. The mixture was then spotted on a stainless 
steel MALDI target (with a total of 1 µl for each spot) and allowed to dry under vacuum. MALDI 
mass spectrometric (MS) data were acquired by using the 4800 MALDI-TOF/TOF analyser mass 
spectrometer (Applied Biosystems, USA) in positive ion and reflectron mode by using DHB as 
the matrix. The instrument was calibrated by using peptides from the 4700 mass standards kit 
with CHCA as the matrix. Tandem mass spectrometric (MS/MS) data were acquired by using the 
same instrument with the collision energy set at 1 kV. Argon was used as the collision gas with a 
pressure at 3.5 10-6 Torr.  
 
2.2.9.3 ESI-QTOF tandem mass spectrometry 
ESI-QTOF-MS/MS data were acquired by using the Qstar Pulsar Hybrid System mass 
spectrometer (Applied Biosystems/MDS Sciex, Toronto, Canada) in the positive ion mode and 
pre-calibrated with 10-100 fmol/µL of [Glu1]-fibrinopeptide B in 5% (v/v) acetonitrile/acetic 
acid. A few µl of permethylated samples dissolved in methanol were injected manually via 
syringe into the instrument. The collision energy used was varied between 30 eV and 90 eV 
depending on the size and nature of the target glycan. The collision gas used was nitrogen with a 
pressure at 5.3 x 10-5 Torr.  
 
2.2.9.4 GC-EI mass spectrometry 
The partially methylated alditol acetate samples were reconstituted in a small amount of 
hexane. Data were acquired by using the Clarus 560 D GC mass spectrometer (Perkin Elmer, 
USA) fitted with an RTX-5MS column (30 m x 0.25 mm internal diameter) (Thames Restek, 
UK). The samples were injected into the column at 60oC and then the temperature was increased 
at 8oC/min to 300oC.   
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2.2.9.5 MALDI-QIT-TOF mass spectrometry and tandem mass spectrometry 
Permethylated glycan samples were resuspended in 5 µL of 80% methanol/water. 1 µl of 
sample was then spotted on a stainless steel MALDI target and allowed to air-dry. Then, 1 µl of 
DHB matrix solution was deposited onto the same position and allowed to air-dry. Samples were 
analysed by using an Axima Resonance MALDI-QIT-TOF mass spectrometer (Shimadzu, UK) 
in ‘mid 850’ positive ion mode. The instrument was calibrated by using peptide standards in 
CHCA (5 mg/ml in 50/50 acetonitrile/0.1% TFA. Argon was used as the CID gas. 
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3 High sensitivity O-glycomic analysis of wild type and C2GnT knockout murine 
tissues 
3.1 Background 
Core 2 β1,6-N-acetylglucosaminyltransferase (C2GnT), which exists in 3 isoforms, 
C2GnT1, C2GnT2 and C2GnT3, is one of the key enzymes in the O-glycan biosynthetic 
pathway, as discussed in Section 1.2.2.3. These isoenzymes produce core 2 O-glycans and have 
been correlated with the biosynthesis of core 4 O-glycans and I-branches. Our collaborators, 
Jamey Marth and colleagues from the University of California San Diego have generated mice 
with single and multiple deficiencies of C2GnT isoenzyme(s) and have evaluated the biological 
consequences of the loss of core 2 function. We at Imperial College have performed 
comprehensive O-glycomic analyses of neutral and sialylated glycans expressed in the colon, 
small intestine, stomach, kidney, thyroid/trachea and thymus of wild type, C2GnT2 and C2GnT3 
single knockouts and the C2GnT1-3 triple knockout mice. This work contributed to most of the 
optimisation of our O-glycomic methodologies and knowledge of murine O-glycan structures 
that were then utilised in other work described in this thesis. 
 
3.2 Results 
3.2.1 O-Glycomic strategies 
The murine tissues analysed are listed in Table 3.1. Tissues were selected based on the 
expression profiles of C2GnTs supplemented by phenotypic data emerging throughout the study. 
The glycomic strategy employed was a refinement of earlier methodologies. A variety of 
extraction procedures were assessed with respect to O-glycan recovery and mass spectral quality. 
Two approaches were found to be best suited to the range of tissues examined (described in 
Chapter 2). Most tissues were homogenised using the technique without glycolipid removal 
(Section 2.2.1.1), but for stomach the homogenisation procedure which included glycolipid 
removal (Section 2.2.1.2) was used instead as that methodology appears to give the best O-glycan 
data for stomach tissues. Tissue lysates were then reduced/ carboxymethylated and digested with 
trypsin to facilitate subsequent release of N- and O-glycans. After N-glycan digestion by PNGase 
F, the O-glycans were released by reductive elimination. However, for stomach O-glycans the 
best data were acquired when O-glycans were analysed without prior N-glycan removal.  Purified 
O-glycans were permethylated to increase the sensitivity of detection and to direct the subsequent 
mass spectrometric fragmentation. Both the 35% and 50% acetonitrile/water fractions from Sep-
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Pak C18 purification were subjected to mass spectrometric analysis. Glycans were detected as 
singly charged sodiated molecular ions [M+Na]+ in the positive ion mode. Consistent and 
reproducible data were obtained from at least two repeats of experiments. Most O-glycans were 
detected in the 35% fraction, but data acquisition from both fractions was combined in some 
instances to have better signals of the high-mass glycans. 
 
Table 3.1. List of tissues analysed in this study derived from the wild type (WT), C2GnT2 KO (KO2), 
C2GnT3 KO (KO3) and C2GnT triple KO (TKO) mice. 
 
 
Additional O-sulphoglycomic analysis was also performed on colon tissues. Methods 
were based on the work of K.H. Khoo and colleagues as described in Chapter 2. In this analysis, 
the workflow was the same as described for the non-sulphated glycans up to the derivatisation 
stage, at which a modified permethylation technique was used instead, aimed to preserve the 
sulphate groups as well as to ensure the recovery of the sulphated glycans (see Section 2.2.5). The 
subsequent C18 Sep-Pak purification (Section 2.2.5) resulted in two fractions, the 25% 
acetonitrile/water fraction that contains most of the sulphated glycans and the 50% 
acetonitrile/water fraction that contains most of the non-sulphated glycans. The 25% fraction was 
then subjected to amine column fractionation (see Section 2.2.6) to separate neutral glycans (non-
sulphated), which elute in the unbound fraction, from charged glycans (sulphated) in the 2.5 mM 
and 10 mM ammonium acetate/acetonitrile elutions. The 50% acetonitrile fraction from the Sep-
Pak purification and both the ammonium acteate/acetonitrile fractions were analysed in both 
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positive and negative ion modes of MALDI-TOF/TOF-MS and MS/MS. In the negative ion 
mode, sulphated O-glycans were detected as singly charged deprotonated molecular ions [M-H]-, 
whereas in the positive ion mode, they were detected as singly charged disodiated deprotonated 
molecular ions [M+2Na-H]+.  
 
3.2.2 Exhaustive tandem mass spectrometric analysis of permethylated products of 
reductive elimination differentiates glycan isoforms and terminal epitopes 
Mass fingerprinting and sequencing were primarily carried out using a MALDI-
TOF/TOF mass spectrometer. Additional analyses using ESI-QTOF-MS, MALDI-QIT-TOF-MS 
and GC-EI-MS were performed on selected samples. The MS/MS analysis enabled 
differentiation of the structures and sequences of glycans with the same m/z value and 
composition. Figure 3.1 shows an example of how MS/MS data were used to characterise glycan 
structures. The stomach of the wild type and C2GnT2 knockout mice shared a molecular ion at 
m/z 1331 in their mass fingerprint (Figure 3.1A and B) and the MS/MS spectra of each of these 
ions are reproduced in the figure. It is evident that in the wild type mice the ion at m/z 1331 
corresponds to a core 2 O-glycan (see annotated cartoon in Figure 3.1C).  However, in the 
C2GnT2 knockout mice, the fragmentation was clearly different (Figure 3.1D). In this case, 
fragment ions attributable to the core 2 O-glycan are relatively minor and all major fragment ions 
are assignable to the elongated core 1 O-glycan shown in the annotation.  Definitive fragments 
for the core 1 O-glycan are m/z 298, 520 and 1056.  This MS/MS strategy for unambiguously 
differentiating between core 1 and core 2 antennae, and assigning antennae sequences, was 
applied to all analyses throughout this thesis.  
 
3.2.3 Glycomic analysis of the colon from wild type and knockout mice 
The O-glycomic analysis of the colon from wild type mice is presented in a partial mass 
spectrum from m/z 1000-2000 for comparison with the knockout tissues in Figure 3.2A as well as 
in a full range mass spectrum with detailed annotations in Figure 3.3A.  All major glycan 
structures detected, including from the knockout tissues, are collated in Table 3.2. The results 
showed that the wild type colon is dominated by core 2 O-glycans, for example at m/z 1024 
(HexNAc3Hex1) and 1763 (HexNAc3Hex2Fuc1NeuAc1) (Table I). Core 1 O-glycans are of lower 
abundance, for instance at m/z 1198 (HexNAc3Hex1Fuc1) and 1950 (HexNAc3Hex2NeuAc2). I-
branches on the Gal of core 1 arm were also detected on both core 1 and core 2 O-glycans, for 
instance at m/z 1432 (HexNAc3Hex3) and 1881 (HexNAc4Hex4), respectively. It was also evident 
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that the colon was rich with glycans that are terminated with the Sda epitope, for example at m/z 
1140 (HexNAc2Hex1NeuAc1) and 2196 (HexNAc4Hex2NeuAc2), with the latter carrying two Sda 
epitopes (Table 3.2).      
 
 
Figure 3.1. MALDI-TOF/TOF-MS and MS/MS spectra of the molecular ion m/z 1331 [M+Na]+ detected 
in the mass fingerprinting of the stomach from wild type and C2GnT2 knockout mice.   
Selected sections from O-glycomic mass fingerprinting of the stomach from wild type (A) and C2GnT2 
knockout (B) mice showing several [M+Na]+ peaks with the same m/z. High sensitivity tandem mass 
spectrometric data differentiates glycans of the same composition (HexNAc2Hex2Fuc2) and mass (m/z 
1331) but with different O-glycan core types.  In the wild type stomach (C), the core 2 O-glycan was the 
only isoform detected whereas in the C2GnT2 knockout mice (D), there was a mixture of core 2 and core 1 
O-glycans with the latter as the major component.  
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Figure 3.2. MALDI-TOF-MS profile of O-glycans from the colon of wild type and knockout mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the colon of (A) wild 
type, (B) C2GnT2 knockout, (C) C2GnT3 knockout and (D) C2GnT triple knockout mice. Cartoon 
structures assigned were based on mass spectrometric data and knowledge of O-glycan biosynthetic 
pathways for the selected range of m/z 1000 to 2000. X, impurities. 
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Table 3.2. O-glycan structures from the colon of wild type and knockout mice.  
This table summarises major structures [M+Na]+ observed in the MALDI-TOF-MS spectra of colon tissues 
from wild type, C2GnT2 knockout, C2GnT3 knockout and C2GnT triple knockout mice. 
 
 
C2GnT2 is highly expressed in the colon relative to other tissues (Stone et al., 2009). As 
expected, the deficiency of this isoenzyme caused immense structural changes (As shown in 
partial mass spectrum in Figure 3.2B, full range mass spectra in Figure 3.3B and collated 
structures in Table 3.2). Analysis of the colon from C2GnT2 knockout mice showed that most 
core 2 O-glycan structures have been replaced with linear core 1 structures. For example, the 
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glycan at m/z 1157 (HexNAc2Hex2Fuc) in the wild type mice was a core 2 O-glycan terminated 
with the H antigen (Table 3.2). In the C2GnT2 knockout colon, it was revealed by MS/MS 
analysis that the same glycan composition was a linear core 1 O-glycan still terminated with the 
H antigen (Table 3.2). Interestingly, there were also changes in the type of terminal epitopes 
consequent upon loss of the core 2 branch. For example, there was an increase in fucosylation 
density on individual glycan antennae leading to the formation of the atypical glycan epitope Ley 
on the core 1 O-glycan at m/z 1331 (HexNAc2Hex2Fuc2). The isobaric glycan in the wild type has 
a core 2 structure terminated with two H antigens (Table 3.2). In addition, there was also a 
reduction of glycans carrying the I-branch in the C2GnT2 knockout colon compared to the wild 
type, for example at m/z 1432 and 1881 (Table 3.2). 
 
C2GnT3 is expressed at relatively low abundance in the colon (Stone et al., 2009). As 
shown by the mass spectrometric analysis (Figure 3.2C, Figure 3.3C and Table 3.2), O-glycan 
structures from the colon of C2GnT3 knockout mice were similar to the colon of wild type mice. 
For example, the glycan at m/z 1157 in the wild type and C2GnT3 knockout tissues were both 
core 2 type (Table 3.2). Another example, at m/z 1432, there was a mixture of core 1 and core 2 
isoforms with the same composition in the wild type colon and the mixture remained similar in 
the C2GnT3 knockout.            
 
The triple knockout mice lack the ability to synthesise all three known isoforms of 
C2GnT. This multiple deficiency caused a complete absence of core 2 O-glycans in the colon 
(Figure 3.2D, Figure 3.3D and Table 3.2). In addition, there was also a complete disappearance of 
I-branches on both core 1 and core 2 O-glycans.  For example, in the wild type colon, glycans at 
m/z 1432 consisted of core 2 and branched core 1 structures, whereas in the triple knockout colon, 
an elongated linear core 1 structure was detected (Table 3.2). 
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Figure 3.3. The full range MALDI-TOF-MS spectra of permethylated O-glycans from the colon of 
wild type and knockout mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the colon of (A) wild 
type, (B) C2GnT2 knockout, (C) C2GnT3 knockout and (D) C2GnT triple knockout mice. Cartoon 
structures assigned were based on mass spectrometric data and knowledge of O-glycan biosynthetic 
pathways. The black arrow showing a signal with -14 mass units in each profile corresponds to 
underpermethylation of that particular glycan. All unannotated signals with similar intervals from annotated 
glycan peaks correspond to their respective underpermethylated form. X, impurities. 
 
3.2.4 O-sulphoglycomic analysis of the colon from wild type and knockout mice 
As previous work has indicated significant levels of sulphated O-glycans in colonic 
mucins (Inoue & Yosizawa, 1966; Thomsson et al., 2010), we considered it important to 
determine if similar reductions of core 2 O-glycans could be observed in the profile of sulphated 
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O-glycans derived from C2GnT2 knockout mice in comparison to the wild type. To this end we 
investigated whether the newly proposed methodology for sulphoglycomics (Yu et al., 2009) was 
suited to the analysis of mucinous tissues. This was, indeed, found to be the case. The O-
sulphoglycomic analysis was done according to the adapted strategy as described in Section 
3.2.1. The best O-sulphoglycomic profiles in terms of high intensity of sulphated O-glycans and 
low contamination by their non-sulphated counterparts were observed from the 2.5 mM 
ammonium acetate fractions in the negative ion mode [M-H]-. A significant number of sulphated 
O-glycans was also detected in the 10mM ammonium acetate fractions but with slightly higher 
contamination. MS/MS analyses, however, were acquired from both ammonium 
acetate/acetonitrile fractions and gave better fragmentation in the positive ion mode (as [M+2Na-
H]+) compared to the negative ion mode. Exemples of the MALDI-TOF-MS profiles of sulphated 
O-glycans from the colon of wild type and C2GnT2 knockout mice are shown in Figure 3.4A and 
B, respectively. 
 
The results showed that the wild type colon, similar to the non-sulphated profile (Figure 
3.2A), is dominated by core 2 O-glycans, for example at m/z 1270 [(SO3)HexNAc3Hex2)] and 
m/z 1444 [(SO3)HexNAc3Hex2Fuc1)] (Figure 3.4A). Core 1 O-glycans are of lower abundance, 
for instance at m/z 1025 and 1199, the earlier as a mixture with an isobaric core 2 O-glycan 
structure.  I-branches on the Gal of core 1 that were quite abundant in the non-sulphated wild type 
colon profile however were not detected here. In the C2GnT2 knockout mice, there was a 
complete loss of sulphated core 2 O-glycans concomitant with the increase in elongated sulphated 
core 1 O-glycans. All sulphated O-glycan compositions detected in the wild type, except for the 
glycan at m/z 1760, were also observed in the knockout profile entirely as core 1 isoforms. We 
detected only one sulphate per O-glycan molecule (monosulphated) either on the reducing or the 
non-reducing end in both wild type and C2GnT knockout colon. Due to the complexity of the 
MS/MS data and the limited fragmentation observed, not all sulphate moieties managed to be 
determined their exact positions. However, unexpectedly we have discovered an unusual 
sulphation on the reducing GalNAc of the glycans at m/z 1025 and 1270 ([M-H]-) in the wild type 
and C2GnT2 knockout colon, respectively (see MS/MS annotations in Figure 3.5A and B, 
respectively). Especially relevant are the signals at m/z 708 in Figure 3.5A and m/z 953 in Figure 
3.5B because they correspond to elimination of the core 1 branch without including any sulphate 
group. To our knowledge and also by searching the CFG database, such modification has not 
been reported. Sulfotransferase (ST) isoforms that act on the non-reducing terminal GalNAc have 
been described in mice, namely GalNAc-4-ST1 and -2 (Boregowda et al., 2005), however none 
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has been associated with the reducing GalNAc. Therefore, this unique modification is intriguing 
and should be further investigated, particularly using the MSn analysis, in future studies.    
 
 
Figure 3.4. MALDI-TOF-MS profile of sulphated O-glycans from the colon of wild type and C2GnT2 
knockout mice. 
The glycomic profiles of reduced and permethylated sulphated O-glycans [M-H]- detected in the colon of 
(A) wild type and (B) C2GnT2 knockout mice for the selected range of m/z 1000 to 2000. MS/MS data 
were acquired in the positive ion mode [M+2Na-H]+. The black arrow showing a signal with -14 mass units 
corresponds to underpermethylation of that particular glycan. All unannotated signals with similar intervals 
from annotated glycan peaks correspond to their respective underpermethylated form.  X, impurities/ 
unknown peaks; S, sulphate. 
 
3.2.5 Glycomic analysis of the stomach from wild type and knockout mice 
O-Glycomic analysis of the stomach from wild type mice revealed that this tissue, similar 
to the colon, was dominated with core 2 O-glycans (Figure 3.6A; structures are summarised in 
Table 3.3). Because the wild type murine stomach was also extensively characterised and 
presented in the next chapter of this thesis (see Figure 4.1), the full range mass spectrum of this 
tissue is not included here due to the high similarity between them. One of the unique features of 
the wild type stomach is the detection of high-mass O-glycan structures up to m/z 3926 (Figure 
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4.1). The most abundant terminal epitope in the stomach was found to be the H antigen, for 
example at m/z 1157 and 1331 (Figure 3.6A and Table 3.3). In addition, core 1 and core 2 O-
glycans in this tissue were found to be highly branched on the core 1 arm, similar to what was 
seen in the colon, for example glycans at m/z 1431 and 1881. Interestingly, the glycan at m/z 1473 
(HexNAc4Hex2) which is a core 2 O-glycan carrying HexNAc terminated antennae, was detected 
at a significant level. This glycan has been postulated to carry the rare and functionally important 
GlcNAcα1-4Gal epitope which was recently identified in the wild type mouse stomach 
(Kawakubo et al., 2004; Lee et al., 2008). However, enzymatic digestion with β-N-
acetylhexosaminidase/HEXase I caused a significant reduction of this glycan showing that the 
terminal HexNAc residues observed here are mainly β-linked GlcNAc. 
 
 
Figure 3.5. The MALDI-TOF/TOF-MS/MS spectra of the sulphated O-glycans showing the unusual 
reducing GalNAc sulphation. 
The fragmentation of (A) the glycan at m/z 1071 [M+2Na-H]+ corresponding to the molecular ion m/z 1025 
in the negative ion mode mass spectrum of the wild type colon and (B) the glycan at m/z 1316 [M+2Na-H]+ 
corresponding to the molecular ion at m/z 1270 in the negative ion mode mass spectrum of the C2GnT2 
knockout colon. Due to the complexity of the fragmentation pathway, not all fragments were able to be 
assigned. 
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Figure 3.6. MALDI-TOF-MS spectra of O-glycans from the stomach of wild type and knockout mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the stomach of (A) 
wild type, (B) C2GnT2 knockout, (C) C2GnT3 knockout and (D) C2GnT triple knockout mice. Cartoon 
structures assigned were based on mass spectrometric data and knowledge of O-glycan biosynthetic 
pathways for the selected range of m/z 1000 to 2000. 
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Table 3.3. O-glycan structures from the stomach of wild type and knockout mice.  
This table summarises major structures [M+Na]+ observed in the MALDI-TOF-MS spectra of stomach 
tissues from wild type, C2GnT2 knockout, C2GnT3 knockout and C2GnT triple knockout mice. 
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In the C2GnT2 knockout mice, as expected, due to the relatively high expression level of 
C2GnT2 in the stomach (Stone et al., 2009), there was a great reduction of core 2 O-glycans 
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compared to the wild type mice (Figure 3.6B, Figure 3.7A and Table 3.3). Glycans at m/z 1473, 
1677 and 1922 are examples of the remaining core 2 structures, all carrying one or two terminal 
HexNAc residues (Figure 3.6B and Table 3.3). The C2GnT2 deficient mice synthesised abundant 
extended core 1 O-glycans in the stomach, for instance at m/z 1187, 1331 and 1361. Moreover, a 
significant reduction of branched O-glycans was also observed in the stomach for example at m/z 
1606 and 1780. Similar to the colon of C2GnT2 knockout mice, there was an increase in 
fucosylation density on individual glycan antennae leading to the formation of Lewisy, which was 
not detected in the wild type, for instance on the glycan at m/z 1331. Another interesting finding 
from this tissue was an emergence of O-linked mannosyl glycans at m/z 738 and 912, which were 
not detected in the wild type stomach. 
 
C2GnT3 is also not the main C2GnT isoenyzme in the stomach, similar to the colon 
(Stone et al., 2009). There were no substantial changes in the O-glycomic profile of the stomach 
from C2GnT3 knockout mice (Figure 3.6C, Figure 3.7B and Table 3.3). However, unexpectedly, 
there was an increase of the glycan at m/z 1473 (HexNAc4Hex2) which is a core 2 O-glycan 
carrying HexNAc terminated antennae as seen in the wild type and C2GnT2 knockout stomach.  
 
In the stomach of C2GnT triple knockout mice, there was a complete loss of core 2 O-
glycans (Figure 3.6D, Figure 3.7C and Table 3.3). A significant reduction of non-fucosylated O-
glycans compared to the wild type and both single knockouts was also observed, for example at 
m/z 1024, 1432, 1473, 1677 and 1922 in the stomach (Figure 3.6D and Table 3.3). There was also 
an emergence of highly fucosylated and elongated O-linked mannose structures, for instance at 
m/z 1187, 1535, 1709, 1810 and 1985, which were not detected at significant levels in the 
stomach of wild type and C2GnT3 knockout mice and were very minor in the C2GnT2 knockout 
stomach (Figure 3.6D and Table 3.3). The existence of O-linked mannose is supported by the 
detection of 2-linked mannitol by GC-EI-MS linkage analysis (data not shown). 
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Figure 3.7. The full range MALDI-TOF-MS spectra of permethylated O-glycans from the stomach of 
knockout mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the colon of (A) 
C2GnT2 knockout, (B) C2GnT3 knockout and (C) C2GnT triple knockout mice. The black arrow showing a 
signal with -14 mass units in each profile corresponds to underpermethylation of that particular glycan. All 
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unannotated signals with similar intervals from annotated glycan peaks correspond to their respective 
underpermethylated form.  X, impurities 
 
3.2.6 Glycomic analysis of the small intestine from wild type and knockout mice 
The O-glycomic analysis of small intestine from wild type mice showed that, similar to 
the stomach and colon, it was dominated by core 2 O-glycans, for example at m/z 1402 and 1647 
(Figure 3.8A, Table 3.4 and Figure 3.9A). The most abundant terminal epitopes were the H 
antigen (for example on glycans at m/z 1157 and 1331) and Sda (for example at m/z 1140 and 
1589). 
 
  In contrast to the stomach and colon, core 2 O-glycans were still the major structures in 
the small intestine of C2GnT2 knockout mice (Figure 3.8B, Table 3.4 and Figure 3.9B). There 
was a moderate emergence of core 1 structures whose glycan compositions were not detected in 
the wild type such as m/z 1501 and 1950, both carrying the Sda epitope. An increase in core 1 
structures sialylated with NeuAc and/or NeuGc such as at m/z 1256, 1286 and 1316 were also 
observed. In addition there were increases in the abundance of molecular ions whose MS/MS 
spectra  showed that they were mixtures of core 1 and core 2 structures, for example at m/z 1157 
and 1589. 
 
C2GnT3 is highly expressed in the small intestine relative to other tissues (Stone et al., 
2009). The C2GnT3 deficiency in the small intestine caused a relatively moderate reduction of 
core 2 structures with or without an increase of their core 1 isoforms compared to the wild type 
mice, for example at m/z 1331 and 1589 (Figure 3.8C, Table 3.4 and Figure 3.9C). In contrast to 
the wild type small intestine, there was a global reduction of glycans carrying the H antigen (for 
example at m/z 1157 and 1402), leaving the Sda epitope as the most abundant terminal epitope, 
for example at m/z 1140 and 1589. Similar to the C2GnT2 deficient small intestine, there were 
increases in sialylated core 1 structures compared to the wild type, for instance at m/z 1256, 1286 
and 1316.  
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Figure 3.8. MALDI-TOF-MS profile of O-glycans from the small intestine of wild type and knockout 
mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the small intestine of 
(A) wild type, (B) C2GnT2 knockout, (C) C2GnT3 knockout and (D) C2GnT triple knockout mice. Cartoon 
structures assigned were based on mass spectrometric data and knowledge of O-glycan biosynthetic 
pathways for the selected range of m/z 1000 to 2000.  
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Table 3.4. O-glycan structures from the small intestine of wild type and knockout mice.  
This table summarises major structures [M+Na]+ observed in the MALDI-TOF-MS spectra of small 
intestine tissues from wild type, C2GnT2 knockout, C2GnT3 knockout and C2GnT triple knockout mice. 
 
 
The small intestine of the triple knockout mice again demonstrated a complete 
disappearance of core 2 structures (Figure 3.8D, Table 3.4 and Figure 3.9D). Similar to the 
C2GnT3 deficient small intestine, the Sda epitope was the most abundant type of terminal 
structure, for instance at m/z 1140 and 1589. Interestingly, at m/z 1344, it was shown by the 
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MS/MS analysis that there was a mixture of sialylated core 1 O-glycans and an elongated O-
linked mannose structure terminated with the Sda epitope. O-linked mannosyl glycans were not 
detected at any significant levels in the wild type and single knockouts of small intestine.  
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Figure 3.9. The full range MALDI-TOF-MS spectra of permethylated O-glycans from the small 
intestine of wild type and knockout mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the small intestine of 
(A) wild type, (B) C2GnT2 knockout, (C) C2GnT3 knockout and (D) C2GnT triple knockout mice. The black 
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arrow showing a signal with -14 mass units in each profile corresponds to underpermethylation of that 
particular glycan. All unannotated signals with similar intervals from annotated glycan peaks correspond to 
their respective underpermethylated form. X, impurities; N, reduced N-glycans. 
 
3.2.7 Glycomic analysis of the thyroid/trachea, kidneys and thymus from wild type 
and knockout mice 
O-Glycomic analysis of the thyroid/trachea and kidneys from wild type mice showed 
that, similar to other tissues, core 2 structures were the most abundant type of O-glycan (Figure 
3.10A and Figure 3.11A), whereas in the wild type thymus, core 1 structures were the most 
abundant (Figure 3.12A). In the thyroid/trachea, a relatively low number of glycan structures 
were detected and mostly were terminated with sialylation either on its own or as part of the Sda 
epitope, for example at m/z 1344 and 1589, respectively (Figure 3.10A). In the wild type kidneys, 
however, the core 2 O-glycans were moderately fucosylated leading to the formation of H and 
Lewisx/y terminal epitopes, for example on glycans at m/z 1157 and 1780 (Figure 3.11A). In the 
thymus, similar to the thyroid/trachea, few O-glycan structures were detected (Figure 3.12A). The 
O-glycans were also highly sialylated with NeuAc or NeuGc, for example at m/z 1256 and 1316.     
 
Remarkably the kidneys from C2GnT2 knockout mice exhibited a significant reduction in 
the abundance of some of the core 2 O-glycans with no concomitant compensation by extended 
core 1 sequences (Figure 3.11B; note loss of m/z 1402 and higher compared with the wild type). 
Thus, only a single glycan structure of the core 1 type (m/z 1256) was detected in the mass range 
of m/z 1000 – 2000, accompanied by residual core 2 O-glycans. The thymus and thyroid/trachea 
of C2GnT2 knockout mice were not analysed due to the absence of any interesting phenotypic 
findings from these tissues, in addition to the relatively very low expression of C2GnT2 in the 
wild type thymus and thyroid/trachea (Stone et al., 2009).  
 
Even though C2GnT3 is believed to play important biological roles in the human thymus 
(Schwientek et al., 2000), our O-glycomic screening has revealed that there were no significant 
changes, if any, with respect to glycan structures and abundances between the thymus of wild 
type and the C2GnT3 knockout mice (Figure 3.12B). Similar effects were also observed in the 
kidneys of C2GnT3 knockout mice (Figure 3.11C). In the thyroid/trachea, however, there was a 
minor disappearance of core 2 structures, and if detected, they were at a much reduced abundance 
relative to the wild type, for example glycan at m/z 1157, 1589 and 1763, with the latter two 
being decorated with the Sda epitope (Figure 3.10B). 
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In the C2GnT triple knockout mice, the thyroid/trachea and the kidneys also exhibit a 
complete absence of core 2 O-glycans (Figure 3.10C and Figure 3.11D), similar to that seen in 
other tissues. In the thyroid/trachea of C2GnT triple knockout there was also a complete absence 
of glycans bearing the Sda epitope (Figure 3.10C). Meanwhile in the kidneys, the glycomic 
analysis revealed a remarkable loss of O-glycans with only two structures having simple core 1 
type sequences being detected (Figure 3.11D). The thymus of C2GnT triple knockout mice was 
not analysed. 
 
 
Figure 3.10. MALDI-TOF-MS profile of O-glycans from the thyroid/trachea of wild type and 
knockout mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the thyroid/trachea of 
(A) wild type, (B) C2GnT3 knockout and (C) C2GnT triple knockout mice. Cartoon structures assigned 
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were based on mass spectrometric data and knowledge of O-glycan biosynthetic pathways for the 
selected range of m/z 1000 to 2000.  
 
 
Figure 3.11. MALDI-TOF-MS profile of O-glycans from the kidneys of wild type and knockout mice. 
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The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the kidneys of (A) wild 
type, (B) C2GnT2 knockout, (C) C2GnT3 knockout and (D) C2GnT triple knockout mice. Cartoon 
structures assigned were based on mass spectrometric data and knowledge of O-glycan biosynthetic 
pathways for the selected range of m/z 1000 to 2000.  
 
 
Figure 3.12. MALDI-TOF-MS profile of O-glycans from the thymus of wild type and knockout mice. 
The glycomic profiles of reduced and permethylated O-glycans [M+Na]+ detected in the thymus of (A) wild 
type and (B) C2GnT3 knockout mice. Cartoon structures assigned were based on mass spectrometric 
data and knowledge of O-glycan biosynthetic pathways for the selected range of m/z 1000 to 2000.  
 
3.2.8 Determination of branching sites in the stomach and colon 
Stomach and colon tissues exhibited very varied O-glycan structures accompanied by 
dramatic changes in the knockout tissues. In addition, the MS/MS data provided evidence for a 
number of potentially biologically important glycan epitopes in these tissues. To put some of 
these structural assignments on a firmer footing, we were fortunate to have access to a novel 
MALDI-QIT-TOF mass spectrometer (Ojima et al., 2005) which has been developed for high 
accuracy, ultra-high sensitivity MSn analyses. Thus, we performed MS3 analysis on selected 
glycan MS/MS fragments that contain branched N-acetyllactosamine (LacNAc) chains in order to 
define the I-branching sites.  
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As an example, Figure 3.13 shows MALDI-QIT-TOF-MS/MS data for the glycan at m/z 
1780 (HexNAc3Hex3Fuc2) of wild type stomach (A), together with MS3 spectrum from 
collisional activation of the fragment at m/z 1143 (B). MS/MS of the glycan at m/z 1780 has 
proven that the core 1 Gal of this glycan is branched (see annotation on Figure 3.13A). In fact, 
this is the only location of the I-branch that we have detected in both stomach and colon in this 
study even when the core 1 antenna is elongated with an additional GlcNAc residue, for example 
m/z 2617 in the stomach tissues (Table 3.3), which carries one more GlcNAc residue on both the 
core 1 antenna and the I-branch than m/z 1780. MS3 on the fragment at m/z 1143 further 
confirmed the branched Gal, as well as providing additional verification of the known I-branch 
linking position (Figure 3.13B). The cross-ring fragment of m/z 720 has provided the evidence of 
a branching on either the positions 4 or 6. Additionally, GC-EI-MS linkage analysis has shown 
the existence of a 3,6-linked Gal residue (data not shown).   
 
 
Figure 3.13. Determination and verification of the I-branching site and position. 
(A) MALDI-QIT-TOF-MS/MS spectrum of m/z 1780 [M+Na]+ from wild type stomach shows evidence of 
branching on Gal of the core 1 arm (fragments m/z 506 and 1143) and the terminal epitope blood group H 
antigen on each of the branches (fragments m/z 660 and 1370). (B) MALDI-QIT-TOF-MS3 spectrum of the 
MS/MS fragment at m/z 1143 from (A) has provided additional evidence for the branched Gal residue of 
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the core 1 arm and verification of the branch attachment on position 6 (cross ring fragment at m/z 720). For 
simplicity, not all fragments are annotated. 
 
3.2.9 Characterisation of RM2-like structure in the colon 
We have detected an unusual terminal epitope in the O-glycan observed at m/z 1950 
(HexNAc3Hex2NeuAc2) in the wild type and knockout tissues of colon (Figure 3.2 and Table 
3.2). Initial MS/MS fragmentation data from the MALDI-TOF/TOF suggested a sialylated Sda 
epitope (HexNAc2Hex1NeuAc2) whose composition is identical to a rare epitope originally found 
on a glycolipid and called the RM2 antigen (Ito et al., 2001). For further confirmation of this 
structure, we have performed additional MS/MS analysis on m/z 1950 (Figure 3.14A) as well as 
MS3 analysis on two major MS/MS fragments, namely m/z 1108 and 1453 using MALDI-QIT-
TOF (Figure 3.14B and C). Glycosidic and cross-ring fragmentation data of the MS3 experiment 
explicitly showed that one of the NeuAc residues was attached to the internal GlcNAc residue 
rather than the GalNAcitol residue, which is another possible position for sialylation. The latter 
was detected in the small intestine tissues and C2GnT triple knockout colon tissues. Overall, 
these MS3 data supported the RM2 structural assignment of the initial MS/MS analysis.  
 
 
Figure 3.14. Structural confirmation of the RM2-like epitope found in the colon tissues. 
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(A) MALDI-QIT-TOF-MS/MS spectrum of glycan at m/z 1950 [M+Na]+ from wild type stomach shows 
evidence for a sialylated Sda terminal epitope. This assignment is further supported by the subsequent 
MS3 analysis on the MS/MS fragments of (B) m/z 1108 and (C) m/z 1453. Glycosidic and cross-ring 
fragments at m/z 673, 472, 520, 819 and 865 from both MS3 spectra verified the existence of the Sda 
epitope with additional sialylation on the internal GlcNAc therefore confirming the structural assignment of 
the MS/MS analysis. For simplicity, not all fragments are annotated. 
 
3.3 Discussion 
O-Glycomic analyses were performed on mice deficient in C2GnT2, C2GnT3 and all 
three C2GnT isoenzymes (C2GnT triple knockouts). This work aimed to further clarify the 
functional properties of each of the isoenzymes in various tissues and to associate structural 
changes with observed phenotypes of the knockout mice. This study also aimed to optimise the 
O-glycomic methodology as well as providing detail O-glycan fingerprinting of selected wild 
type murine tissues as a reference database for current and future studies. High quality mass 
spectrometric and tandem mass spectrometric data were obtained by using a MALDI-TOF/TOF 
mass spectrometer in concert with ESI-QTOF, GC-EI and MALDI-QIT-TOF mass 
spectrometers. 
 
Generally, C2GnT2 knockout mice showed a significant decrease of core 2 O-glycans 
especially in the colon and stomach compared to the wild type mice. This was expected as this 
isoenzyme is highly expressed in these tissues. The glycosylation machinery synthesised more of 
the extended core 1 O-glycans possibly to compensate for the diminishing core 2 O-glycans. 
Position 6 of the GalNAcitol of core 1 O-glycans was either left unmodified or sialylated. 
Previous work has characterised core 3 and core 4 O-glycans in human intestine (Robbe et al., 
2004; Holmen Larsson et al., 2009). In contrast these core types are hardly expressed in the 
murine intestine. Because trace amounts could not be unambiguously determined in the presence 
of the abundant core 1/2 sequences, addressing possible changes in their abundance as a 
consequence of loss of C2GnT2 was not feasible. Nevertheless, our collaborators did not detect a 
significant level of C4GnT enzymatic activity in colon, small intestine and stomach of C2GnT2 
knockout mice (Stone et al., 2009), thus suggesting that C2GnT is entirely responsible for the 
production of core 4 O-glycans.  
 
Branching of the core 1 arm of both core 1 and core 2 O-glycans was found to be very 
abundant especially in the stomach of wild type mice. C2GnT2 deficiency in mice caused a major 
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reduction and disappearance of glycan branches, therefore demonstrating that C2GnT2 has a 
strong capability to branch the LacNAc chains specifically on position 6 of the Gal of the core 1 
arm. To our knowledge, this analysis is the first to show the I-branching activity of C2GnT2 in 
vivo using definitive structural analysis. This finding supports previous work that has shown in 
vitro that human and mouse C2GnT2 have the I-branching capability quite similar to IGnT, but 
no structural proof was provided (Yeh et al., 1999; Hashimoto et al., 2007). Based on in vitro 
assays, Yeh et al. (1999) suggested that human C2GnT2 possess higher distally acting IGnT 
(dIGnT) activity than centrally acting IGnT (cIGnT) activity, although the difference was merely 
5%. However, the current finding has shown that centrally attached glycan branches were greatly 
affected by the loss of C2GnT2 activity. The centrally attached glycan branches specifically on 
the Gal residue of the core 1 arm was the only type identified in this study, even though the arm 
was elongated with two LacNAc units. All these data suggest that, C2GnT2 acts differently in 
vivo where it prefers to branch O-glycans centrally instead of distally. Similar branching of the 
Gal residue of the core 1 arm has previously been characterised rigorously on O-glycans derived 
from human Tamm-Horsfall glycoprotein (THP) during pregnancy (Easton et al., 2000). 
Therefore, it is tempting to speculate that C2GnT2’s natural substrate is the Gal of GlcNAcβ1-
3Galβ1-3GalNAc-serine/threonine, with or without the core 2 arm attached and elongation on the 
core 1 arm. The fact that we did not detect other types of branched LacNAc on O-glycan is most 
likely because the IGnT isoenzymes, the only other enzymes known for I-branching activity, are 
not significantly expressed in murine GI tract (Twu et al., 2003). We are unable to conclude 
whether this finding is tissue-specific due to the lack of branched O-glycan structures detected in 
other tissues analysed. 
 
It was also evident from our data that branched core 1 O-glycans were not completely 
absent in the stomach and colon of the C2GnT2 single knockout, but were totally lost in the 
C2GnT triple knockout mice. Therefore, it can be speculated that C2GnT1 and/or C2GnT3 
possess a weak I-branching activity and, instead of IGnT, compensated for C2GnT2 I-branching 
activity in C2GnT2 knockout mice. These results are however in contrast with previous 
immunohistochemical findings on IGnT deficient mice which concluded that IGnT is the major 
enzyme that synthesises I-branches in the murine stomach (Chen et al., 2005). This discrepancy 
might be due to the method the previous study applied to detect the reduction of IGnT activity. It 
is conceivable that the monoclonal antibody against I antigen that was used could be specific only 
to I-branches that are attached towards the non-reducing end of a poly-LacNAc chain (distally) 
which are supposed to be produced by IGnTs instead of C2GnTs.  
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Our collaborators have demonstrated that C2GnT2 deficient mice have impaired mucosal 
barrier and increased susceptible to dextran sodium sulphate (DSS)-induced colitis compared to 
the wild type mice (Stone et al., 2009). In 2007, An et al. reported that mice with glycosylation 
changes in their GI tract are more susceptible to colitis (An et al., 2007). The mechanism of DSS-
induced colitis is not clear but destruction of the mucin content is one of the proposed 
mechanisms (Melgar et al., 2005). It is anticipated that a similar situation is being observed here. 
The loss of glycan branches (core 2 branches and/or I-branches) of both sulphated and non-
sulphated O-glycans that was observed in the C2GnT2 knockout mice could possibly disrupt the 
normal glycan structures which protect the underlying proteins in mucin layers. The interrupted 
conformation of mucins in the GI tract therefore facilitates DSS’s destructive action. These 
changes might be recognised as foreign by the immune system, which is possibly the reason for 
the increased susceptibility to inflammation which causes colitis. In addition, a direct relationship 
between immune cells and C2GnT2 has been demonstrated by the up regulation of this 
isoenzyme by T helper 2 cytokines in human airway mucins (Beum et al., 2005). On the other 
hand, Johansson et al. suggested that the disruption of colonic mucins by DSS causes the mucin 
layer to become more permeable to bacterial intrusion followed by colonisation on the epithelial 
lining and thus triggering inflammatory reaction (Johansson et al., 2010). Furthermore, the loss of 
sulphation on colonic mucins also has been indicated to increase the susceptibility towards colitis 
in humans and mice (Corfield et al., 1993; Corfield et al., 1996; Tobisawa et al., 2010). 
Therefore, it can be speculated that sulphated branched O-glycans of colonic mucins have a 
protective role in colitis.  
 
C2GnT3 was originally shown by Northern blot analysis to be highly expressed in human 
thymus and has been implicated to play important roles in T-cell development and lymphocyte 
trafficking (Schwientek et al., 2000). From our structural O-glycomic analysis of the C2GnT3 
knockout mice, generally there were no substantial changes on the abundance of core 2 O-
glycans in any tissues that have been analysed, albeit a minor reduction was observed in the small 
intestine and thyroid/trachea. The lack of any significant changes to O-glycan structures and 
abundances in the thymus of C2GnT3 knockout mice confirms quantitative polymerase chain 
reaction (qPCR) findings by our collaborators that indicated low expression of that isoenzyme in 
murine thymus (Stone et al., 2009), as opposed to human thymus. This indicates that either the 
other C2GnT isoenzymes can substantially compensate for the loss of C2GnT3 activity, or 
C2GnT3 is not normally responsible for synthesising the vast majority of core 2 O-glycans in the 
murine tissues examined.  
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As noted above, the loss of C2GnT3 activity caused a slight but reproducible reduction of 
core 2 O-glycans in the thyroid, the thyroxine producing gland. Our collaborators have shown 
that in C2GnT3 deficient mice there is a decrease in circulating levels of alkaline phosphatase and 
thyroxine, but the thyroid stimulating hormone was not affected (Stone et al., 2009). This 
observation is associated with hypothyroidism but the mechanism is still not fully understood 
(Fliers et al., 2006). The major reduction of core 2 O-glycans carrying the Sda epitope in the 
C2GnT3 deficient thyroid/trachea is intriguing, supported by the complete loss of Sda terminated 
glycans in the C2GnT triple deficient thyroid/trachea, which could illustrate that in the 
thyroid/trachea, the Sda epitope can be synthesised efficiently only on the core 2 arm.  We 
postulate that the population of core 2 O-glycans in the thyroid/trachea whose biosynthesis is 
dominantly controlled by C2GnT3 are somehow necessary in the production of thyroxine. 
Reduced thyroxine levels will subsequently contribute to the hypothyroidism and the reduction of 
alkaline phosphatase. Whether the presence of the Sda epitope is functionally important in the 
thyroid remains to be established. The Sda epitope has been found on a limited repertoire of 
interesting glycoproteins in mammals, including human Tamm-Horsfall protein (Serafini-Cessi et 
al., 1986), the murine zona pellucida (Dell et al., 2003), bovine pregnancy-associated 
glycoproteins (Klisch et al., 2008) and glycoproteins on murine cytotoxic T-lymphocytes (Smith 
& Lowe, 1994), although no specific function has so far been attributed to this epitope. 
Glycoproteins from the thyroid which carry these core 2 O-glycans would be an important target 
for further investigations.  
 
Clostridium perfringens and Helicobacter pylori are common bacteria that colonise the 
GI tract. Recently, it has been revealed that C. perfringens contains an endo-β-galactosidase that 
is able to release the disaccharide epitope GlcNAcα1-4Gal from glycoconjugates as part of its 
pathogenicity (Ashida et al., 2001). It can be interpreted that C. perfringens uses this epitope as a 
binding site to initiate infection. On the other hand, the terminal α1,4-linked GlcNAc residue has 
been shown to affect the growth of H. pylori in the stomach (Kawakubo et al., 2004). Core 2 O-
glycans capped with this epitope were found to be capable of serving as a natural antibiotic 
against H. pylori infection (Lee et al., 2008). Expression cloning of human α1,4-N-
acetylglucosaminyltransferase has shown that this epitope is efficiently transferred to core 2 O-
glycans forming the structure GlcNAcα1-4Galβ1-4GlcNAcβ1-6(GlcNAcα1-4Galβ1-3)GalNAc 
(Nakayama et al., 1999).  We have detected a putative GlcNAcα1-4Gal epitope on the similar 
core 2 O-glycan that is observed at m/z 1473 in stomach tissues (Figure 3.6 and Table 3.3). 
However, the terminal HexNAc residues in murine stomach have been established to be 
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dominated by β-GlcNAc, using a β-HexNAc specific exoglycosidase. Previously, the α-GlcNAc 
residue has been shown to be expressed specifically on class III mucin in the deeper layer of 
gastric mucosa (Nakamura et al., 1998), hence it is very low in abundance and could possibly 
constitute the residual undigested terminal HexNAc in our samples. Intriguingly, this glycan at 
m/z 1473 was well preserved as a core 2 isoform in the C2GnT2 and C2GnT3 single knockout 
mice, and in fact was augmented in the latter tissue, hence illustrating its potential functional 
importance. Detailed characterisation of differences in the glycosylation profile especially in the 
GI tract is fundamental to better understand host-pathogen interplay (Dell et al., 1999; van Kooyk 
& Rabinovich, 2008), which is also the main topic of the next chapter of this thesis.  
 
From the analysis on C2GnT triple knockout mice, we observed a complete absence of 
core 2 O-glycans in all tissues. This is supported by the findings from enzyme assay experiments 
done by our collaborators that indicated very little C2GnT activity in these mice that remarkably 
were viable and fertile (Stone et al., 2009). Therefore, we propose that there is no other C2GnT 
isoenzyme in mouse. In addition, we have also noted that due to the major loss of the core 2 
antennae and the I-branches on core 1 antennae, several unique glycans that were not originally 
being synthesised in the wild type murine tissues have emerged, for instance the triply 
fucosylated glycan at m/z 1505 in the stomach which is predicted to be a novel structure (Figure 
3.6D and Table 3.3). Our tandem mass spectrometric, linkage analysis and enzymatic digestion 
data have shown that LacNAc chain type 2 dominated murine stomach (data shown and 
discussed in Chapter 4), therefore the immense amount of fucosylated Gal and difucosylated 
LacNAc terminals are likely to be H type 2 and Lewisy antigens, respectively. 
 
O-linked mannosyl glycans were first identified in 1969 in yeast and were found to be 
very abundant in the cell wall (Sentandreu, 1969). The modification was only discovered in the 
mammalian system about ten years later on a brain proteoglycan (Finne et al., 1979). 
Subsequently, it has been recognised to constitute about 30% of brain O-glycans (Chai et al., 
1999) and also to be a crucial modification on α-dystroglycan especially in the muscle tissues 
(Endo, 1999; Yoshida-Moriguchi et al., 2010), as has been discussed in Section1.2.2.1 in Chapter 
1. Unexpectedly, O-linked mannosyl glycans were up-regulated in the stomach of the triple 
knockout mouse, being barely detected in the wild type and single knockouts. Cells possibly 
amplified the addition of complex antennae to O-linked mannose in order to replace the 
diminished core 2 O-glycans. Reduced competition for UDP-GlcNAc, which is the donor 
substrate for both C2GnT and the O-mannose elongating enzyme POMGnT1 (Takahashi et al., 
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2001), might explain this observation. To our knowledge, our findings reported here constitute the 
first structural characterisation of O-linked mannose in the mucin-rich GI tract. Our linkage 
analysis has so far provided evidence only for the 2-substituted mannitol residue and not for the 
branched 2,6-substituted mannitol that has been additionally shown to be present in neural tissues 
(Yuen et al., 1997). Terminal modification such as sialylation and Lewis antigens have been 
described on O-linked mannosyl glycans (Chiba et al., 1997; Smalheiser et al., 1998). In this 
study we have identified multi-fucosylated components of elongated O-linked mannose with up 
to three fucose and three LacNAc repeats in the stomach of C2GnT triple knockout mice (m/z 
1709 and m/z 1985, respectively in Figure 3.6D). In addition, a glycan whose composition is 
consistent with a unique elongated O-linked mannose sequence terminated with the Sda epitope 
was detected in the small intestine of C2GnT triple knockout mice (m/z 1344 in Figure 3.8D). To 
our knowledge these modifications of O-mannosyl glycans have not been reported elsewhere. It 
is anticipated that the current findings will open up new avenues for research of O-linked 
mannose.  
 
In contrast to the GI tract, there seems to be no induction of any types of O-glycan 
accompanying the loss of core 2 O-glycans in the kidneys of single and triple deficient mice. In 
the kidneys of C2GnT2 knockout but not the C2GnT3 knockout mice, we observed a substantial 
reduction in some of the core 2 sequences, most notably those with extended core 1 and core 2 
antennae (see Figure 3.11, glycans at m/z 1402 and higher), although between these two 
isoenzymes, the latter was shown by our collaborators to have slightly higher expression level in 
the kidneys. The structural changes were unexpected because Ellies et al. have shown previously 
that the kidneys of the C2GnT1 knockout mouse exhibit over 90% reduction in core 2 activity 
compared with the wild type (Ellies et al., 1998) suggesting that the C2GnT1 isoform is 
responsible for most of the core 2 synthesis in this organ. We consider it likely that C2GnT2 plays 
an important role in biosynthesis of a portion of the O-glycan repertoire in the kidney and that 
C2GnT1 is not able to compensate for its absence, thereby leading to the disappearance of certain 
core 2 O-glycan sequences. Furthermore, only two O-glycan structures of core 1 type were 
detected in the kidneys of C2GnT triple knockout mice. It is intriguing that the glycosylation 
system in the kidneys was unable to compensate for the loss of core 2 O-glycans by synthesising 
other types of O-glycans, as has been seen in the stomach and colon. The structural 
compensations observed in the latter two tissues could be resembling the mechanism of 
homeostatic regulatory via lectin-glycan interactions leading to changes in gene expression for 
the purpose of maintaining cell surface glycan density (Dam & Brewer, 2010). Dam and Brewer 
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also suggested that the density of glycan epitopes on the surface is at least as important as the 
affinity of single epitopes for the function of lectin receptors (Dam & Brewer, 2010). 
 
Sulphation is a common modification of both N- and O-glycans however, in vertebrates, 
glycan sulphation is generally restricted to Gal, GlcNAc and GalNAc at internal or terminal 
positions (Stanley & Cummings, 2009). Sulphated oligosaccharides have posed particular 
analytical challenges due to their acidity and lability (Zaia, 2004). Nevertheless, it is crucial to 
develop a robust technique to structurally characterised these glycans since they consist of a 
number of functionally important glycoepitopes, for instance sulfo-SLex/a and sulfo-Lex/a, both are 
ligands for mammalian selectins (see Section 1.2.3 of Chapter 1). In addition to the correlation to 
increase the susceptibility towards colitis as discussed above, reduction in glycan sulphation has 
also been associated with adenocarcinoma development (Vavasseur et al., 1994). Over the years, 
various strategies have been proposed in order to optimise mass spectrometric characterisation of 
sulphated oligosaccharides, in particular sulphated N- and O-glycans. For instance, Dell and 
colleagues have proposed the short Hakomori permethylation method for FAB-MS analysis of 
sulphated samples (Dell et al., 1994). Sequencing of underivatised sulphated glycans isolated 
from mucins of porcine stomach and large intestine and human colonic MUC2 have been done 
by using LC-ESI-MS/MS (Thomsson et al., 2000; Holmen Larsson et al., 2009). The same group 
also has proposed that LC-ESI-MS analysis done at higher pH can improved the detection of 
sulphated glycans (Thomsson et al., 2010). Recently, a novel sodium hydroxide methylation 
strategy has been presented by the Khoo group (see Section 1.4.8.3 in Chapter 1) who 
successfully isolated and characterised sulphated O-glycans from murine secondary lymph nodes 
using MALDI-TOF/TOF-MS/MS (Yu et al., 2009). This method has been adapted for the 
analysis of murine colons in this study.  
 
O-sulphoglycomic analysis was only done on the wild type and C2GnT2 knockout colons 
due the limited time available for investigating this new methodology. The choice of colon was 
driven by the findings of previous work that have indicated sulphated O-glycans in this tissue 
from humans and animals (Corfield et al., 1996; Holmen Larsson et al., 2009; Thomsson et al., 
2010). However the main objective of this preliminary experiment was to adapt the proposed 
sulphoglycomic strategy by the Khoo group to complex mucinous tissues. We observed a 
complete loss of core 2 branches in the C2GnT2 knockout colon with concomitant increase of 
elongated core 1. Only linear LacNAc chains and monosulphated structures were detected in both 
wild type and knockout tissues. These preliminary results indicated that sulphated glycans are 
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affected by the loss of C2GnT2 similar to the non-sulphated glycans. Now that the 
sulphoglycomic methodologies have been shown to be robust, future glycomic studies should 
include sulphoglycomic analysis to enable more holistic assessment of the structural changes in 
C2GnT deficient mice. Analysing the sulphated glycans has proven to be more challenging than 
the non-sulphated glycans. It was noted that sulphated O-glycans in these tissues are almost 
equally divided between the 2.5 mM and 10 mM ammonium acetate fractions, and therefore 
contributed to the rather low intensity of sulphated glycan peaks in the mass spectra of each 
fraction. Combining these fractions would not be feasible as the latter fraction also contains non-
sulphated glycans while the former are reasonably clean. Therefore, eluting with an intermediate 
concentration of ammonium acetate could be a good resolution. Furthermore, MS/MS 
sequencing was only beneficial in the positive ion mode which requires the conversion of each of 
the m/z of the detected negatively charged molecular ions in the MS analysis to positively 
charged molecular ions that usually carry more than one sodium ion. MS/MS in the negative 
mode entails high energy CID to gain useful fragment ions, as has been demonstrated previously 
(Yu et al., 2009), but requires instrumentation that is not widely available.  
 
Another interesting finding from the murine GI tract is the detection of a sialylated Sda 
terminal sequence (HexNAc2Hex1NeuAc2) on the glycan at m/z 1950 in the colon of wild type 
and knockout mice (Table 3.2). This structure has been confirmed with tandem mass 
spectrometry and is found to share its terminal sequence with the RM2 antigen of glycolipids; 
therefore it is designated as RM2-like antigen. The RM2 antigen was originally reported as a 
novel ganglioside in 2001 after being detected by the RM2 antibody (Ito et al., 2001), and is now 
well recognised as a prostate cancer marker (Saito et al., 2005). To our knowledge, this work is 
the first to characterise the RM2 antigen in glycoproteins. In addition, we also have detected a 
putative fucosylated version of this glycan at m/z 2125 in the colon of wild type and C2GnT3 
knockout mice (Table 3.2). In addition, we have performed immunoblotting experiments of gel-
separated wild type colon homogenates using the RM2 antibody, kindly donated by Professor 
Sen-itiroh Hakomori (data not shown). However, the blotted samples failed to be significantly 
recognised by the RM2 antibody. The complex nature of unpurified colonic lysate in addition to 
the relatively very low abundance of the RM2-like epitopes might contribute the lack of binding, 
hence this experiment needs to be done on purified mucins. The RM2-like structure, therefore, 
remains to be rigorously characterised and its possible functional similarities with the RM2 
antigen remain to be studied.  
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Understanding the functional consequences of the changes to glycan terminal epitopes 
and branching observed in the knockout tissues, especially the triple knockouts, will require 
considerable further work, although clues have already been provided by the published 
phenotypic studies of our collaborators (Stone et al., 2009). Often, the terminal epitopes are the 
biologically important part of any particular glycan. Research has shown numerous examples of 
glycan epitopes serving as messengers between cells of similar or different types including cancer 
cells and microorganisms (Ashida et al., 2001; Rydell et al., 2009; Cazet et al., 2010). The type of 
chain or branch where these antigens reside is not of any less significance in many cases (Mitoma 
et al., 2003; Muramatsu et al., 2008). Therefore, it would be interesting to challenge these 
knockout mice with more biological stress and microorganism infection and evaluate the effects 
of the structural aberrations. 
 
As a summary, we have performed detailed O-glycomic analysis of neutral and sialylated 
O-glycans of selected tissues from mice with deficiency in C2GnT2, C2GnT3 and C2GnT1-3. 
This work also comprises among the very few rigorous O-glycan structural characterisations even 
in the wild type mice. We have demonstrated the critical functions of C2GnT isoenzymes in 
producing core 2 O-glycans and I-branches. Putative pathological consequences of the loss of 
these structures in mice include the increase in susceptibility to colitis and hypothyroidism. In 
addition, we have serendipitously identified RM2-like antigen from colonic glycoproteins. We 
also have performed preliminary O-sulphoglycomic analysis of colon and demonstrated similar 
structural changes in the knockout mice as have been observed for the non-sulphated glycans. It 
is increasingly clear that C2GnT isoenzymes have similar and also distinct functional properties; 
each may regulate the synthesis of different subset of structures that have different biological 
roles. Nevertheless, the fact that C2GnT single- and triple-deficiencies in mice demonstrated 
relatively mild phenotypic impact may reflect the apparent extensive compensation provided by 
the induction of elongated core 1 and, unexpectedly, the O-mannosyl glycans carrying the 
biomedically relevant epitopes.  
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4 O-glycosylation profiling of gastric mucosa from FuT2-null mice in relation to 
Helicobacter pylori adhesion 
4.1 Background 
Glycoconjugates expressed on gastric mucosa play a crucial role in host–pathogen 
interactions, as has been described in Chapter 1. In this study, O-glycomic analyses were carried 
out on the stomach and mucosal scrapings (isolated gastric mucosal layer) of wild type and FuT2-
null mice, which represent the secretor and non-secretor models, respectively. The purpose of 
analysing the mucosal scrapings is because it constitutes the mucosal layer of the stomach surface 
where the vital initial adhesion by H. pylori occurs. Lectin and antibody staining and H. pylori 
adhesion studies were also performed on gastric mucosa of both mouse models by our 
collaborators, Celso A. Reis and colleagues at the University of Porto, Portugal. 
 
4.2 Results 
4.2.1 Mass spectrometric strategy 
All samples that were analysed in this study are listed in Table 4.1. Stomach and mucosal 
scrapings samples were prepared for mass spectrometric analysis similar to that of stomach 
tissues described in Chapter 3, which used the homogenisation with glycolipid removal technique 
and without N-glycan digestion prior to O-glycan release. Immunoprecipitated samples prepared 
by our collaborators were first in-gel-tryptic digested prior to O-glycan release and analysis.  O-
Glycomic profiles of samples from both wild-type and Fut2-null mice were acquired by MALDI-
TOF-MS, and components of interest were sequenced by collision induced tandem mass 
spectrometry using both MALDI and ESI methods, as explained in the previous chapter. 
 
Table 4.1. List of all samples analysed in this study. 
Mouse genotype Sample type 
FuT2 knockout Stomach (whole) 
Stomach mucosal scraping 
Stomach lysates immunoprecipitated using anti-Lea antibody (SPM279) 
Stomach lysates immunoprecipitated using anti-Muc5AC antibody (45M1) 
Wild type Stomach (whole) 
Stomach mucosal scraping 
Stomach lysates immunoprecipitated using anti-Lea antibody (SPM279) 
Stomach lysates immunoprecipitated using anti-Muc5AC antibody (45M1) 
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4.2.2 Glycomic profiling of wild type stomach and mucosal scrapings 
Representative MALDI-TOF-MS data of stomach and mucosal scrapings from wild type 
mice are shown in Figure 4.1 and Figure 4.2, respectively. Glycan structures were assigned based 
on their mass value, fragment ion data, and knowledge of the biosynthetic pathways of mucin-
type O-glycosylation. Generally, both samples gave highly similar profiles in terms of O-glycan 
composition and sequences. However, as expected due to the larger sample size, more glycan 
peaks and structures were detected in the stomach. For example O-glycans at m/z 895, 912 and 
1579 managed to be sequenced in the stomach. Furthermore, the stomach showed O-glycans with 
compositions up to 18 monosaccharides with m/z of 3926 (Figure 4.1). Mucosal scrapings, on the 
other hand, allowed glycan detection only up to m/z 3027. Due to the limited amount of samples, 
high mass glycans especially those above m/z 3000 were only partially sequenced and remain to 
be fully characterised. In both samples, the most abundant types of O-glycan are core 2 
structures, many of which are branched on their core 1 arm, as noted in the stomach and colon 
tissues analysed in Chapter 3. The terminal epitopes are dominated by blood group H antigens 
(Fucα1,2Galβ1,3/4GlcNAc), for instance at m/z 1157 and 1331. No monofucosylated Lewis 
structures were detected. However, some of the larger glycans, for example m/z 2578, carry 
difucosylated antenna which could either be Leb or Ley. Some of the high mass glycans at m/z 
3027 and above are multifucosylated, thus are also likely to carry more than one fucose on a 
single antenna. Only a few sialylated glycans were detected; m/z 895 and 1579 in the stomach, as 
well as m/z 1316 and 1374 in both stomach and mucosal scrapings. 
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Figure 4.1. The MALDI-TOF-MS O-glycomic profile of reduced and permethylated O-glycans 
[M+Na]+ detected in the stomach of wild type mice. 
Cartoon structures assigned were based on mass spectrometric data and knowledge of O-glycan 
biosynthetic pathways. X, impurities/ contaminant peaks.  
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4.2.3 Glycomic profiling of FuT2-null stomach and mucosal scrapings 
As expected, the MALDI-TOF-MS profiles of stomach and mucosal scrapings from 
FuT2-null mice showed a major loss of glycans carrying the H epitope (Figure 4.3 and Figure 
4.4). For example, glycans at m/z 1331, 1535 and 1780 were detected at high abundance in the 
wild type but were missing in the knockout tissues. However, it was possible to observe minor 
fucosylated terminal galactose, as demonstrated by m/z 708, which on MS/MS analysis gave the 
same fragment ions (the major ions are m/z 298, 433 and 520, see Figure 4.5) as the isobaric 
glycan found in the wild type, indicating that a residual α1,2-fucosyltransferase activity remains 
in the stomach and mucosal scrapings of the FuT2-null mice. In contrast to the wild type samples, 
the largest O-glycan structure which could be sequenced was at m/z 2617 for both stomach and 
mucosal scrapings of the knockout mice. Due to the massive loss of fucosylated glycans, the 
overall number of glycan structures detected was far less than that of wild type samples. Both 
FuT2-null stomach and mucosal scrapings provided almost similar numbers of structures, 
Figure 4.2. The MALDI-TOF-MS O-glycomic profile of reduced and permethylated O-
glycans [M+Na]+ detected in the mucosal scrapings of wild type mice.  
Cartoon structures assigned were based on mass spectrometric data and knowledge of O-
glycan biosynthetic pathways. X, impurities/ contaminant peaks. 
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however a few structures are unique in either tissue. For example, the glycan at m/z 1579 was 
only detected in the mucosal scrapings whereas glycans at m/z 953 and 1514 were only found in 
the stomach. Surprisingly, there were losses in sialylated glycans in both tissues. Only a single 
structure at m/z 1579 in the mucosal scrapings was revealed to carry a sialylated Gal or sialylated 
Galα1,3Gal terminal. 
 
4.2.4 Differentiation of fucosylated histo-blood group antigens. 
Both stomach and mucosal scrapings samples from wild type and FuT2-null mice gave a 
molecular ion at m/z 1157 whose composition is compatible with putative singly fucosylated 
Lewis or H antigens. In order to establish what terminal epitope contributes to this molecular ion, 
MS/MS experiments were first carried out using MALDI-TOF/TOF-MS/MS. However, due to 
the very low amount of this component in the FuT2-null mice, no definitive fragments were 
acquired (data not shown). Then, analysis was repeated on the corresponding doubly charged ion 
at m/z 590 using ESI-QTOF-MS/MS. These experiments successfully revealed that the dominant 
wild type glycans carry the H epitope on either the core 1 or the core 2 arm (Figure 4.6A). In the 
latter case, the fragment ions are consistent with the H antigen being of the type 2 sequence in 
which the Gal is attached to position 4 of GlcNAc. An especially definitive signal is the fragment 
at m/z 529 which correspond to the concomitant elimination and cleavage of two hexose residues, 
one of which is fucosylated. Elimination is only possible when the moiety being eliminated is 
linked to position 3 of a HexNAc. The absence of a fragment ion at m/z 511 demonstrates that 
only one hexose moiety was 3-linked. However, we cannot rule out minor amounts of the type 1 
sequence. Also, because of the dominant H-containing structures it is not possible to determine 
whether any Lewis structure is contributing to m/z 1157 in the wild type. 
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Figure 4.3. The MALDI-TOF-MS O-glycomic profile of reduced and permethylated O-glycans 
[M+Na]+ detected in the stomach of FuT2-null mice.  
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Figure 4.4. The MALDI-TOF-MS O-glycomic profile of reduced and permethylated O-glycans 
[M+Na]+ detected in the mucosal scrapings of FuT2-null mice.  
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Figure 4.5. The MALDI-TOF/TOF-MS/MS spectrum of the molecular ion m/z 708 [M+Na]+ from the 
stomach of FuT2-null mice. 
The fragmentation of the glycan at m/z 708 provides evidence of a fucosylated core 1 structure with the 
fucose being on the Gal. *, impurities/ unknown fragments. 
 
 In contrast to the wild type, the Fut2-null mice showed strong evidence for the Lex 
structure (Figure 4.6B), despite the relevant glycan (m/z 1157 in the MALDI-TOF-MS data) 
being only a small fraction of a percent of the total glycan mixture. Because of the very low 
abundance of this component, contaminant signals are prominent below m/z 500 in the ESI-
QTOF-MS/MS spectrum. Fortunately, however, the region of the MS/MS spectrum which 
contains structurally useful fragment ions (above m/z 600) is relatively free from contaminating 
ions. Especially relevant are the signals at m/z 951 and m/z 715 because they correspond to 
elimination of fucose and separate eliminations of fucose plus hexose, respectively. As shown on 
the cartoon annotations, these signals can only be derived from a Lex structure. Elimination is 
only possible when the moiety being eliminated is linked to the position 3 of a HexNAc, 
therefore Lea will not eliminate fucose, and instead should eliminate galactose. Importantly there 
was no detectable signal at m/z 685 which would be expected for Lea (i.e. elimination of Hex 
from Lea concomitant with elimination of the core 1 galactose from the GalNAcitol). 
Nevertheless, some of the H-structure is also present because m/z 747 can only be derived from a 
glycan which carries the fucose attached to a penultimate galactose because this ion is produced 
by elimination of fucose plus hexose via a single cleavage event (see cartoon annotations).  
 
In order to put the identification of Lex structure and not Lea in the FuT2-null samples on 
a firmer footing, we have performed MS/MS and MS3 analysis on the singly charged molecular 
ion at m/z 1157 using MALDI-QIT-TOF-MS as described in the previous chapter. The MS/MS 
provided fragment ions similar to those previously acquired using ESI-QTOF-MS, thereby 
supporting the assignment of the Lex antigen as the most abundant terminal epitope (Figure 
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4.7A). However, the spectrum quality was better than the previous experiment therefore allowing 
the detection of low molecular weight fragment ions below m/z 520 which were undetected in the 
ESI-QTOF-MS/MS. Structurally useful low molecular weight fragments are m/z 486 and 433. 
The first fragment ion corresponds to a non-reducing terminal of unmodified LacNAc and the 
latter corresponds to non-reducing terminal fucose and Gal eliminated via a single cleavage. Both 
these fragments support the existence of the residual H antigen. To confirm the linkage position 
of the monosaccharide constituents of the Lewis epitope, MS3 analyses were performed on the 
MS2 fragment ion of m/z 660 Figure 4.7B. The fragments confirm that the fucose is mainly 
attached to the GlcNAc residue and not Gal, supported by the absence of the fragment at m/z 433. 
However, due to the very low abundance of this component, cross-ring fragment ions observed 
were unable to provide additional evidence that can definitely confirm or refute the minor 
existence of Lea antigen.  
 
 
 
Figure 4.6. The ESI-QTOF-MS/MS spectrum of glycans at m/z 590 [M+2Na]2+ from the stomach of 
(A) wild type and (B) FuT2-null mice. 
In the wild type, there is only evidence of fucose being on the terminal Gal whereas in the FuT2-null 
stomach, the main signals are consistent with fucose being on the GlcNAc. Fragments observed are of 
[M+Na]+ ions. *, impurities/ unknown fragments. 
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Both stomach and mucosal scrapings from wild type mice also gave a molecular ion at 
m/z 2578, with composition of which is compatible with two H antigens and a putative 
difucosylated Lewis antigen. The MS/MS data for this component from MALDI-TOF/TOF gave 
evidence for two H antigen terminated antennae and a Ley terminated antenna. The latter structure 
is supported by fragment ions showing that one antenna is difucosylated (m/z 834 and 1766) and 
by a convincing signal for the elimination of fucose from the molecular ion (m/z 2372), 
confirming that a portion of the fucose in the glycan is attached to position 3 of GlcNAc (Figure 
4.8). 
 
Figure 4.7. The MALDI-QIT-TOF analysis of the glycans at m/z 1157 [M+Na]+ from the 
stomach of FuT2-null mice. 
(A) MALDI-QIT-TOF-MS/MS analysis of the molecular ion at m/z 1157 and (B) the subsequent MS3 
analysis of the fragment ion at m/z 660 (HexNAc1Hex1Fuc1). The fragmentation data from both 
analyses supports previous assignment using ESI-QTOF-MS/MS indicating major signals for fucose 
being on the GlcNAc residue and minor signals for fucose being on the terminal Gal of core 1 or core 
2 arm. *, impurities/unknown fragments. 
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4.2.5 Determination of N-acetyllactosamine unit type 
The class of terminal epitope is determined by the type of N-acetyllactosamine (LacNAc) 
chain upon which it resides. Therefore, to further support the mass spectrometric assignment of 
type 2 antigens in wild type and FuT2-null mice, exhaustive MS3 analysis was performed on 
selected glycan MS/MS fragments that contain LacNAc units, plus additional enzymatic 
digestion and GC-MS linkage analysis in order to define backbone linkages.  
 
The LacNAc chain type 1 consists of the repeating unit [Galβ1-3GlcNAcβ1-3], whereas 
type 2 consists of [Galβ1-4GlcNAcβ1-3]. As an example of the determination of LacNAc chain 
type, Figure 4.9 shows MALDI-QIT-TOF-MS/MS data for the glycan at m/z 1780 
(HexNAc3Hex3Fuc2) of wild type stomach (A), together with MS3 spectra from collisional 
activation of the fragments at m/z 660 (B). The glycan at m/z 1780 was chosen as an exemplar 
because it produced an intense 660 fragment ion which is derived from glycosidic cleavages of 
two separate fucosylated LacNAc units, as shown in Figure 4.9A. The fragment ion m/z 660 was 
in fact an excellent precursor ion to produce quality data for the subsequent MS3 experiment. The 
fragment ion at m/z 834 in the MS/MS spectrum shows that a minor portion of the LacNAc unit 
is difucosylated. In the MS3 spectrum (Figure 4.9B), the cross-ring fragments at m/z 503 and 586 
unequivocally have proven that the Gal residue is linked to the position 4 of GlcNAc. Therefore 
this LacNAc unit is confirmed to be type 2. Moreover, the fucose residue was shown to be 
attached to Gal making this trisaccharide a blood group H type 2 antigen.  
Figure 4.8. The MALDI-TOF/TOF-MS/MS spectrum of glycan at m/z 2578 [M+Na]+ with the putative 
Ley antigen from the stomach of wild type mice. 
This spectrum illustrates the instrument’s capability to exhaustively characterise a minor high-mass glycan 
from a complex sample. *, impurities/ unknown fragments. 
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Figure 4.9. Determination and verification of N-acetyllactosamine unit type.  
(A) MALDI-QIT-TOF-MS/MS spectrum of m/z 1780 [M+Na]+ from wild type stomach shows evidence of 
branching on Gal of the core 1 arm (fragments m/z 506 and 1143) and the terminal epitope blood group H 
antigen on each of the branches (fragments m/z 660 and 1370). Evidence for a minor difucosylated 
LacNAc unit is shown at m/z 834. (B) MALDI-QIT-TOF-MS3 spectrum of the fragment m/z 660 from (A) 
shows evidence for 4-linked GlcNAc (cross-ring fragments at m/z 503 and 586) indicating LacNAc unit 
type 2 as well as a fucose residue linked on the Gal residue (cross-ring fragment at m/z 313) establishing 
the epitope as H type 2. *, impurities/ unknown fragments. 
 
In addition, enzymatic digestion by using a specific β1,4-galactosidase displayed a major 
reduction of glycans that are terminated with unmodified Gal in the wild type stomach compared 
to the undigested tissue (Figure 4.10), confirming a significant composition of Gal attached to 
position 4 of GlcNAc in this tissue. For example glycans at m/z 983, 1677, 1881 and 1923 in the 
enzyme digested glycomic profile were reduced in abundance by comparing their respective 
adjacent peaks, relative to the wild type profile. This finding is further supported by GC-EI-MS 
linkage analysis which has shown the existence of 4-linked GlcNAc in the stomach, whereas 3-
linked GlcNAc was not detected (data not shown). Taken together our MS3, enzymatic digestion 
and GC-MS linkage data support the absence of type 1 LacNAc sequences in the stomach. This 
conclusion can be extended to type 1 histo-blood group antigens. 
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Figure 4.10. The O-glycomic profile of permethylated glycans from the stomach of wild type mice 
before and after β1,4-galactosidase digestion. 
MALDI-TOF-MS O-glycomic profile of (A) undigested stomach of wild type mice and (B) β1,4-
galactosidase digested stomach of wild type mice. Peaks with reduced abundances relative to the 
undigested tissue are highlighted in yellow. 
 
4.2.6 Glycomic analysis of immunopurified stomach lysates 
In order to increase the possibility of detecting putative O-glycans carrying the Lea 
antigen in the mouse, stomach lysates were concentrated by immunoprecipitation using 
antibodies against Lea and Muc5AC. The latter is the most probable carrier of Lea in human 
stomach (De Bolós et al., 1995). The samples were then separated using gel electrophoresis and 
identified using Western blotting against the same antibodies. Our collaborators supplied several 
excised gel bands from this experiment for mass spectrometric analysis. We included several 
bands of murine IgA standard from electrophoresis gel under reducing condition as control for the 
in-gel tryptic digestion and the subsequent O-glycomic analysis. Unfortunately, no glycan 
structures were detected in any of the immunoprecipitated samples (data not shown). However, 
the experimental control using murine IgA electrophoresis bands gave positive results (Figure 
4.11), proving that the extraction of glycopeptides from gel and the O-glycomic analysis were in 
fact reliable.    
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Figure 4.11. The MALDI-TOF-MS O-glycomic profile of reduced and permethylated O-glycans 
[M+Na]+ detected in the experimental control murine IgA bands. 
This indicates the reliability of the in-gel tryptic digestion and the subsequent O-glycomic experiments. X, 
impurities/contaminant peaks. 
 
4.2.7 Discussion 
This study aimed to perform O-glycosylation profiling of secretor and non-secretor 
mouse models and to characterise murine histo-blood group antigens in relation to the adhesion 
of H. pylori. Specific objectives of this study were: 1) to evaluate the glycosylation changes of the 
stomach and mucosal scrapings of FuT2-null mice, 2) to differentiate Lewis antigen type 1 and 
type 2 structures and determine the most abundant type in the gastric mucosa and 3) to associate 
the changes in glycosylation with immunohistochemistry findings and the binding capability of 
various strains of H. pylori. To this end O-glycomic analyses were performed on stomach and 
stomach mucosal scrapings of wild type and FuT2-null mice. This work was done in 
collaboration with Celso A. Reis group from the University of Porto, Portugal, who have 
produced the samples and also performed phenotypic experiments. Mass spectrometric analysis 
for this type of tissue was optimised while analysing wild type and C2GnT knockout mice in the 
previous chapter. 
 
O-Glycomic profiles of wild type stomach and mucosal scrapings were found to be 
dominated with glycans terminated with the H antigen. For all monofucosylated glycans, the 
MS/MS data are fully consistent with the fucose being on the terminal Gal in the vast majority of 
the glycans. This finding corroborates with previous analysis on cervical mucins using LC-ESI-
MS that also suggested the H antigen as the most abundant terminal epitope; however only 
glycan compositions, not sequences, were presented in the earlier study (Domino et al., 2009). 
Nevertheless, we cannot rule out the possibility of very minor components having fucose on 
GlcNAc but, if present, they are below the sensitivity limit for MS/MS detection on our 
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instruments. A similar theme pertains for the more heavily fucosylated glycans. If multiple 
antennae are available, the fucoses prefer to be on separate antennae, for example the MS/MS 
data for the glycan at m/z 1780 (Figure 4.9) indicate that the vast majority of the fucoses are 
attached to Gal of each antenna. Some of the larger glycans, however, have more fucoses than 
can be attributed to H antigen and therefore carry difucosylated antennae. For example, the 
MS/MS data for the glycan at m/z 2578 (Figure 4.8) confirms that one antenna is difucosylated 
and there is also a convincing signal for the elimination of fucose from the molecular ion, 
confirming that a portion of the fucose in the glycan is attached to position 3 of GlcNAc, 
indicating the structure Ley. However, we cannot rule out Leb as a minor component but on the 
other hand we have no evidence for its presence. In summary, the MS/MS data have not yet 
yielded evidence for Le antigens type 1. Importantly the quality of the MS/MS data is generally 
excellent and it is expected to detect minor isomers if they are present at the level of 5-10% of 
their isobaric relatives, which is a very small fraction of the overall glycan mixture.  
 
Glycosylation profiles of the stomach and mucosal scrapings from FuT2-null mice were 
compared to wild type mice. As expected, FuT2-null stomach and mucosal scrapings suffered a 
major loss of H antigens which were the most abundant terminal epitope in the wild type. Except 
for the disappearance of most of the fucosylated components, other O-glycan structures were 
almost identical to the wild type. This finding is supported by hematoxylin and eosin staining of 
gastric mucosa indicating no histological differences between wild type and FuT2-null mice 
(Magalhaes et al., 2009). Generally there was very low sialylation in these tissues. O-Glycomic 
analysis showed that sialylation in the knockout tissues was further reduced, with the absence of 
most of the sialylated glycans detected in the wild type tissues. This is unexpected since the loss 
of the dominant H antigen terminated glycans should allow better detection of these minor 
sialylated glycans. Furthermore, the deficiency of α1,2-fucosyltransferase is expected to result in 
less competition for sialyltransferases to modify the terminal Gal residues. In contrast to the 
glycomics data, a minor increase in staining with Maackia amurensis lectin-I (MAL-I), which 
recognises Siaα2,3Galβ1,4GlcNAc or Galβ1,4GlcNAc structure, was observed in the FuT2-null 
gastric mucosa (Magalhaes et al., 2009). However, the binding of the Siaα2,6Gal/GalNAc-
specific Sambucus nigra (SNA) lectin was similar in both types of mice indicating no differences 
in α2,6-sialylation. A possible explanation for the discrepancy between the MAL-1 and glycomics 
results is that there could be improved accessibility to the minor sialylated glycans by the MAL-1 
lectin in the absence of heavily fucosylated glycans. In any event it is clear that the absence of 
terminal Fuc does not result in enhanced sialylation.   
Chapter 4   152 
 
 The immense loss of fucosylated glycans in FuT2-null mice is supported by the complete 
loss of binding of the α1,2-fucose-specific lectin ulex europaeus (UAE-I) to FuT2-null mice 
(Magalhaes et al., 2009). However, based on the MS data on the knockout tissues, there were two 
residual glycan molecular ions, m/z 708 and 1157, whose compositions are consistent with 
monofucosylated structures. Surprisingly, minor fucosylation on terminal Gal could be detected 
in the FuT2-null mice as demonstrated by the molecular ion at m/z 708 and the fragment ions at 
m/z 747 and 433 (Figure 4.5). Furthermore, this sequence is the only biosynthetically possible 
sequence for the O-glycan composition Fuc1Hex1HexNAc1. This remaining α1,2-fucosylation 
could be derived from the activity of FuT1, the only other α1,2-fucosyltransferase known in 
mouse. Murine FuT1 RNA was shown to be expressed in stomach and this enzyme can utilise 
both type 1 and type 2 LacNAc as fucosylation substrate (Domino et al., 1997). However, the 
previous work also suggested that FuT1 is not the main α1,2-fucosyltransferase in murine 
stomach. 
 
The absence of significant levels of H-containing glycans in the knockout meant that the 
presence of putative Lewis structures could be rigorously confirmed by MS/MS analysis. This 
was accomplished by using ESI-QTOF and MALDI-QIT-TOF techniques. The molecular ion m/z 
1157 in both FuT2-null stomach and mucosal scrapings is very minor indeed. Nevertheless high 
quality ESI-QTOF-MS/MS data were acquired by selecting a small window centred on the 
doubly charged molecular ion (m/z 590). The data showed evidence for a Lewis sequence being 
at least as abundant as the H-sequence. Especially important diagnostic signals are m/z 951 and 
715 because they correspond to the elimination of fucose, and separate eliminations of fucose 
plus hexose, respectively. Therefore, it can be concluded that Lex is readily detectable using 
MS/MS, despite the relevant glycan (m/z 1157) being only a tiny fraction of a percent of the total 
glycan mixture, yet no ions characteristic of Lea were observed in the MS/MS data. This result 
was further confirmed by MS/MS and MS3 analyses using MALDI-QIT-TOF. 
 
 The detection of a Lex containing glycan in the O-glycomic spectra of FuT2-null mice, 
but not in the wild type, is likely to be an experimental consequence of the disappearance of 
interfering signals in the former, rather than being due to the augmentation of α1,3-fucosylation. 
Therefore, it is anticipated that Lex was also present in the wild type tissues, but below the 
detection levels of current structural strategies. This is supported by the similar immunoreactivity 
between gastric mucosa of wild type and FuT2-null mice against anti-Lex antibody 
SH1(Magalhaes et al., 2009). Surprisingly, antibody staining has also indicated the existence of 
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Le antigens type 1, Lea and Leb, in the wild type mice. This is not expected since mice lack an 
orthologue of the human FUT3 gene and no α1,4-fucosyltransferase has so far been described in 
mice (Nairn et al., 2008). Gastric mucosa staining using Ca3F4 and 7LE (anti-Lea) antibodies 
indicate that there was an increase in Lea expression in Fut2-null mice compared to the wild type, 
suggesting that the lack of α1,2-fucosyltransferase activity has led to the accumulation of Lea 
structures. However, rigorous mass spectrometric analysis has provided no structural evidence for 
that epitope in either mouse. There is a possibility of antibody cross-reactivity, although the 7LE 
antibody was shown to display excellent specificity in carbohydrate microarray experiments in a 
previous study (Manimala et al., 2007). 
 
Complementing their anti-Lea results, the Reis team observed that two anti-Leb 
antibodies, BG6 and 2.25LE, bound to the mucous cells of wild type gastric mucosa but not to 
the FuT2-null mice. This contrasted with our MS experiments which identified only its isobaric 
type 2 structure, Ley, in the wild type mice. One possible interpretation for the anti-Leb staining is 
antibody cross-reactivity. It has been demonstrated previously that BG6 cross-reacted 
significantly with LacNAc unit type 1, Ley and H antigen type1 (Monteiro et al., 1998; Manimala 
et al., 2007) whereas the 2.25LE antibody displayed weak cross-reactivity with Lea (Good et al., 
1992; Manimala et al., 2007) although the latter would not explain the loss of binding to Fut2-
null mice tissue sections. However, there was also a reduction in the anti-Ley antibody AH6 
staining in FuT2-null gastric mucosa, and together with the loss of anti-Leb antibodies staining, 
this is consistent with mass spectrometric data as there were no detectable difucosylated glycan 
structures in FuT2-null tissues. These findings support the classical model of the Le antigen 
biosynthetic pathway involving FuT2 enzyme, in which Leb and Ley are synthesised from H 
antigens (Ma et al., 2006). In the context of the current work where only type 2 histo-blood group 
antigens were characterised, it can be summarised that FuT2 is critical in the synthesis of H 
antigens and Ley in murine gastric.    
 
We complemented the structural evidence for fucosylated type 2 antigens by determining 
the type of LacNAc chains in wild type stomach. Rigorous MS3 experiments accompanied by 
enzymatic digestion and GC-MS linkage analysis have collectively provided evidence that 
substantial amounts of terminal Gal are 4-linked to GlcNAc. Therefore, it can be concluded that 
this tissue is dominated with type 2 LacNAc chains, thus supporting the existence of type 2, but 
not type 1, Le antigens in the murine stomach. Although the same strategies were not applied to 
FuT2-null mice due to sample constraints, MS/MS and MS3 experiments on these tissues (for 
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example MS/MS on m/z 1157 and MS3 on m/z 660 in Figure 4.7) also suggested type 2 LacNAc 
chains.  
 
It was evident that there were no significant structural differences between the whole 
stomach and mucosal scrapings in both wild type and knockout mice, other than slight 
discrepancies in the relative abundances of limited glycan structures observed in the wild type 
tissues. Therefore, it could be postulated that the mucosal barrier is the most highly glycosylated 
component of the stomach and occupied most of the O-glycan population in the whole organ. 
 
The purpose of immunoprecipating stomach lysates using antibodies against Lea and 
Muc5AC was to concentrate the protein carrier of Lea terminated glycans. This optimistically 
should aid mass spectrometric characterisation of the speculated minute amount of Lea antigens 
in the stomach of wild type and FuT2-null mice. However, no glycan structures were detected in 
any immunoprecipitated samples although experimental controls, the IgA bands, gave positive 
results. The negative findings are probably due to the non-specific antibody binding during the 
immunoprecipitation and/or immunoblotting thus giving false staining on the blotted membrane. 
A similar strategy was applied previously and successfully isolated and analysed O-glycosylation 
of human MUC1 from a number of cancer cell lines (Backstrom et al., 2008). Therefore it is 
anticipated that improvements on the application of this technique should yield better Lea antigen-
concentrated samples for future studies. 
 
In summary, our mass spectrometric characterisation of histo-blood group antigens has 
established that only type 2 Lewis structures are detectable in murine gastric mucins, consistent 
with murine genetic incapability to express Lewis type 1 structures (Gersten et al., 1995). The 
discrepancies observed between the immunohistochemical staining data and mass spectrometric 
structural characterisation regarding the detection of Le type 1 and type 2 epitopes in wild type 
tissues, as aforementioned, could be due to antibody cross-reactivity. In addition to that, the 
stomach is dominated with branched O-glycans (core 2 branch and I-branch), which are often 
terminally monofucosylated. The core 2 branch and I-branch are 6-linked on GalNAc and Gal, 
respectively, hence forming a more flexible conformation. It is tempting to speculate that O-
glycans having monofucosylated branches (for example glycans at m/z 1331, 1780, 2026 and 
2404 in the wild type tissues, see Figure 4.1 and Figure 4.2) could have similar spatial 
conformation as a difucosylated antenna. Therefore, those glycan structures could be perceived as 
having Ley/b by antibodies. Hence, caution should be taken when drawing conclusions based only 
Chapter 4   155 
 
on binding assays. Mass spectrometry, on the other hand, is a more reliable and definitive method 
for evaluating the expression of carbohydrate structures from complex samples.  
 
If antibody cross-reactivity is not the correct explanation for the aforementioned 
discrepancies, the absence of type 1 Lewis antigens in the O-glycomic profiles could perhaps be 
explained by a higher sensitivity of immunohistochemistry compared with mass spectrometry. As 
indicated by anti-Lewis antigen antibodies, these structures are only expressed on specific 
stomach sections (Magalhaes et al., 2009). Lea antigens were indicated at surface mucous cells 
whereas Leb and Ley were found at superficial mucous cells of the foveolar epithelium. Lex 
expression, on the other hand, was slightly more widespread at the surface mucous cells and neck 
cells. These findings are supported by the section-selective binding of BabA and/or SabA positive 
H. pylori strains (see below). Therefore, mass spectrometric analysis of the whole stomach and 
mucosa scrapings could easily swamp low abundance structures expressed on a limited number 
of cells. Mass spectrometric analysis of specific stomach sections should be performed in future 
studies, provided advances in technology yield the required sensitivity, and this optimistically 
would be a good alternative to immunoprecipitation of stomach lysates to concentrate specific 
epitopes.  
 
H. pylori has been suggested to bind fucosylated histo-blood group antigens Leb and H 
type 1 in humans mediated by BabA adhesin (Ilver et al., 1998; Bovenkamp et al., 2003). This 
adhesin is encoded by the gene babA2 (Gerhard et al., 1999). Another important adhesin is SaBA 
which is encoded by JHP662 gene and binds to sialylated glycans including SLea and SLex 
(Mahdavi et al., 2002).  In the current study, a panel of BabA and/or SabA positive and negative 
model strains of H. pylori have been evaluated for their binding capacity on gastric mucosa of 
wild type and FuT2-null mice (Magalhaes et al., 2009). H. pylori strain J99 expresses both BabA 
and SabA active adhesins with known bacterial binding to antigens including Leb, H type 1, SLex, 
SLea and sialyl-lactosamine (Aspholm-Hurtig et al., 2004; Aspholm et al., 2006). Our 
collaborators have shown that this strain bound to the surface mucous cells and glands of both 
wild type and FuT2-null mice. However, the binding to the surface mucous cells was decreased 
in the FuT2-null mice. In order to determine the involvement of α1,2-fucosylated glycans to the 
observed decrease, the adhesion of 17875/Leb strain was evaluated (Magalhaes et al., 2009). This 
strain expresses both BabA and SabA adhesins but lacks binding capability to sialylated glycans 
(Aspholm et al., 2006). Binding of this strain was restricted to the surface mucous cells of wild 
type mice and completely absent in the null mice, indicating the importance of fucosylated 
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glycans in BabA-mediated adherence. In addition to that, a BabA mutant strain 17875babA1A2 
which only binds to sialylated glycans has been tested. As expected, this strain bound similarly in 
both wild type and FuT2-null mice to the faveolar and surface mucous cells, thus illustrating the 
fucosylation-independence binding in BabA-negative strains. Interestingly, this strain also 
adhered more to the glandular region of FuT2-null mice than of the wild type mice. 
 
In addition, the binding capacity of a larger panel of H. pylori strains from clinical isolates 
with different active adhesins were tested on wild type and FuT2-null mice and the results in 
general supported earlier findings of H. pylori model strains. Generally, strains with active BabA 
adhesin have reduced binding to FuT2-null mice, with the presence or absence of active SabA, 
whereas SabA active strains and strains without any adhesin showed similar binding to both mice. 
The FuT2-null mouse model resembles the human non-secretor phenotype which has been 
demonstrated to have similar reduced susceptibility to H. pylori infection compared to the wild 
type (secretor phenotype) (Ikehara et al., 2001; Azevedo et al., 2008). Collectively, based on all 
the adhesion studies and our mass spectrometric structural data, it can be concluded that α1,2-
fucosylated glycans, particularly those decorated with H type 2 and/or Ley, play important roles 
in the adhesion of H. pylori BabA-postitive strains and therefore can critically influence the 
bacterial pathogenicity. Furthermore, a recent finding has shown that both BabA and SabA 
adhesins play substantially bigger roles in inducing cell death than the proinflammatory factor 
CagA (Lindén et al., 2009). It is also worth highlighting that greater than 80% of known H. pylori 
strains were shown to express type 2 Lewis antigens aimed to mimic the gastric epithelial surface 
in order to evade the host immune system (Wang et al., 2000), thus suggesting the significance of 
the type 2 carbohydrate structures at H. pylori’s colonisation sites. 
      
As mentioned in Chapter 1, persistent colonisation by H. pylori results in inflammation 
and has been shown to promote synthesis of sialylated glycoconjugates purposely to guide 
leukocyte migration (Mahdavi et al., 2002). Previously, H. pylori mutant strain babaA1A2 (BabA 
negative, SabA positive) was demonstrated by Mahdavi et al. to lack binding to healthy gastric 
mucosa but not to H. pylori-infected (inflamed) tissues (Mahdavi et al., 2002). It is important to 
highlight here that H. pylori adhesion seems to promote substantial changes to the glycosylation 
profile of gastric mucosa. To date, rigorous structural characterisation of H. pylori infected tissues 
in comparison with the healthy ones has not been accomplished. Therefore, it is not known 
whether H. pylori infection induced glycosylation changes other than sialylation, for instance 
downregulation of fucosylated glycans, and if these changes are also influenced by the secretor 
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status. As an example, Holmen et al. previously have demonstrated transient induction of FuT2 
concomitant with the increase of oligosaccharides containing H antigen during the infectious 
cycle of parasite Nippostrongylus brasiliensis (Holmen et al., 2002).  Furthermore, as a long term 
and common inhabitant of human gastric tissue since birth, it is also not impossible for H. pylori 
to be involved in gut development, as has been suggested by Hooper and colleagues for other 
microbes (Hooper, 2004). These workers found that during the weaning stage, human intestinal 
microflora changed from being dominated by Escherichia coli and Streptococci to Bacteroides 
and Clostridium species, accompanied by marked functional and morphological maturation of the 
gut. It is similarly important for future work to also establish the type of sialylated glycans that 
are utilised by H. pylori for adhesion. SLex, sialyl-Tn, sialylated terminal Gal, sialylated GlcNAc 
and Sda are among the possible sialic acid containing structures in mice and, in contrast to 
humans, could include either NeuAc or NeuGc.  
 
In summary, we have demonstrated a major loss of fucosylated O-glycans in the FuT2-
null murine gastric mucosa. Extensive glycan sequencing has proven that type 2 histo-blood 
group antigens, especially the H antigen and at a lower extent the Ley, dominate the mucins of 
murine gastric. Also our data and that of others have clearly demonstrated that H. pylori binds to 
fucosylated glycan receptors on gastric mucosa, and later also to the sialylated counterparts, in 
order to initiate gastric colonisation on the epithelial layer. The adherence to the cell surface 
constitutes the crucial step for a successful H. pylori infection, as deficiency in α1,2-fucosylated 
glycans severely affected the BabA-positive strains.  
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5 Investigation of cellular regulation of protein O-glycosylation by Src 
5.1 Background 
Previous findings and recent revelations by our collaborators (Gill et al., 2010) have led 
to the postulation that activated Src regulates mucin-type protein O-glycosylation through 
redistribution of polypeptide-N-acetylgalactosaminyltransferases (ppGalNAcTs) from the Golgi 
to the ER. The preliminary O-glycomic analyses described in Chapter 1 (Figure 1.13) have 
demonstrated a reduction of core 2 O-glycans relative to core 1 in Src activated cells which could 
be the consequence of higher O-glycosylation density, but were done only on a single murine 
fibroblast (SYF) cell line. Therefore, the work in this chapter aimed to determine whether the 
observed glycomic alterations were a cell-specific response or were indicative of a more general 
phenomenon by extending the semi-quantitative analysis to two different cell lines. Thus O-
glycomic analysis was performed on two samples of NIH3T3 Src murine fibroblast cell lines, 
namely 3T3 Src wild type (3T3 WT) and 3T3 Src-vSrc (3T3 vSrc). Analyses were also 
performed on four samples of NBT-II rat epithelial cell lines, namely NBT-II wild type (NBT-II 
WT), NBT-II with active exogenous ppGalNAcT-2 in the Golgi (NBT-II WT Golgi), NBT-II with 
active exogenous ppGalNAcT-2 in the ER (NBT-II WT ER) and NBT-II with inactive exogenous 
ppGalNAcT-2 in the ER (NBT-II H2 ER). The differences between the cell lines and samples are 
described below. This work was done in collaboration with Frederic Bard and colleagues from 
the National University of Singapore. 
 
5.2 Results 
5.2.1 Mass spectrometric strategy 
All samples that were analysed in this study are listed in Table 5.1. Cells were disrupted 
via sonication in lysis buffer followed by reduction/carboxymethylation and tryptic digestion as 
described in Chapter 2. In the first set of experiments for NIH3T3 cells, samples were subjected 
to O-glycan release without prior N-glycan removal. In the second experiment on NIH3T3 cells 
and all experiments involving NBT-II cells, samples were first treated with PNGase F. 
Additionally, in the second experiment for NBT-II cells, samples were also subjected to 
enzymatic and chemical treatments prior to mass spectrometric analysis. Mass spectrometric 
profiling and sequencing of permethylated O-glycans were carried out using MALDI-TOF/TOF-
MS and MS/MS, respectively, in the positive ion mode. 
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Table 5.1. List of cell line samples analysed and their descriptions. 
Cell lines Sample names Sample descriptions 
NIH3T3 Src 
mouse 
fibroblast 
3T3 WT (1) & (2) NIH3T3 wild type with normal level of Src 
3T3 vSrc (1) & (2) NIH3T3 transformed with viral Src with about 2.5 fold 
elevated Src activity than WT 
NBT-II rat 
epithelial cells  
NBT-II WT (1) NBT-II wild type 
NBT-II WT Golgi 
(1) & (2)  
NBT-II stably expressing full-length ppGalNAcT-2 with a 
C-terminal mCherry* tag. Exogenous active ppGalNAcT-
2 present in the Golgi 
NBT-II WT ER (1) 
& (2) 
NBT-II stably expressing ppGalNAcT-2 fused to the N-
terminus of MHC class II with a C-terminal mCherry tag. 
Exogenous active ppGalNAcT-2 present in the ER. 
NBT-II H2 ER (1) & 
(2) 
NBT-II stably expressing a mutant ppGalNAcT-2 fused to 
the N-terminus of MHC class II with a C-terminal 
mCherry tag. The mutation H226D of ppGalNAcT-2 
inactivates the enzyme due to inability to bind an 
essential Mn2+ co-factor ion. Exogenous inactive 
ppGalNAcT-2 present in the ER. 
*mCherry is a gene encoding a red fluorescent protein utilised as a protein tag to aid live cell imaging, 
detection and isolation. 
 
5.2.2 O-Glycomic analysis of NIH3T3 cells without N-glycan digestion 
Direct removal of O-glycans without prior digestion of N-glycans, as observed while 
optimising the methodology for the work in the previous chapters, usually gives the best O-
glycan data most likely due to shorter processing steps thus allowing better sample recovery. 
Therefore, it was sensible for the first set of NIH3T3 cells to be analysed according to this 
strategy. MALDI-TOF mass spectra of permethylated O-glycans as singly charged sodiated 
molecular ions from 3T3 WT (1) and 3T3 vSrc (1) are shown in Figure 5.1 and Figure 5.2, 
respectively. All detected O-glycan structures and their assignments are collated in Table 5.2, 
including those from the second set of experiments (see next section).  Data for both samples 
showed a mixture of N- and O-glycans because a portion of the N-glycans was hydrolysed from 
Asn under the alkaline conditions of the reductive elimination. The spectra are dominated by 
reduced (labelled N in figures) and non-reduced (labelled nN) N-glycans in addition to chemical 
artefacts (labelled X). This unique pattern of N-glycans allows their discrimination from the O-
glycans even without MS/MS analysis. In addition, the N-glycan peaks can be regarded as 
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internal controls indicating the experimental measures were in fact working fine and similar in 
both samples. 
 
 
Figure 5.1. MALDI-TOF-MS spectra of O-glycans from 3T3 WT (1) cells without N-glycan removal 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in 3T3 WT cells. N, 
reduced N-glycans; nN, non-reduced N-glycans; X, impurities.  
 
Generally, both samples exhibited a very low number and abundance of core 1 and core 2 
O-glycans and therefore would not be an ideal set of samples for the comparison of the O-glycan 
core ratio. Only three O-glycan structures were detected in 3T3 WT (1) (m/z 534, 1187 and 1548) 
(Table 5.2). Similar molecular ions were observed in 3T3 vSrc (1) except for m/z 534, which was 
not detected. It was speculated that the high abundance of N-glycans might have interfered with 
the reductive elimination step resulting in low O-glycan release, thereby cancelling out the 
aforementioned advantage of having N-glycan peaks as internal controls for assessing the quality 
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of O-glycan data. Therefore experiments were repeated on another set of the samples with O-
glycan release being carried out after N-glycan digestion. 
 
 
Figure 5.2. MALDI-TOF-MS spectra of O-glycans from 3T3 vSrc (1) cells without N-glycan removal. 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in 3T3 vSrc cells. N, 
reduced N-glycans; nN, non-reduced N-glycans; X, impurities. 
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Table 5.2. Summary table of O-glycan structures observed in both sets of experiments of NIH3T3 
cell line. 
 
  √, detected; X, not detected. 
 
5.2.3 O-Glycomic analysis of NIH3T3 cells with N-glycan digestion 
MALDI-TOF mass spectra of permethylated O-glycans as singly charged sodiated 
molecular ions from 3T3 WT (2) and 3T3 vSrc (2) with N-glycan removal prior to reductive 
elimination are shown in Figure 5.3 and Figure 5.4, respectively. The spectra are relatively clear 
from N-glycans and other contaminants compared to the first set of data. However, the number of 
detected O-glycan structures has not been much improved, as listed in Table 5.2. Therefore, 
taking together the findings of both sets of experiments, it can be concluded that 3T3 cells are 
naturally low in O-glycosylation. However, interestingly, it appears that this second set of 3T3 
cell data exhibited additional sialylated structures that were absent in the first set, i.e. at m/z 895 
and 1256 (Table 5.2). 
 
In 3T3 WT (2), O-glycans of both core1 (m/z 534 and 895) and core 2 (m/z 1187 and 
1548) were observed. The Src-induced cells, 3T3 vSrc (2), unexpectedly exhibited a very similar 
profile to the wild type cells but with a slight increase in sialylated structures. This was 
demonstrated by the higher abundance of the glycan at m/z 895 and the emergence of a 
disialylated core 1 O-glycan at m/z 1256. It is important to note that in both 3T3 WT (2) and 3T3  
vSrc (2), core 1 O-glycan structures are mostly sialylated whereas core 2 structures are 
predominantly capped with Galα1,3Gal alone or both Galα1,3Gal and sialic acid (on separate 
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antenna). Due to the very limited number of structures observed and the lack of significant 
differences in term of peak abundances, we were unable to make any firm conclusions 
concerning changes in the core 2/core 1 ratio.  
 
 
Figure 5.3. MALDI-TOF-MS spectra of O-glycans from 3T3 WT (2) cells with N-glycan removal 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in 3T3 WT cells. X, 
impurities. 
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Figure 5.4. MALDI-TOF-MS spectra of O-glycans from 3T3 vSrc (2) cells with N-glycan removal 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in 3T3 vSrc cells. X, 
impurities. 
 
5.2.4 O-Glycomic analysis of NBT-II cell lines 
Since there were no useful differences observed between the O-glycomic profiles of 
normal and induced Src in the NIH3T3 cells, our collaborators designed experiments aimed at 
investigating the effect of the relocalisation of ppGalNAcT from the Golgi apparatus to the ER in 
NBT-II cells. The cells they provided for O-glycomic analysis are described in Table 5.1.  The O-
glycomic profiles of NBT-II WT (1), NBT-II WT Golgi (1), NBT-II WT ER (1) and NBT-II H2 
ER (1) are shown in Figure 5.5, Figure 5.6, Figure 5.7 and Figure 5.8, respectively. These cells 
displayed a complex repertoire of core 1 and core 2 O-glycans which are variously capped with 
fucose, Galα1,3Gal and sialic acid. Generally, all samples exhibited similar glycan compositions 
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and sequences except for the molecular ion at m/z 1505, whose composition is compatible with 
putative core 2 O-glycans carrying fucosylated Gal and Lex/y epitopes, which was absent in NBT-
II WT.  
 
 
Figure 5.5. MALDI-TOF-MS spectra of O-glycans from NBT-II WT (1) cells 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in NBT-II WT cells. X, 
impurities; U, underpermethylations. 
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Figure 5.6. MALDI-TOF-MS spectra of O-glycans from NBT-II WT Golgi (1) cells 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in NBT-II WT Golgi cells. 
X, impurities; U, underpermethylations. 
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Figure 5.7. MALDI-TOF-MS spectra of O-glycans from NBT-II WT ER (1) cells 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in NBT-II WT ER cells. X, 
impurities; U, underpermethylations. 
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Figure 5.8. MALDI-TOF-MS spectra of O-glycans from NBT-II H2 ER (1) cells 
The glycomic profile of reduced and permethylated O-glycans [M+Na]+ detected in NBT-II H2 ER cells. X, 
impurities; U, underpermethylations. 
 
Major peaks in the m/z range of 700 to 1730 from all spectra are collated in a single panel 
to assist semi-quantitative analysis (Figure 5.9). NBT-II WT (1) has the highest abundance of 
core 1 O-glycans (taking into account the abundance of m/z 708 and 912) compared to the other 3 
cell lines. All these cells exhibited a similar level of the basic core 2 structure (m/z 983) but varied 
in the levels of elongated core 2 structures. By comparing the abundances of the sialylated 
glycans at m/z 1548 to their non-sialylated counterparts at m/z 1187 in all samples, it appears that 
sialylation in NBT-II WT (1) and WT ER (1) is higher compared to WT Golgi (1) and H2 ER (1). 
The differences in terminal capping of these glycans, in addition to not being close enough in m/z 
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value, has complicated semi-quantitative analysis of these glycomic profiles thus preventing 
rigorous comparison of the core 2/core 1 ratio. Therefore, a second set of NBT-II cell line 
samples were subjected to chemical and enzymatic sugar degradations prior to mass 
spectrometric analysis aimed to trim down the structures to simple core 1 and core 2 structures, 
except for NBT-II WT which was no longer available.  
 
 
Figure 5.9. Combined O-glycomic spectrum of NBT-II cell lines showing only major peaks. 
 
5.2.5 Trimming NBT-II cell glycomes to basic core 1 and core 2 structures 
In the second set of experiments, NBT-II WT Golgi, WT ER and H2 ER released O-
glycans were treated with Sialidase A (neuraminidase that cleaves non-reducing terminal sialic 
acids of all linkages), α-galactosidase (cleaves all non-reducing terminal α-galactose residues) 
and α1,2-fucosidase (cleaves non-reducing terminal α1,2-fucose residues) concurrently prior to 
permethylation. The results (data not shown) suggested incomplete trimming of O-glycans, 
indicated by the existence of residual α1,2-fucosylated components and possibly other types of 
fucose linkages in the mass spectra. Therefore, these permethylated glycans were subjected to 
TFA hydrolysis at room temperature to remove all the remaining fucose residues. Figure 5.10 
shows O-glycomic profiles of glycosidases and TFA treated NBT-II WT Golgi (2), NBT-II WT 
ER (2) and NBT-II H2 ER (2). It is evident that only two simple O-glycan structures were 
detected at m/z 534 (core 1) and m/z 983 (core 2), thus allowing the comparison of core 1 and 
core 2 abundances. Relative to the core 1 structure, NBT-II H2 ER (2) showed the lowest 
abundance of the core 2 structure (20%), followed by NBT-II WT Golgi (2) (40%). 
Unexpectedly, NBT-II WT ER (2) showed the highest core 2 O-glycan relative abundance (60%), 
although the percentage is just slightly above that of NBT-II WT Golgi (2).   
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Figure 5.10. MALDI-TOF-MS spectra of enzyme- and TFA-treated NBT-II cell lines. 
O-glycomes of (A) NBT-II WT Golgi (2), (B) NBT-II WT ER (2) and (C) NBT-II H2 ER (2) were trimmed to 
basic core 1 and core 2 structures to aid semi-quantitative analysis. X, impurities; N, reduced N-glycans.    
 
It was of concern that TFA hydrolysis could have caused minor degradation of core 2 
structures. Therefore, two wild type kidney tissues were used to test the stability of core 2 
sequences towards TFA hydrolysis at room temperature. This organ was chosen because it is rich 
in fucosylated core 2 O-glycans (see Figure 3.11 in Chapter 3). O-Glycomic analysis of kidney 
tissues were performed according to the same strategies applied in the analysis of kidney tissues 
in Chapter 3. After permethylation, each sample was split into two, one for direct mass 
spectrometric analysis whilst the other was given prior treatment with TFA hydrolysis. 
Representative O-glycomic spectra of wild type kidney with and without TFA hydrolysis are 
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shown in Figure 5.11. The loss of fucosylated glycans leads to an increase in abundance of their 
respective non-fucosylated counterparts. For instance, after the removal of fucose, the glycan at 
m/z 1157 is now detected at m/z 983, contributing to the increase in intensity of that glycan peak 
(Figure 5.11B) compared to the control (Figure 5.11A). The loss of detection of originally non-
fucosylated glycans after the treatment, for instance at m/z 1187 and 1473, might indicate minor 
hydrolysis of non-fucose residues by TFA. However, by assessing the highly similar ratio 
observed between the abundances of the basic core 1 structure at m/z 534 and the basic core 2 
structure at m/z 779 before and after the hydrolysis, it can be concluded that, even if TFA 
hydrolysis at room temperature cleaves residues other than fucose, the degradation was similar 
between core 1 and core 2 structures. Hence, the data analysis of enzyme and TFA-treated NBT-II 
cell samples above is valid.     
 
 
Figure 5.11. MALDI-TOF-MS spectra of TFA-treated and non-treated wild type kidneys. 
 O-Glycomic profiles of (A) control and (B) TFA-treated permethylated O-glycan from wild type kidneys for 
investigation on the stability of O-glycan structures in TFA hydrolysis. X, impurities; U, 
underpermethylations. 
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5.3 Discussion 
O-Glycomic profiling of two cell lines was performed in order to investigate and confirm 
previous findings on the postulated role of Src in the regulation of protein O-glycosylation. In a 
preliminary analysis done by a colleague, a marked decrease in core 2 O-glycans was 
demonstrated by SYF cells when active Src was introduced. In this more comprehensive thesis 
work, NIH3T3 cells were prepared to contain different levels of activated Src as well as NBT-II 
cells having different localisation of exogenous ppGalNAcT-2 between the ER and Golgi. This 
was done to allow assessment of the effects of viral induction of Src and ppGalNAcT 
relocalisation from the Golgi to the ER, respectively, on cellular O-glycomes. Particularly this 
study was aimed to verify whether the level of activated Src or the localisation of ppGalNAcT 
influences the ratio between core 1 and core 2. High quality mass spectrometric and tandem mass 
spectrometric data were obtained by using a MALDI-TOF/TOF mass spectrometer aided by 
enzymatic and chemical digestions. 
 
The first set of 3T3 cells were analysed according to the strategy that usually gives the 
best O-glycan data, that is via direct reductive elimination without prior digestion of N-glycans. 
As well as O-glycans, this strategy also resulted in the release of some N-glycans which are 
observed in both reduced and non-reduced forms. Their presence can be useful in assessing the 
quality of the data but they can be a problem if they dominate the spectra. This protocol also 
seems to discriminate against small sialylated O-glycans compared to the second set of 3T3 cells 
that were subjected to N-glycan release prior to reductive elimination. For instance, a 
monosialylated (m/z 895) and a disialylated core 1 O-glycan (m/z 1256) were completely absent 
in 3T3 WT (1) and 3T3 vSrc (1) (Table 5.2). Unlike the monosialylated structure that was present 
in both 3T3 WT (2) and 3T3 vSrc (2), the disialylated structure was only detected and indeed 
gave an intense signal in 3T3 vSrc (2), the cells with induced Src. This might indicate Src’s 
influence on the level of sialylation. This is further supported by our finding on the NBT-II cell 
line that cells with overexpressed ppGalNAcT-2 in the ER demonstrated higher sialylation than 
cells that overexpressed the enzyme in the Golgi. Since an increase in sialylation is one of the 
hallmarks of cancerous cells (Brockhausen, 1999) and has been implicated to be important in 
metastatic process (Bresalier et al., 1996), this finding corroborates previous correlations of Src 
with the increase in metastatic potential of tumour cells (Boyer et al., 2002). However, the targets 
of Src activity that may be crucial for this process are still unknown. Based on the recent findings 
by our collaborators, it can be hypothesised that activated Src phosphorylates and activates 
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component(s) of COP-I vesicles thereby inducing the redistribution of Golgi enzymes (possibly 
including ppGalNAcTs relocalisation to the ER) leading to the changes in protein glycosylation, 
particularly alterations that benefit the progression of cancer cells. Putting together the facts that i) 
GEF1, a GTPase exchange factor that is involved in the formation of COP-I vesicles, and other 
GEFs such as Lfc and Ect2 are substrates for protein kinases (Meiri et al., 2009; Moseley & 
Nurse, 2009; Fields & Justilien, 2010) and ii) GEFs including Lfc and Ect2 are oncogenes 
(Cerione & Zheng, 1996), it is tempting to speculate that GEF1 could be the substrate for Src 
kinase.      
 
As discussed earlier (Section 1.2.6 in Chapter 1), previous O-glycomic analysis by a 
colleague (unpublished work) has demonstrated that core 2 O-glycans, found in significant 
amount relative to core 1 O-glycans in cells deficient in Src (SYF), were substantially reduced in 
cells with induced Src (SYFsrc) (Figure 1.13). However, from the current O-glycomic analyses of 
3T3 cell lines with or without prior N-glycan removal, there were no significant differences 
regarding the core 2/core 1 ratio observed between the wild type cells and Src-induced cells. 
Furthermore, without internal standards, quantitation by peak heights is unreliable in these cells 
since the core 1 and core 2 components are differently capped (mainly sialic acid for the former 
and Galα1,3Gal for the latter) and insufficiently close in m/z value to have similar ionisation 
properties for any valid quantitative conclusions to be drawn. Due to the limited availability of 
this cell line, we were unable to perform enzymatic/chemical degradation as has been carried out 
for the NBT-II cells. In addition, it was also evident that the 3T3 cells have a rather low 
abundance of O-glycans, thus they are not an ideal cell line to accomplish the aims of this work. 
 
O-Glycomic analysis of NBT-II cells was expected to illustrate the effects of ppGalNAcT 
redistribution from the Golgi to ER, which has been speculated to be part of the cellular events 
regulated by activated Src. The localisation of ppGalNAcTs in the ER is hypothesised to increase 
the total O-glycosylation initiation by exposing protein substrates to ppGalNAcTs earlier and for 
a longer time.  From our analysis, these cells appeared to be much richer in O-glycans than the 
NIH3T3 cells. Similar to the 3T3 cells, they exhibited a complex repertoire of core 1 and core 2 
O-glycans which are variously capped with fucose, Galα1,3Gal and sialic acid. However, there 
were insufficient types of core 1 O-glycans to serve as internal standards to their core 2 
counterparts, thus preventing direct assessment of the relative abundances of the two cores. 
Therefore, these cells were subjected to enzymatic and chemical degradations aimed to trim their 
O-glycomes to basic core 1 and core 2 structures. By treating the cells with a cocktail of 
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glycosidases, the sequences were partially trimmed indicating incomplete defucosylation. Further 
hydrolysis with TFA eliminated the remaining fucosylated components without significantly 
degrading other non-fucose residues. The results unexpectedly revealed that NBT-II WT ER has 
the highest core 2/core 1 ratio in contrast to previous findings on SYF cell lines demonstrating an 
increase in core 1 O-glycans parallel to Src activation. Therefore current findings are not in line 
with the hypothesis that relocalisation of ppGalNAcTs to the ER should produce more core 1 O-
glycans due to the higher number of O-glycosylation sites occupied resulting in steric inhibition 
of core 2 branching of GalNAc. In addition, the dissimilarities between NBT-II H2 ER (cells with 
overexpressed non-functional ppGalNAcT-2) and NBT-II WT (Figure 5.9) raises the possibility 
that the observed O-glycomic changes in the modified cells (WT ER and WT Golgi) might be 
partly influenced by the disruption in the expression and/or distribution of endogenous 
glycosyltransferases as a result of the expression of the exogenous ppGalNAcT-2.  
 
 There are a few possible explanations of the disagreement between the NBT-II and SYF 
cell lines regarding the core 2/core 1 ratio in active Src conditions. One reason could be that the 
observed glycosylation alterations in SYF cell lines might have been a cell-type specific response 
to Src activation. The NBT-II cell line has not been studied for cellular organisation and 
ppGalNAcT distribution upon stimulation by growth hormone or Src induction, as has been 
demonstrated previously on SYF, WI38 and HeLa cell lines by our collaborators (Gill et al., 
2010). The NBT-II cell line is derived from murine epithelia whereas SYF cells are derived from 
murine fibroblasts, WI38 are human fibroblasts and HeLa are human cervical cancer cells, 
illustrating the possibility of variations in cell morphology and physiology. Previously, an 
increase in Src activity in the NBT-II cell line has been shown to contribute to the enhanced 
metastatic potential but not to cell proliferation (Boyer et al., 2002). In contrast, Src has also been 
demonstrated to induce cancer cell growth and division but not metastatic potential on a number 
of human colon adenocarcinoma cell lines (Irby et al., 1997; Staley et al., 1997). Thus, it can be 
envisaged that Src acts differently in different types of cells. Accordingly, Boyer et al. have also 
concluded that the biological effects of Src are subjected to the cellular context, particularly to the 
type of cell proliferation (Boyer et al., 2002). 
 
While the SYF cell line was shown to be very rich in α2,3/6-sialylated terminal epitopes 
(see Figure 1.11), NBT-II cells are dominated by the Galα1,3Gal terminal epitope. Sialylation can 
occur at very early stages of the O-glycan biosynthetic pathways, i.e. on the Tn and T antigens, 
thus completely inhibiting elongation and/or core 2 synthesis. Galα1,3Gal, on the other hand, 
Chapter 5   176 
 
requires at least the T antigen and it is not known to block the synthesis of core 2 branch. 
Furthermore, recently it has been suggested that core 2 biosynthesis is co-regulated by the 
substrate peptide sequence and existing glycosylation patterns of glycoproteins (Brockhausen et 
al., 2009). A combination of substrate interactions with the enzyme and steric accessibility was 
shown to be important factors determining C2GnT1 activity (Brockhausen et al., 2009). In 
addition, ppGalNAcT-1 (Brockhausen et al., 1996) and C1GalT(Granovsky et al., 1994; Gerken 
et al., 2002)  was also shown to be influenced by similar properties. Hence, the nature of peptides 
being synthesised and the expression of glycosyltransferases in each cell type highly influences 
the number of O-glycosylation sites and the O-glycome, in particular core 1 and core 2 profiles. 
All these observations might explain the distinctive responses of SYF and NBT-II cells towards 
ppGalNAcT relocalisation to the ER.  
 
As mentioned in Chapter 1 (Section 1.2.2.2), ppGalNAcTs can bind to the Tn antigen on 
their protein substrates via the lectin domain, and this interaction may inhibit or enhance their 
glycosylating activity on the catalytic domain (Brockhausen et al., 2009). The ppGalNAcT 
isoform used by our colloborators in this study, ppGalNAcT-2, is possibly not the best model for 
the ppGalNAcT family. Even though ER-targeted ppGalNAcT-2 has been demonstrated to 
increase the glycosylation of a reporter protein when the enzyme is active (Gill et al., 2010), 
ppGalNAcT-2 has also been implicated to be inhibited by neighbouring glycosylations (Hanisch 
et al., 2001). The latter result is suggesting that ppGalNAcT-2 tends to keep the distance between 
its glycosylation sites regardless of how easily accessible they are on unfolded or folding 
proteins, thus the speculated steric inhibition of core 2 branching might not be applicable in this 
case. In contrast, other ppGalNAcTs, for instance ppGalNAcT-7 and -9, exhibit preferential 
addition of successive GalNAc residues next to those already present (Ten Hagen et al., 1999; 
Ten Hagen et al., 2001). It is evident that O-glycosylation of multisite substrates can proceed in a 
hierarchical manner depending on the available ppGalNAcTs in situ (Ten Hagen et al., 2003). 
Therefore, overexpressing ppGalNAcT-2 alone in the ER is a rather poor representation of Src 
mediated regulation of protein O-glycosylation. 
 
Our collaborators have observed higher staining of Helix pomatia lectin (HPL) in cells 
with activated Src compared to Src-deficient cells indicating an increase in O-glycosylation 
initiation (Gill et al., 2010). However, HPL only recognises GalNAc residues which have been 
exposed (Hammarstrom et al., 1977). Our collaborators also demonstrated an increase of O-
glycosylated proteins in SYFsrc compared to the wild type SYF cell line and a specific increase 
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of O-glycosylation on a Muc1 prototypical protein when cotransfected with active Src in human 
fibroblast HEK293T cells, both via metabolic labelling with GalNAz (N-
azidoacetylgalactosamine) and detection on Western blotting (Gill et al., 2010). GalNAz however 
needs to compete with endogenous GalNAc to be incorporated in O-glycosylation initiation, thus 
reducing the efficiency of this technique to about 30% according to Dube et al. (Dube et al., 
2006), but this is likely to vary according to cell type.  
 
Therefore, more definitive strategies are needed for instance by using reporter mucin-like 
glycoproteins with known sequences that will allow rigorous determination of their O-
glycosylation sites. The Muc1 prototypical protein mentioned above can be used for this purpose 
by expressing it in cells under study. The protein would need to be digested optimally in terms of 
glycopeptide length and the number of glycosylation sites per digest. The glycopeptides could 
then be treated with glycosidases to trim the glycan structures to as simple as possible, preferably 
until T or Tn antigens without affecting the stability of the peptide backbones. This should be 
followed by glycopeptide separation using online or offline LC prior to mass spectrometric 
sequencing. Mass spectrometric techniques have been proven to be valuable for O-glycopeptide 
analysis even as early as the 1970’s when EI-MS was the main tool. For instance, the 
determination of O-glycosylation sites and/or site-specific glycan analysis has been accomplished 
on anti-freeze glycoproteins (Morris et al., 1978). Subsequently FAB-MS was shown to be a 
more powerful technique for example in the characterisation of interleukin-2 and erythropoietin 
(Robb et al., 1984; Sasaki et al., 1988). Mass spectrometric analysis of this kind of sample has 
become a relatively routine since then. However, this pioneering work was done on glycopeptides 
with only a limited number of O-glycans attached, preceded by simple fractionation using 
chromatography. On mucin or mucin-type glycoproteins, on the other hand, it is usually more 
difficult for proteolytic enzymes to digest to glycopeptides especially the tandem repeat regions 
due the lack of digestion sequences. Even if digestion is possible, determination of the mass or 
composition of the glycopeptides does not directly give indications on the number of 
glycosylation sites. This is because, unlike N-glycosylation, O-glycosylation has no consensus 
sequences that could allow determination of the sites of glycosylation. For example, a 
glycopeptide having two sites occupied each with a core 1 O-glycan will have the same 
molecular weight as the glycoform which has only one site occupied with a core 2 O-glycan with 
the same overall composition as the two core 1 O-glycans. Moreover CID MS/MS analysis on 
the glycopeptides causes the sugar molecules to fall off thus resulting in ambiguities regarding 
their sites of attachment. 
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Future work should take advantage of the more recent technology for glycoproteomic 
analysis. Analysis of glycopeptides using modern mass spectrometry techniques, such as LC-ESI-
MS and MALDI-TOF-MS, has been shown to be able to identify post-translationally modified 
amino acids on increasingly complex glycopeptides, such as MUC1 and fetuin, accompanied by 
rigorous isolation strategies (Carr et al., 1993; Yang & Orlando, 1996; Müller et al., 1997; Müller 
et al., 1999). Continuous optimisation of these and related techniques are providing better and 
more reliable tools for site mapping of O-glycosylation on more complicated glycoproteins, for 
instance site-specific analysis on human and murine ZP3 glycoproteins using nanoLC-ESI-
QTOF-MS (Chalabi et al., 2005). They have identified a specific O-glycosylation domain on ZP3 
consisting of two closely spaced O-glycan sites that are conserved between humans and mice. 
Multiple stage tandem mass spectrometry using ETD ionisation has been shown to directly 
elucidate glycan structures and chemically/enzymatically tagged glycosylation sites without LC 
separation (Wang et al., 2010). Although very promising, this technology remains unproven for 
characterising highly glycosylated glycopeptides with the complex structures usually seen in 
mucins. In addition, tagging methods have rarely been shown to work well with mucinous 
samples (Wada et al., 2010). Therefore much work still needs to be done to ensure that 
glycoproteomic methodologies are suited to the suggested future work for investigating Src 
function.  
 
In summary, although the current study has not conclusively described the effects of Src 
induction and the associated ppGalNAcT relocalisation to the ER on cellular O-glycomes, 
particularly regarding the core 1 and core 2 ratio that appears to be in contrast with the previous 
analysis on SYF cells, valuable information has been acquired which is guiding further studies of 
the role of Src in protein O-glycosylation. By taking into account the current and previous data, it 
is likely that different types of cells respond distinctively to Src overexpression and to the 
controversial Src-mediated ppGalNAcT redistribution. In addition, we have demonstrated a 
possible connection between activated Src and increased in sialylation. However, it remains to be 
seen whether the sialylation changes are linked to the predicted relocalisation of ppGalNAcTs to 
the ER. New knowledge that has been assembled here hopefully will lead to a more 
comprehensive elucidation of the regulation mechanism of O-glycosylation, thus boosting 
understanding of O-glycan biological roles, particularly in cancer metastasis.  
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6 Concluding remarks 
This thesis encompasses a significant amount of experimental work and discussion that 
could open up new avenues for glycobiological research, particularly on O-glycoconjugates. As 
discussed in the first chapter, with O-glycans, mucins, glycan-protein interactions, mouse models 
and mass spectrometry as the main themes, it is increasingly clear that comprehensive 
characterisation of the O-glycome is a prerequisite in order to better understand the functional 
properties of O-glycans. Whilst the genome encodes the synthesis of functional proteins via 
nucleic acid sequences, the glycome carries explicit functional properties via highly varied glycan 
sequences and modifications that can be decoded usually by GBPs. It is evident now that 
glycome alterations can result in the disruption of cellular interactions and may lead to 
pathological conditions. Mouse models are an exceptionally powerful tool in demonstrating the 
function of glycans and are also widely utilised across various life sciences, but throughout the 
work of this thesis, it was surprising to learn that much is still ambiguous concerning their 
glycosylation machineries. Three separate but related research projects documented in this thesis, 
by using mouse models and cultured cell lines, have provided the platform for the optimisation as 
well as application of O-glycomic methodology with the ultimate goal to better appreciate glycan 
structure-function correlation. The first project (Chapter 3) addressed the effects of the disruption 
in O-glycan biosynthetic pathways from a system point of view, whereas the second project 
(Chapter 4) focused on the interaction between fucosylated O-glycans with H. pylori infection. 
The third project (Chapter 5), on the other hand, has discussed the dynamics of cellular O-
glycomes from the perspective of biosynthetic regulation.  
 
In comparison with genomics and proteomics, the progression of glycomics has faced 
unique challenges in the pursuit of developing analytical and biochemical tools and biological 
interpretations to investigate glycan structure-function relationships, mainly because of the 
diversity in terms of glycan chemical structure and information density. The situation is arguably 
even worse for the analysis of O-glycoconjugates due to the existence of different types and cores 
and the lack of consensus glycosylation sequences. As a result, structural analysis of O-glycans 
has been much hampered, as can be illustrated by the relatively low amount of data available for 
characterised O-glycans, as opposed to studies providing compositional data only, compared to 
that for N-glycans. Throughout the work of this thesis, a number of discoveries and contributions 
in terms of O-glycomic methodology, O-glycan sequencing and structure-function relationships 
have been made. By using a combination of MALDI-TOF/TOF, ESI-QTOF, GC-EI MS/MS 
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sequencing capabilities, supplemented by MALDI-QIT MSn technology, we have performed 
detailed O-glycomic analyses to unravel a number of biological challenges raised by our 
collaborators. As exemplified in Chapters 3 and 4, the manipulation of glycosyltransferases 
leading to O-glycome aberrations has paved the way for exhaustive O-glycan structural 
characterisation in correlation with phenotypic studies. This thesis has illustrated possible 
correlations between core 2 and branched core 1 O-glycans in several murine pathological 
conditions including hypothyroidism and colitis (Chapter 3). The improvement in methodology 
and instrumentation was best exemplified by the characterisation of complex and high-mass O-
glycans, rigorous sequencing of terminal epitopes as well as the discovery of the RM2-like 
antigen and O-mannosyl glycans in the GI tract. The apparent extensive compensation seen in the 
C2GnT knockout tissues provided by the induction of elongated core 1 O-glycans and O-
mannosyl glycans carrying terminal epitopes with higher density of fucosylation is consistent 
with the recently proposed homeostatic regulatory mechanism for the maintenance of cell surface 
glycan density (Dam & Brewer, 2010). 
  
The mucins of the GI tract are rich in various terminal epitopes that have been linked to 
symbiotic or pathogenic interactions with diverse species of microbes (Chapter 4). The 
elimination of the dominating H-antigen capped glycans has led to the sequencing of the lower 
abundance Lewis antigens in the stomach, which has proven to be helpful for better 
understanding of H. pylori pathogenicity. This work also constitutes one of the first detailed 
descriptions of type 2 histo-blood group antigens as the dominant epitopes in murine GI tissues. 
The expression and sorting of glycosyltransferases require proper regulation as their actions can 
highly influence the messages that cells are presenting on their surfaces. As exemplified in 
Chapter 5, extracellular signals that are passed via signalling molecules, such as Src family 
kinases, can alter the localisation of glycosyltransferases, thereby promoting changes in O-glycan 
biosynthesis. A complete elucidation of the cellular regulation of O-glycosylation is highly 
anticipated to bring our understanding of functional glycomics to a whole new level. During the 
course of this thesis work, other groups have also done some excellent work in improving O-
glycan sequencing. Perhaps the most notable is the work of the Karlsson group that has 
rigorously characterised O-glycans from purified mucinous glycoproteins with m/z up to 3000 
using LC-ESI-MSn (Issa et al., 2010). 
 
Profiling glycosylation from a whole tissue or organ is a reasonable first step towards 
understanding glycan functions. However, as glycoconjugates work individually, it is crucial to 
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be able to push forward the acquired data to identify and characterise the molecules that are 
biologically important.  Although very promising and encouraging, the current technology is still 
limited with respect to this aspect of structural analysis particularly on biological samples that are 
often complex and heterogeneous. As discussed in Chapter 5, various purification and mass 
spectrometric techniques have been deployed in order to investigate specific glycoconjugates and 
their glycosylation even since the 1970’s, however the samples that were addressed were 
relatively low in complexity. A very good example of the current status of O-glycopeptide 
analysis worldwide is the recent Human Proteome Organisation (HUPO) Human Disease 
Glycomics/Proteome Initiative (HGPI) which coordinated the evaluation of methodologies that 
are widely used for defining the O-glycans by using glycopeptides of IgA1 (Wada et al., 2010). It 
is important to note that IgA1 bears only up to 5 O-glycosylation sites with glycan compositions 
up to 5 monosaccharides, yet some laboratories failed to identify all structures. In real 
mammalian tissues, mucins or mucin-type glycoproteins can contain from dozens to several 
hundreds of O-glycosylation sites (Rose & Voynow, 2006) with glycan compositions, as 
presented in Chapter 3 and 4, of up to 18 monosaccharides, thus illustrating how far the 
technology needs to be improved in order to achieve similar high quality data on these molecules. 
A very promising strategy for O-glycosylation site analysis that is getting increasing attention is 
by expressing a selected portion of the glycoprotein or mucin under study in a cell line with 
limited glycosyltransferases to make complex structures. For instance, a single tandem repeat of 
MUC1 with 20 amino acids and up to 5 potential O-glycosylation sites has been characterised 
from mutant Chinese hamster ovary cell lines (Sihlbom et al., 2009). However, this strategy is 
only possible when the biologically important glycoconjugates have been identified, which is not 
always the case.  
 
Techniques to improve the isolation and purification of specific cellular organelles, such 
as the Golgi, or specific glycoproteins of interest also need to be further exploited and developed. 
Immunoaffinity isolation/purification using lectins and antibodies have been a very useful means 
to fish-out specific glycoconjugates from complex biological samples (Taylor & Drickamer, 
2009). Nevertheless this type of methodology still requires improvements in its applicability as 
well as resolution of specificity issues, as exemplified in Chapter 4. These techniques could be 
valuable, for instance, in the isolation of glycoproteins with core 2 O-glycans in the murine 
thyroid that have a possible connection with the synthesis of thyroxine (Chapter 3). It also would 
be interesting to be able to pull out glycoproteins that are O-mannosylated in the GI tract as this 
type of modification is extremely rare. Ongoing research on methodology and technology to 
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analyse glycoproteins and their associated glycans hopefully will help to push the limit of what is 
currently achievable. For instance the work of the Hanisch group involving in-gel and on-column 
de-O-glycosylation methods that can preserve the peptide backbones shows promise for defining 
glycosylation sites in mucins (Hanisch et al., 2009).  
 
As we enter the second decade of the 21st century, the field of glycobiology is expanding 
and the demand for knowledge is now even more challenging, therefore continuous optimisation 
of the analytical methods and technology are necessary. Both the HGPI studies of N- and O-
glycans convincingly endorsed mass spectrometry as the technique of choice for glycomic 
profiling, with MALDI and ESI as the most efficient and reproducible techniques instead of FT-
ICR and linear trap quadrupole (LTQ) (Wada et al., 2007; Wada et al., 2010). This partly 
highlighted that the newer and more sophisticated mass spectrometric instrumentations are not 
yet capable of rivalling the overall performance of the more established techniques in 
comparative glycomics. Other than improving the sensitivity and reproducibility, methodology 
optimisation should also consider ways to reduce cost and processing time. This is in accord with 
the current economic situation as well as the increasing demand for high-throughput analysis.  
 
 Histochemical approaches to analyse molecular and cellular dynamics can provide useful 
guidance to answering questions about glycan biological functions associated with pathology and 
were well exemplified by the work of our collaborators. However, development of glyco-
biomarkers will require a systems view of the biological systems via the integration of all these 
approaches including bioinformatics with the structural data from glycomic analysis. 
Comparative glycan analysis of biological samples with and without disease lesions as presented 
in this thesis could provide clues to help indentify biomedically important molecules and provide 
better insights into the molecular properties of carbohydrate related diseases. One of the obstacles 
of comparative glycomics is the lack of well characterised and comparable glycan standards for 
quantitative analysis. For this purpose, comprehensive cataloguing of glycan structures in nature, 
for instance the work of the Dell group (North et al., 2010), as well as optimisation of methods to 
synthesise these structures, for example the work of the Seeberger group (Weishaupt et al., 2010), 
are essential. In conclusion, as the glycobiology field moves towards a more holistic 
understanding of glycosylation function, the expansion and cross-linking of the currently 
available bioinformatic platforms such as the CFG (www.functionalglycomics.org), 
GlycoWorkbench (http://www.glycoworkbench.org), GlycoSuite (//glycosuitedb.expasy.org), 
Carbohydrate-Active Enzymes (www.cazy.org), UniProtKB (www.uniprot.org) and Mouse 
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Genome Informatics (www.informatics.jax.org) are of importance to integrate the diverse 
datasets generated using different technologies and approaches.  
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